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Summary I 
Type II testicular germ cell tumours (TGCTs) represent the most common malignancy 
in young men (19-35 years). They are classified as seminoma or embryonal carcinoma 
(EC; the stem cell population of non-seminomas). TGCTs are highly sensitive to radio- 
and chemotherapy, however 1-5% of TGCTs may develop resistance mechanisms to 
standard therapy regimens. Epigenetic drugs open a new avenue to cancer therapy 
and may present a promising alternative to treat recurrent TGCTs. JQ1 is an inhibitor 
of the BET family of bromodomain reader proteins. In TGCT cell lines, JQ1 treatment 
leads to upregulation of stress markers (i.e. CDKN1C, DDIT4, TSC22D1, TXNIP), 
induction of the differentiation marker HAND1, and downregulation of pluripotency-
associated genes (i.e. LIN28, DPPA4, UTF1) [1]. This results in growth arrest and 
apoptosis in cisplatin-sensitive and cisplatin-resistant EC cells (at doses ≥ 100 nM) and 
seminoma cells (at doses ≥ 250 nM) [1, 2]. In line, EC xenografts in nude mice show 
reduced tumour burden when treated with JQ1 (50 mg / kg) compared to solvent 
controls. Additionally, JQ1-treated tumours showed reduced blood vessel count (lower 
CD31+), possibly due to JQ1-mediated downregulation of VEGFB. Altogether, this 
reflects the therapeutic potential of bromodomain inhibition for TGCTs. However, 
similar to TGCT cells, somatic control cells (here: Sertoli cells) responded with cell 
cycle arrest and apoptosis to JQ1 treatment. Thus, a more detailed analysis of possible 
side effects of JQ1 administration is recommended, before commissioning the drug for 
clinical use. Interestingly, JQ1 treatment had similar effects on TGCT cells as the 
HDAC inhibitor romidepsin (i.e. induction of stress markers GADD45A, GADD45B, 
RHOB, ID2) [1-3]. I now showed that JQ1 and romidepsin may elicit additive or 
synergistic effects on cytotoxicity levels of TGCT cells in vitro and in vivo. Since a 
combination of both drugs may, however, also increase potential side effects, the exact 
efficacy vs toxicity relationship of this treatment strategy needs further evaluation.
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Summary II 
TGCTs can be characterized as seminoma or EC. While seminomas display limited 
differentiation capacities, ECs display features of pluri- to totipotency. Previous data 
suggests that pluripotency in EC cells is maintained by cooperative binding of SOX2-
OCT4 to the canonical (SOX2/OCT4) motifs at pluripotency genes. Indeed, SOX2 
binding in EC cells is enriched at canonical motifs and SOX2 target genes showed 
significant overlap with embryonic stem cell signatures. In contrast, seminomas lack 
expression of SOX2, but display high levels of OCT4 and SOX17. In embryonic stem 
cells cooperative binding of SOX17-OCT4 to the compressed (SOX17/OCT4) motif on 
DNA induces endodermal differentiation. However, seminomas maintain an 
undifferentiated state, indicated by expression of pluripotency genes and lack of 
expression of typical differentiation markers. We therefore asked, whether the SOX17-
OCT4 complex in seminoma cells binds to canonical (SOX2/OCT4) binding sites to 
regulate and maintain seminoma pluripotency. High-throughput chromatin 
immunoprecipiation (ChIP)-sequencing analysis revealed that the majority of genes 
bound by SOX17 in seminoma cells has functions in neuronal differentiation and that 
26% of SOX17 peaks contain the compressed (SOX17/OCT4) binding motif. These 
findings are is in disagreement with the latent pluripotent state of seminoma cells. 
However, a small subset of SOX17-bound genes has roles in pluripotency 
maintenance (e.g. NANOG, POU5F1 (OCT4), PRDM1 and TFAP2C) and 10% of 
SOX17 peaks include the described canonical (SOX2/OCT4) binding motif. This 
suggests that, next to somatic genes, SOX17 regulates pluripotency genes in 
seminoma cells by binding to the canonical motif. In line, CRISPR/Cas9-mediated 
deletion of SOX17 in TCam-2 resulted in a strong reduction of OCT4 and TFAP2C 
protein levels, as well as alkaline phosphatase activity. qRT-PCR analysis showed that 
loss of SOX17 induces differentiation into trophoblast-like lineages. I conclude that 
SOX17 shares a similar role in seminoma cells as in primordial germ cells (PGC), 
which is to maintain a latent pluripotent state and to suppress cellular differentiation 
(i.e. via downstream activation of the PGC specifiers PRDM1 and TFAP2C and by 
direct activation of pluripotency genes such as NANOG and POU5F1).  
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1. Introduction 
 
1.1. Male germ cell development 
Germ cells are the founder cells of new life. They harbour all necessary genetic and 
epigenetic information, which is propagated from one generation to the next. Like in 
other mammals, human germ cells are formed early during embryogenesis. These 
germ cells then later undergo meiosis to form haploid spermatocytes (in males) or 
oocytes (in females). 
 
1.1.1. Transcription factors determining male germ cell fate 
Human germ cell development is initiated two weeks after fertilization with the 
formation of primordial germ cells (PGCs). Similar to PGCs in primates, it is believed 
that human PGCs are specified in the nascent amnion, which expresses BMP4 and 
WNT3A at high levels [4]. Both signalling molecules are crucial for human germ cell 
development [4]. Recent data suggests that WNT signalling leads to EOMES induction, 
which in turn transactivates SOX17, resulting in upregulation of BLIMP1 [5]. At the 
same time BMP2 (expressed in the extraembryonic mesoderm) and BMP4 activate 
TFAP2C expression [5]. Together, SOX17, BLIMP1 and TFAP2C form a tripartite 
transcription factor network and the core circuitry for human germ cell specification [5-
7] (Fig. 1). Each factor exerts unique, but also overlapping roles in activating the germ 
cell program and in sustaining the epigenetic program of PGCs, thereby maintaining 
pluripotency and suppressing somatic differentiation [8]. Once specified, human PGCs 
migrate along the hindgut to the genital ridges. During this migration PGCs are stalled 
in G2 phase of the cell cycle, while they undergo global DNA demethylation and 
imprinting erasure [9]. 4-6 weeks following implantation of the embryo in the uterus, 
PGCs arrive in the genital ridge where they continue to amplify by mitosis [9]. From 
now on the male germ cells are referred to as gonocytes and express the following 
markers: MAGE-A4, DAZL, KIT, PLAP, POU5F1, TFAP2C, UTF1, VASA [10]. 
Approximately 6 months after birth the undifferentiated gonocytes (Adark-
spermatogonia) settle at the basal membrane of the seminiferous tubules of the testis, 
where they lose their pluripotent state and develop further into Apale-spermatogonia [3, 
11]. These remain quiescent until the age of ~ 10 years, when spermatogenesis starts 
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with the development of B-spermatogonia, which differentiate further into primary 
spermatocytes and subsequently undergo two rounds of meiotic division to become 
haploid spermatids [12]. During meiosis the developing spermatocytes lose contact 
with the basal membrane and migrate toward the lumen of the seminiferous tubules 
[12]. Finally, the haploid round spermatids differentiate into mature, motile 
spermatozoa (a process referred to as spermiogenesis) [13]. This process starts within 
the seminiferous tubules, from which the elongated spermatozoa are transported via 
the rete testis into the epididymis, where they mature and are stored [14]. The whole 
process of spermatogenesis (including spermiogenesis) in humans consumes 
approximately 74 days [15]. 
 
 
 
 
 
Figure 1: Germ cell specification in the human system. Modified from [8] 
BMP2 and BMP4 are released from extra-embryonic mesoderm and the nascent amnion, triggering 
human germ cell development by activating TFAP2C expression [4, 5]. Further, WNT signalling activates 
expression of EOMES, which transactivates SOX17, resulting in upregulation of BLIMP1 [5]. SOX17, 
TFAP2C and BLIMP1 form a tripartite transcription factor network, regulating epigenetic reprogramming, 
germ cell fate and suppression of somatic differentiation.  
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1.2. Malignant germ cell development 
Testicular germ cell cancer is the most common form of cancer among males between 
15 and 35 years [16]. It comprises a heterogeneous group of neoplasms that originates 
from male germ cells and is therefore anatomically distributed along the migration route 
of PGCs [17, 18]. Although the exact cause of germ cell cancer is unknown, it is 
believed that environmental factors, e.g. endocrine disruptors, may contribute to the 
risk of developing germ cell cancer [19]. Germ cell cancer incidence is globally 
increasing, however the development of novel chemotherapeutic treatment regimens 
has led to a drastic decline in mortality rates [20]. There are three types (I-III) of 
testicular germ cell tumours (TGCTs), which can be discriminated according to their 
anatomical site, stage of maturation and pattern of genomic imprinting [21] (Fig. 2). 
 
 
 
Figure 2: Male testicular germ cell tumours (type I-III). Modified from [8, 21] 
Type I TGCTs comprise of teratoma and yolk-sac-tumour of children and infants. They putatively arise 
early during primordial germ cell development. Type II TGCTs comprise of seminomas and non-
seminomas of adolescents and adults. These tumours arise from a common precursor lesion, the germ 
cell neoplasia in situ (GCNIS), which develops from an error in late primordial germ cell (PGC) 
maturation. Type III TGCTs are spermatocytic seminomas, which frequently occur in older men and 
develop from late spermatogonia or spermatocytes.  
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1.2.1. Type I testicular germ cell tumours 
Type I TGCTs account for 1-2% of solid tumours in children [22]. The vast majority of 
type I TGCTs may either be classified as teratoma or yolk-sac-tumour (YST) according 
to tumour histology and marker expression [21]. YSTs are defined by high levels of 
alpha-fetoprotein (AFP) and morphologically present as endodermal or yolk-sac-like 
tissue [23]. These tumours account for ~ 50% of testicular tumours in children [24, 25]. 
Pediatric teratomas are the second most common testicular tumours in children with a 
relative frequency of ~ 15% [24, 26]. Pre-pubertal teratomas present as well-
differentiated (mature) and are of benign nature [25, 26]. They are usually derived from 
cells of all three embryonic germ layers (endoderm, mesoderm, ectoderm). 
Chromosomal abnormalities frequently found in pediatric YSTs and teratomas are loss 
of 1p, 4 and 6q, and gain of 1q, 12(p13) and 20q [27]. Since type I TGCTs show a 
partially erased imprinting pattern, it is believed that they develop early during germ 
cell development [28] (Fig. 2), however risk factors remain poorly understood. 
 
1.2.2. Type II testicular germ cell tumours 
Type II TGCTs comprise of seminomas and non-seminomas [21]. These tumours are 
found in young adolescents and adults and are the most frequent cause of cancer in 
young men [29]. Type II TGCTs are characterized by high levels of the pluripotency 
marker OCT4 and gain of the 12 p chromosomal region [30]. Both seminomas and 
non-seminomas arise from a common precursor lesion called germ cell neoplasia in 
situ (GCNIS) [31]. It is generally accepted that GCNIS formation occurs as a 
consequence of an arrest in late PGCs development, due to the acquisition of genetic 
mutations or epigenetic aberrations (Fig. 2) [10, 30-32]. We believe that GCNIS may 
additionally arise from adult stage spermatogonial cells via reacquisition of the germ 
cell pluripotency program, although not formally proven [10]. This is supported by the 
observation that pluripotent cells can be derived from adult murine and human 
testicular cells [10]. GCNIS are non-invasive and asymptomatic and therefore only 
rarely diagnosed [31]. 8-10 years after puberty, however, they transform into a 
malignant seminoma or non-seminoma (Fig. 3).  
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Figure 3: Overview of type II testicular germ cell tumours. Modified from [8, 21] 
Type II TGCTs comprise of seminomas and non-seminomas. Both subtypes arise from the GCNIS 
precursor lesion. Non-seminomas initially present as ECs. ECs are pluri- to totipotent and can further 
differentiate into embryonic (teratoma) and extraembryonic tissues (YST, choriocarcinoma).  
 
Seminomas are highly similar to PGCs and GCNIS in terms of their overall marker 
expression (they express LIN28, OCT4, NANOG, PRDM1, TFAP2C and cKIT) and 
epigenetic profile (global hypomethylation) [10]. Non-seminomas initially present as 
embryonal carcinomas (ECs) (Fig. 3). ECs are described as the stem cell compartment 
of non-seminomas [10]. These cells are pluri- to totipotent and are therefore able to 
differentiate into embryonic (teratoma) and extra-embryonic tissues (choriocarcinoma 
or YST) (Fig. 3) [10]. Similar to seminomas, ECs express TFAP2C, GDF3, DPPA3, 
OCT4 and NANOG at high levels, but additionally express DNMT3B, DNMT3L, 
NODAL, CRIPTO, CD30 and SOX2 [10]. A major distinction between seminomas and 
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embryonal carcinomas is the differential expression of the biomarkers and transcription 
factors SOX2 (EC) and SOX17 (seminoma) [33, 34] (Fig. 3). Chromosomal 
abnormalities that frequently occur in seminomas and non-seminomas are loss of 1p, 
11, 13, 18 and gain of 7, 8, 12p, 21 and X [27]. 12 p gain is the most frequent 
chromosomal alteration in Type II TGCTs, which is why overexpression of pluripotency 
associated genes (e.g. NANOG, GDF3, DPPA3) encoded in this region is a common 
event in these tumours [35]. 
 
1.2.3. Type III testicular germ cell tumours 
Type III TGCTs are spermatocytic seminomas [21]. These tumours are rare (0.3-0.8 
per one million men affected) and predominantly occur in men older than 50 years [36]. 
Spermatocytic seminomas display partial imprinting [21]. Since this imprinting pattern 
resembles the one of spermatogonia or spermatocytes, it is generally believed that 
these tumours develop at later stages during male germ cell development [21] (Fig. 2). 
Gain of chromosome 9 is a common karyotypic alteration in these tumours [36]. 
Looijenga et al. proposed the transcriptional regulator DMRT1, which is encoded on 
chromosome 9, as a driving factor for the development of spermatocytic seminomas 
[37]. 
 
1.3. Model systems for type II testicular germ cell tumours 
Several cell lines have successfully been derived from type II TGCTs and established 
for in vitro culture, reviewed in Nettersheim et al. (2016) [10] (Table 1). Further, 
xenotransplantation of these cell lines into the flank, brain or testes of immunodeficient 
Crl:CD1-Foxn1nu (CD-1 nude) mice allows for in vivo tumour analysis. However, 
changes in the cellular microenvironment following xenotransplantation may cause a 
shift in cell fate (Table 1). For example, the seminoma-like cell line TCam-2 grows as 
EC after injection into the flank of nude mice, while transplantation into the testis results 
in seminoma growth [10] (Table 1). 
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Table 1: Type II TGCT cell lines. From [10] 
Cell Line Origin Growth in vitro as Growth in vivo as Reference 
TCam-2 Seminoma Seminoma EC (flank), CIS / 
Seminoma (testis) 
[38] 
JKT-1 Seminoma, EC Seminoma / EC 
intermediate 
Seminoma [39] 
SEM-1 Seminoma Seminoma / EC 
intermediate 
Mediastinal GCC [40] 
1411HP Seminoma, EC, 
Teratoma, YST 
EC EC, YST [41] 
169A/218A/228A/
240A 
EC EC Not determined [42] 
1777N Retriperitoneal 
metastasis of 
non-seminoma 
EC EC [43] 
2102EP EC, Teratoma EC EC [44] 
833Ke Seminoma, EC, 
Teratoma, 
Choriocarcinoma 
EC EC [45] 
GCT27 EC, Teratoma EC EC, Teratoma, YST [46] 
GCT35 EC, Teratoma EC EC, YST [46] 
GCT44/46/72 EC, Teratoma EC YST [46] 
GCT48 EC, Teratoma EC EC [46] 
H12.1/.5/.7 Seminoma, EC, 
Teratoma, 
Choriocarcinoma 
EC EC [47] 
NCCIT EC, Teratoma EC EC, Teratoma [48] 
NEC-8/-14/-15 EC, YST, 
Choriocarcinoma 
EC EC, Teratoma [49] 
SuSa EC, Teratoma EC Not determined [50] 
TERA1/2 EC, Teratoma EC EC [51] 
577MF/L/RPLN Metastasis of 
non-seminoma 
Undifferentiated 
carcinoma 
Teratoma [52] 
BeWo Choriocarcinoma Choriocarcinoma Choriocarcinoma [53] 
JAR Choriocarcinoma Choriocarcinoma Choriocarcinoma [54] 
JEG-3 Choriocarcinoma Choriocarcinoma Choriocarcinoma [55] 
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1.3.1. The seminoma-like cell line TCam-2 
The only seminoma-like cell line that has been adapted to cell culture is the TCam-2 
cell line [38, 56] (Table 1). Two other cell lines have been isolated from seminoma 
patients (JKT-1, SEM-1), however SEM-1 cells show characteristics of both seminoma 
and non-seminoma components, while JKT-1 lack the typical characteristics of a type 
II TGCT (such as gain of the 12p chromosomal region) [40, 56, 57]. Other attempts for 
the in vitro cultivation of seminoma cells have failed, since these cells undergo 
spontaneous cell death (anoikis) when isolated from their microenvironment [58]. 
However, it is still unclear what determines the survival of TCam-2 cells in vitro.  
Thorough analysis has demonstrated that TCam-2 cells display expression of the early 
germ cell and TGCT markers OCT4, NANOG, TFAP2C and LIN28, and the seminoma 
markers SOX17, PRDM1 (nuclear expression) and KIT [10]. At the same time TCam-
2 lack expression of EC markers SOX2 and CD30 [38, 59]. Furthermore, TCam-2 cells 
show an aneuploid karyotype with the characteristic gain of the 12p region [38]. 
Morphologically, TCam-2 cells appear polygonal and flat in shape, with a large 
cytoplasm and a round nucleus [56, 60]. Further, TCam-2 cells have a relatively long 
doubling time of approximately 58 hours, which is reminiscent of migratory PGCs [56]. 
 
1.3.2. The EC cell lines NCCIT, NT2/D1 and 2102EP 
The NCCIT cell line is a pluripotent EC cell line derived from a mixed germ cell tumour 
[48] (Table 1). NCCIT are positive for alkaline phosphatase and the pluripotent stem 
cell markers TRA-1-60 and TRA-1-81 [48]. They show epithelial-like morphology and 
form dense cell clusters upon in vitro cultivation. When exposed to retinoic acid (RA), 
NCCIT cells differentiate into cells of all three germ layers, mimicking teratoma growth 
[48]. When transplanted into nude mice, NCCIT cells differentiate into mixed non-
seminoma [48]. 
The NT2/D1 (NTERA-2 cl.D1) cell line was derived by cloning the pluripotent EC line 
NTERA-2. NTERA-2 were established from a nude mouse xenograft of the Tera-2 cell 
line (Table 1). Similar to NCCIT cells, NT2/D1 grow in tight colonies and appear 
epithelial-like [61]. In response to RA NT2/D1 cells differentiate into neuronal lineages 
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[62]. When transplanted into nude mice, NT2/D1 cells grow as mixed non-seminoma 
[63]. 
2102EP cells resemble undifferentiated EC cells and stain positive for alkaline 
phosphatase and the pluripotency markers SSEA-4, TRA-1-60 and TRA-1-81 [64] 
(Table 1). Although 2102EP cells resemble human ES cells on transcriptome level and 
express a number of core pluripotency genes (TDGF1, DNMT3A, DNMT3B, POU5F1, 
NANOG, GDF3, UTF1, SOX2), these cells lack the capacity to differentiate [64, 65]. 
This suggests that 2102EP cells have acquired additional mutations restricting their 
differentiation capacities, therefore characterizing 2102EP cells as nullipotent [65]. 
When transplanted into nude mice, 2102EP cells grow as EC. 
 
1.4. Transcription factors determining type II TGCT cell fate 
Seminomas and ECs can be discriminated by their differential expression of SOX17 
(seminoma: high, EC: low) and SOX2 (seminoma: low, EC: high) [33]. Both factors 
belong to the SOX family of transcription factors. SOX factors have important roles in 
orchestrating stem cell self-renewal and differentiation [66]. Along with OCT4, KLF4 
and MYC, SOX2 is also well known for its function in the generation of induced 
pluripotent stem cells (iPSC) and stem cell maintenance [67]. In contrast, SOX17 is a 
known specifier of endodermal lineage decisions [68].  
 
1.4.1. SOX and POU transcription factors in type II TGCTs 
In mouse ES cells it was shown that SOX2 and SOX17 partner with the POU 
transcription factor OCT4 and act as opposing forces in regulating cell fate decisions 
[69]. SOX2 and OCT4 dimerize and bind to the canonical (SOX2/OCT4) binding motif 
on the DNA, which is composed of the SOX and OCT4 binding motifs separated by a 
single basepair [69, 70], (Fig. 4 A).  SOX17 and OCT4 dimerize and bind to the 
compressed motif, which is similarly composed of the SOX and OCT4 binding motifs, 
but lacking the central basepair separating the two motifs [69], (Fig. 4 B). In both 
human and mouse embryonic stem cells (ESCs) SOX2-OCT4 binding to the canonical 
motif results in upregulation of pluripotency and stemness-associated genes [70]. In 
contrast, binding of the SOX17-OCT4 complex to the compressed motif results in 
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upregulation of endodermal-associated genes [69, 71, 72]. Interestingly, the group of 
Prof. Jauch demonstrated that in mouse ESCs the SOX17-OCT4 heterodimer can also 
bind to the canonical (SOX2/OCT4) motif (Fig. 4 C), however with reduced affinity 
compared to binding to the compressed (SOX17/OCT4) motif: 13.6% canonical motif, 
33.5% compressed motif [69]. In contrast, SOX2/OCT4 heterodimer formation on the 
compressed motif is not possible, due to sterical hindrance (Fig. 4 D).  
 
 
 
Figure 4: SOX2/OCT4 and SOX17/OCT4 DNA binding motifs. Modified from [69, 72] 
(A) The canonical motif is composed of the SOX and OCT4 motif, separated by a single basepair. 
Binding of SOX2-OCT4 to this motif regulates pluripotency. 
(B) The compressed motif is composed of the SOX and OCT4 motif, lacking the central basepair 
separating the two motifs. Binding of SOX17-OCT4 to this motif regulates endodermal 
differentiation.  
(C) Similar to SOX2-OCT4, the SOX17-OCT4 complex is able to bind to the canonical motif (additive 
binding).  
(D) SOX2-OCT4 cannot bind to the compressed motif, due to sterical hindrance.  
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Since EC cells show high expression of core pluripotency genes (POU5F1 (OCT4), 
SOX2, NANOG, KLF4 and ZIC3), it was suggested that self-renewal and pluripotency 
in EC cells is also maintained by cooperative binding of the SOX2/OCT4 complex to 
the regulatory regions of these genes. In contrast, seminoma cells display high levels 
of OCT4 and the transcription factor SOX17, therefore Nettersheim et al. hypothesized 
that SOX17 in seminomas is replacing for the lack of SOX2 in regulating pluripotency 
genes [60]. Seminomas maintain a latent pluripotent cell state and do not undergo 
endodermal differentiation, thus it was suggested that SOX17 together with OCT4 in 
seminoma cells regulates pluripotency by binding to the canonical motif [60] (Fig. 4 C). 
 
1.4.2. The plasticity of type II TGCTs 
It was a long-standing belief that seminoma cells were not able to differentiate, due to 
expression of the PGC program, which is inhibiting the differentiation. However, 
Nettersheim et al. demonstrated in 2011 that in vitro cultivation of the seminoma-like 
cell line TCam-2 in medium supplemented with TGFβ1, EGF and FGF4 results in 
conversion into a mixed non-seminomateous or choriocarcinoma-like phenotype [73] 
(Fig. 5). This differentiation process was initiated by inhibition of BMP signalling and 
subsequent downregulation of BLIMP1 expression  [73]. Since BLIMP1 normally 
associates with the histone methyltransferase PRMT5 to regulate symmetrical 
dimethylation of arginine 3 on histone H2A and/or H4 tails [74] (which is characteristic 
for TCam-2 and PGC cells), loss of BLIMP1 additionally led to reduction in H2a/H4 
dimethylation [73].  
In a different study it was shown that xenotransplantation of TCam-2 cells into the 
murine flank or brain results in transition into an EC-like phenotype [75] (Fig. 5). This 
differentiation process was also initiated by inhibition of BMP signalling, leading to 
activation of NODAL signalling and acquisition of a pluripotent state [75]. At the same 
time DNMT3B-mediated de novo methylation silenced seminoma-specific genes, 
leading to an EC-like epigenetic signature [75]. It was shown that SOX2-/- TCam-2 
cells xenotransplanted in the murine flank grow as seminoma-like with a few cell foci 
displaying mixed non-seminoma morphology [60] (Fig. 5). SOX2 upregulation was 
indispensable for this seminoma to EC transition, demonstrating that SOX2 is a key 
determinant of EC cell fate [60]. EC cells are able to differentiate further into a mixed 
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non-seminoma cell fate (teratoma, yolk-sac-tumour or choriocarcinoma) (Fig. 5). This 
can be observed upon xenotransplantation of EC lines into the murine system or in 
patient tumour samples that have been diagnosed with both EC and mixed non-
seminoma components (Fig. 5).  
However, so far it was questionable whether a direct conversion of EC to seminoma 
fate was possible (Fig. 5). Nettersheim et al. suggested that cultivation of EC cells in 
“4i”-medium (+GSK3 inhibitor, +MEK inhibitor, +P38‐kinase inhibitor, +JNK inhibitor) 
supplemented with TGF‐β1 and bFGF may induce seminoma-like cell fate under 
simultaneous overexpression of the PGC and seminoma specifier SOX17 [76] (Fig. 5). 
In a previous study, Irie et al. could already demonstrate successful derivation of PGC-
like cells from ESCs under these conditions [6].  
 
 
 
Figure 5: The plasticity of type II TGCTs. From [76] 
Seminoma cells grow seminoma-like when transplanted into the murine testis. Xenotransplantation of 
seminoma cells into the flank or brain of nude mice results in seminoma to EC transition. SOX2-deficient 
TCam-2 cells keep a seminoma-like cell fate or differentiate into mixed non-seminoma when 
transplanted into the murine flank. EC cells may further differentiate into mixed non-seminoma in vivo 
or in the patient (Ter = teratoma, Ys-t = YST, Cc = choriocarcinoma). EC to seminoma transition may 
be achieved by cultivation of seminoma cells in “4i”-medium supplemented with TGFβ1 and FGF4 under 
simultaneous overexpression of SOX17. 
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1.5. Treatment of type II TGCTs 
Type II TGCTs are diagnosed according to histological appearance and AFP, lactate 
dehydrogenase (LDH) and human chorionic gonadotropin (HCG) serum levels [77]. In 
all cases, radical orchiectomy (removal of the testis) is the first line of treatment [77]. 
Additionally, tumour serum markers are determined both before and after orchiectomy 
to ensure correct tumour classification and staging [77]. Following the EAU and ESMO 
guidelines of clinical practice for Type II TGCTs three stages of seminomas and non-
seminomas can be distinguished and the following treatment strategies have to be 
adjusted accordingly [77, 78].  
 
1.5.1. Treatment of stage I-III seminoma and non-seminoma 
Stage I seminomas (low risk: absence of rete testis invasion and tumour size    < 4 cm, 
high risk: presence of rete testis invasion or tumour size ≥ 4 cm) are typically treated 
by surveillance [78]. In case of relapse, low-risk tumours are alternatively treated with 
radiotherapy [78]. The majority of low-risk patients (70%) respond very well to this 
treatment, since seminoma cells are highly sensitive to radiotherapy [78]. In case of 
relapse following salvage radiotherapy, tumours can additionally be treated by 
chemotherapy [78]. High-risk tumours are directly treated by chemotherapy [77, 78]. 
Stage II/III seminomas are typically treated by 3-4 cycles of chemotherapy and / or 
radiotherapy [77]. In case of relapse, tumour tissue may be surgically removed, if 
feasible, and patients may be treated by either salvage chemotherapy or localised 
radiotherapy [78].  
Stage I non-seminomas are preferably treated by surveillance [77]. However, about 
30% of patients show relapse after being treated with surveillance alone [77]. Patients 
may then additionally be treated by chemotherapy and / or retroperitoneal lymph node 
dissection (RPLND) [77]. In case of post-chemotherapy relapse patients are treated by 
salvage chemotherapy [77]. Stage II/III non-seminomas are treated by chemotherapy 
and, if applicable, additional RPLND [77]. In case of residual disease or relapse, 
tumour tissue may be surgically removed and patients may be treated by salvage 
chemotherapy [77]. 4-8 weeks following therapy, AFP, LDH and HCG serum levels are 
determined and patients are checked for residual tumour masses by X-ray, CT scan 
or MRI [77]. However, 2-3% of type II TGCT patients remain AFP, LDH or HCG-positive 
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and / or show relapse shortly or even ≥ 2 years after therapy [78]. Patients with tumours 
resistant to standard therapeutic approaches should be included in clinical trials for 
individualized therapy and next-generation drugs. 
 
1.6. Epigenetic therapies as alternative treatment option 
The principles of epigenetics were first described by Conrad H. Waddington in 1956, 
when he demonstrated acquisition of the bithorax phenotype in a population of 
Drosophila melanogaster in response to an environmental stimulus [79, 80]. Today, it 
is well-established that certain phenotypic changes do not involve alterations of the 
primary DNA sequence, but can solely be explained by chemical modifications on the 
DNA or on those proteins responsible for DNA compaction (histones) (Fig. 6) [79]. 
These chemical modifications (i.e. DNA methylation, histone acetylation, histone 
methylation) alter the accessibility of DNA and therefore may ultimately result in 
changes in gene expression [79]. Epigenetic modifications are carried out by three 
different classes of enzymes (I-III): writers (I), readers (II) and erasers (III) [79] (Fig. 6). 
Writers add chemical modifications to histones tails or DNA, erasers remove these 
modifications and readers recognize and bind these modifications in order to recruit 
other components of the transcriptional machinery to shut on or to shut off gene 
expression [79].  
  
 
Figure 6: The chromatin landscape. Modified from [79] 
Silent or condensed chromatin is called heterochromatin. In this state of compaction the DNA is highly 
methylated and histones are deacetylated. Active or open chromatin is called euchromatin. In this state 
DNA is unmethylated and histones are highly acetylated. DNA methylation is carried out by de novo 
methyltransferases (DNMTs) and erased by ten-eleven translocation (TET) enzymes. Histone 
acetylation is carried out by histone acetyltransferases (HATs), erased by histone deacetylases 
(HDACs) and recognized or ‘read’ by bromodomain (BRD) proteins. 
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1.6.1. HDAC inhibitors 
Histone deacetylases (HDACs) are important players of the epigenetic machinery. 
These enzymes remove acetyl groups from histone tails, thus producing hypo-
acetylated chromatin regions [79]. In contrast, histone acetyl transferases (HATs) add 
acetyl groups to histone tails, thus producing hyper-acetylated chromatin regions [79]. 
In general, hypo-acetylated regions mark transcriptionally silent chromatin, while 
hyper-acetylated regions mark transcriptionally active chromatin [81]. The balance 
between HDAC and HAT proteins fundamentally regulates chromatin state and 
compaction [81]. In humans, there are 18 HDAC proteins that can be categorized into 
four classes (Class I: HDAC1-3, HDAC8; Class II: HDAC4-7, HDAC9-10; Class III: 
SIRT1-7; Class IV: HDAC11) based on sequence similarity [79, 82]. 
Overrepresentation of a number HDAC proteins was shown to correlate with poor 
prognosis in cancer, for example in neuroblastoma (HDAC8, HDAC10), lung (HDAC1-
3, HDAC5, HDAC10), gastric (HDAC1-3, HDAC4, HDAC10) or liver cancer (HDAC1-
3, HDAC5, HDAC6) [82]. Due to the oncogenic role of HDAC proteins, a number of 
HDAC inhibitors (HDACi) have been developed for cancer therapy (Table 2). 
 
Table 2: Overview of selected HDAC inhibitors. From  [83] 
Class HDAC Inhibitor Target HDAC 
Class 
Clinical Status 
hydroxamic 
acids 
Trichostatin A 
SAHA 
Belinostat 
Panabinostat 
Givinostat 
Resminostat 
Abexinostat 
Quisinostat 
Rocilinostat 
Practinostat 
CHR-3996 
Pan 
Pan 
Pan 
Pan 
Pan 
Pan 
Pan 
Pan 
II 
I, II, IV 
I 
Preclinical 
approved for cutaneous T-cell lymphoma 
approved for peripheral T-cell lymphoma 
approved for multiple myeloma 
phase II clinical trials 
phase I and II clinical trials 
phase II clinical trial 
phase I clinical trial 
phase I clinical trial 
phase II clinical trial 
phase I clinical trial 
short chain 
fatty acids 
Valproic acid 
 
Butyric acid 
I, IIa 
 
I, II 
approved for epilepsia, bipolar disorders 
and migraine 
phase II clinical trials 
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Phenylbutyric acid I, II phase I clinical trials 
benzamides Entinostat 
Tacedinaline 
4SC202 
Mocetinostat 
I 
I 
I 
I, IV 
phase II clinical trials 
phase III clinical trial 
phase I clinical trial 
phase II clinical trials 
cyclic 
tetrapeptides 
Romidepsin I approved for cutaneous T-cell lymphoma 
sirtuins 
inhibitor 
Nicotinamide 
Sirtinol 
Cambinol 
EX-527 
all class III 
SIRT 1 and 2 
SIRT 1 and 2 
SIRT 1 and 2 
phase III clinical trial 
Preclinical 
Preclinical 
cancer preclinical, phase I and II clinical 
trials 
 
In general, HDAC inhibitors were shown to induce cell cycle arrest, apoptosis and / or 
differentiation in tumour cells [83]. These effects often could be enhanced when HDACi 
treatment was combined with already approved treatment regimens like the 
demethylating agent 5-aza-2’-deoxycytidine or the chemotherapeutic drugs 
bortezomib and cisplatin [83]. 
 
1.6.2. BET inhibitors 
The Bromo- and Extra-Terminal domain (BET) family belongs to the class of epigenetic 
readers or BRD proteins [79]. Members of this family include BRD2, BRD3, BRD4 and 
BRDT [84]. BRD proteins recognize acetylated lysine chains on histone tails and 
thereby shape the transcriptome either directly or indirectly by interaction with other 
chromatin-remodelling enzymes or transcriptional co-factors [85]. Similar to HDACs, 
also the malfunction of BRD proteins has been implicated in cancer development. It 
was demonstrated that the development of NUT-midline carcinoma underlies an 
oncogenic fusion of nuclear protein in testis (NUT) with the BRD4 reader protein [86]. 
Similarly, BRD4 was shown to be an important driver of MYC expression, an oncogene 
which is frequently upregulated in cancer [87-89]. In ESCs BRD4 is required for 
pluripotency regulation and maintenance [1, 90, 91]. To date, a number of BET 
inhibitors (BETi) have been developed for cancer therapy, which have reached clinical 
trials [79, 92] (Table 3). In general, these BETi have shown to induce growth arrest 
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and apoptosis in different tumour settings [93-96]. In particular, BETi mediate anti-
tumoural effects by disruption of BRD4 occupancy at super-enhancers that feature key 
oncogenic drivers, such as MYC [79, 97]. To date, there is a number of pre-clinical 
studies showing that BETi-mediated cytotoxicity can be synergistically enhanced by 
simultaneous administration of HDACi, providing a rationale for combination therapy 
[1, 95, 98]. 
 
Table 3: Overview of selected BET inhibitors. Modified from [92] 
BET Inhibitor Target BET Member Clinical Status 
ABBV-075 BRD2/3/4, BRDT I 
CPI-0610 BRD4 I 
FT-1101 BRD2/3/4, BRDT I 
GSK525762/I-
BET762 
BRD2/3/4, BRDT I/II 
GSK2820151/I-
BET151 
BRD2/3/4 I 
OTX015/MK-8628 BRD2/3/4 I 
PLX51107 BRD4 I 
ZEN003694 BRD2/3/4, BRDT I 
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2. Materials and Methods 
 
2.1. Materials 
 
2.1.1. Mouse strains 
Mouse Strain Description Company 
Crl:NU-Foxn1nu Immunodeficient mouse. The animal lacks 
a thymus and is therefore unable to 
produce T-cells. 
Charles River Laboratories 
 
2.1.2. Cell lines 
Cell Line Standard Growth 
Medium 
Reference 
2102EP DMEM (+ 10% FBS, 
50 U/ml P/S, 2 mM L-
glutamine) 
Prof. Dr. L. Looijenga, Erasmus MC, Daniel den Hoed Cancer 
Center, Josephine Nefkens Institute, Rotterdam, Netherlands 
2102EP-R DMEM (+ 10% FBS, 
50 U/ml P/S, 2 mM L-
glutamine) 
Dr. F. Honecker, Breast and Tumor Center, ZeTup 
Silberturm, St Gallen, Switzerland 
FS1 DMEM (+ 20% FBS, 
50 U/ml P/S, 2 mM L-
glutamine, 1x NEAA) 
Dr. Valerie Schumacher, Nephrology Research Center, 
Boston, USA 
HEK-293T DMEM (+ 10% FBS, 
50 U/ml P/S, 2 mM L-
glutamine) 
Dr. Michael Peitz, Bonn University, Institute of Reconstructive 
Neurobiology, Bonn, Germany 
MPAF DMEM (+ 10% FBS, 
50 U/ml P/S, 2 mM L-
glutamine, 1x NEAA) 
Dr. Michael Peitz, Bonn University, Institute of Reconstructive 
Neurobiology, Bonn, Germany 
NCCIT DMEM (+ 10% FBS, 
50 U/ml P/S, 2 mM L-
glutamine) 
Prof. Dr. L. Looijenga, Erasmus MC, Daniel den Hoed Cancer 
Center, Josephine Nefkens Institute, Rotterdam, Netherlands 
NCCIT-R DMEM (+ 10% FBS, 
50 U/ml P/S, 2 mM L-
glutamine) 
Dr. F. Honecker, Breast and Tumor Center, ZeTup 
Silberturm, St Gallen, Switzerland 
NT2/D1 DMEM (+ 10% FBS, 
50 U/ml P/S, 2 mM L-
glutamine) 
Prof. Dr. L. Looijenga, Erasmus MC, Daniel den Hoed Cancer 
Center, Josephine Nefkens Institute, Rotterdam, Netherlands 
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NT2/D1-R DMEM (+ 10% FBS, 
50 U/ml P/S, 2 mM L-
glutamine) 
Dr. F. Honecker, Breast and Tumor Center, ZeTup 
Silberturm, St Gallen, Switzerland 
TCam-2 RPMI (+ 10% FBS, 50 
U/ml P/S, 2 mM L-
glutamine) 
Dr. Janet Shipley, Institute of Cancer Research, Sutton, 
England 
 
2.1.3. Chemicals and reagents 
(2-Hydroxypropyl)-β-cyclodextrin (HP-β-CD) Sigma-Aldrich, St. Louis, USA 
6-Diamidino-2-phenylindole dihydrochloride 
(DAPI) 
AppliChem, Darmstadt, Germany 
Acetic acid AppliChem, Darmstadt, Germany 
Acrylamide Mix Roth, Karlsruhe, Germany 
Ammonium persulfate (APS) Carl Roth, Karlsruhe, Germany 
Bovine Serum Albumin (BSA) Sigma-Aldrich, München, Germany 
Coomassie Brilliant Blue Biomol, Hamburg, Germany 
Diagenode Crosslink Gold Diagenode 
Dimethylsulfoxide (DMSO) Sigma-Aldrich, München, Germany 
dNTPs Thermo Fisher Scientific, Waltham, USA 
Ethanol VWR, Darmstadt, Germany 
Ethylene diamine tetra acetic acid (EDTA) Sigma-Aldrich, München, Germany 
Formaldehyde (37 %) for ChIP AppliChem, Darmstadt, Germany 
Formaldehyde (4%) for immunofluorescence 
and immunohistochemistry 
Merck, Darmstadt, Germany 
JQ1 Jay Bradner, Dana Farber Institute, USA  
Methanol VWR, Darmstadt, Germany 
Oligonucleotide (Primer) Sigma-Aldrich, München, Germany 
PageRuler Prestained Protein Ladder Thermo Fisher Scientific, Waltham, USA 
Paraffin Wax Paraplast Plus McCormick Scientific, St Louis, USA 
Phosphate buffered saline (PBS) tablets  AppliChem, Darmstadt, Germany 
PMS Sigma-Aldrich, St. Louis, USA 
Ponceau S  Sigma-Aldrich, St. Louis, USA 
Propidium Idodide (PI) Sigma-Aldrich, St. Louis, USA 
RNAse A AppliChem, Darmstadt, Germany 
Romidepsin Celgene, Signal Pharmaceuticals, San Diego, USA 
Roti-Load (4× concentrated) Carl Roth, Karlsruhe, Germany 
Rotiphorese Gel 30 Carl Roth, Karlsruhe, Germany 
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Skimmed milk powder Nestle, Soest, Germany 
Sodium Chloride (NaCl) Merck, Darmstadt, Germany 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich, St. Louis, USA 
Tetramethylethylenediamine (TEMED) VWR, Darmstadt, Germany 
TG-SDS running buffer, 10× liquid 
concentrate 
Amresco, Solon, USA 
Tris-HCl Roth, Karlsruhe, Germany 
Triton X AppliChem, Darmstadt, Germany 
Tween 20 AppliChem, Darmstadt, Germany 
XTT (sodium salt) Sigma-Aldrich, St. Louis, USA  
β-Mercaptoethanol Sigma-Aldrich, St. Louis, USA 
 
 
2.1.4. Kits 
Alkaline Phosphatase Detection Kit Merck, Darmstadt, Germany 
BCA protein assay kit Thermo Fisher Scientific, Waltham, USA 
Dynabeads® Protein G Thermo Fisher Scientific, Waltham, USA 
Genomeplex® Single Cell Whole Genome 
Amplification Kit (WGA4) 
Sigma-Aldrich, St. Louis, USA 
Maxima First Strand cDNA synthesis Kit Thermo Fisher Scientific, Waltham, USA 
Maxima SYBR Green Master Mix Thermo Fisher Scientific, Waltham, USA 
PE Annexin V Apoptosis Detection Kit I  BD Biosciences, Heidelberg, Germany 
ProFection® Mammalian Transfection 
System 
Promega, Mannheim, Germany 
RNeasy Mini Kit Qiagen, Hilden, Germany 
Simple ChIP® Enzymatic Chromatin IP Kit 
(Magnetic Beads) 
Cell Signaling Technology, Danvers, USA 
SuperSignal West Pico Chemiluminescent 
Substrate 
Thermo Fisher Scientific, Waltham, USA 
TruSeq ChIP Library Preparation Kit Illumina, San Diego, USA 
 
2.1.5. Buffers and recipes 
1 × Western blot transfer buffer 700 ml H2O, 200 ml methanol, 100 ml 10× Western 
blot transfer buffer 
10 × Western blot transfer buffer 24.2 g Tris base, 144.1 g glycine, 5 ml 20 % SDS, 
H2O ad 1 l 
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12% SDS Gel 12% Separation Gel: 1.6 ml H2O, 2.0 ml 
Rotiphorese Gel 30, 1.3 ml 1.5 M Tris (pH 8.8), 50 
µl 10% SDS, 50 µl 10% APS, 2 µl TEMED 
Stacking Gel: 2.1 ml H2O, 500 µl Rotiphorese Gel 
30, 380 µl 1.0 M Tris (pH 6.8), 30 µl 10% SDS, 30 
µl 10% APS, 3 µl TEMED 
Coomassie Brilliant Blue staining solution 0.25 g Coomassie Brilliant Blue,  10 ml acetic acid, 
45 ml MetOH, 45 ml H2O 
Coomassie destaining solution 10 ml acetic acid, 45 ml MetOH, 45 ml H2O 
Low pH glycine buffer 100 mM Glycine pH 2.5 (adjusted with HCl) 
PBST 1 PBS Tablet, 1000 ml H2O, 1 ml Tween 20 
Ponceau S staining solution 0.5 g Ponceau S, 5 ml acetic acid, H2O ad 500 ml 
RIPA buffer 10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 1% Triton X-
100, 0.1% sodium deoxycholate, 0.1% SDS, 140 
mM NaCl, 1 mM  phenylmethylsulfonyl fluoride 
Western blot stripping buffer 5 ml 20 % SDS, 3.125 ml 1 M Tris (pH 8.8), 390 µl 
β-Mercaptoethanol, H2O ad 50 ml 
 
2.1.6. Consumables 
1.5 ml microcentrifuge tube Sarstedt, Nümbrecht, Germany 
100 µl PCR reaction tubes Axygen, California, USA 
2 ml microcentrifuge tube Sarstedt, Nümbrecht, Germany 
384-well PCR plates for qRT-PCR 4titude, Wotton, United Kingdom 
96-well plates BD Biosciences, Le Pont de Claix, France 
Blotting papers Macherey-Nagel, Düren, Germany 
Cell culture dishes and plates TPP, Trasadingen, Austria 
FACS tubes BD Biosciences, Heidelberg, Germany 
Falcon tubes (15 ml and 50 ml) Greiner, Kremsmünster, Austria 
Filter tips (10 µl, 100 µl, 200 µl, 1000 µl) Nerbe Plus, Winsen/Luhe, Germany 
Parafilm M Pechiney Plastic Packaging, Chicago, USA 
Pipette tips (10 µl, 100 µl, 200 µl, 1000 µl) Greiner Bio-One, Kremsmünster, Austria 
Pipette tips (filtered) Nerbe Plus, Winsen, Germany 
qPCR seals 4titude, Wotton, United Kingdom 
Roti-PVDF membrane Carl Roth, Karlsruhe, Germany 
Steri-pipette Corning, Amsterdam, Netherlands 
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2.1.7. Cell culture accessories 
0.05 % Trypsin-EDTA Thermo Fisher Scientific, Waltham, USA 
Advanced DMEM Thermo Fisher Scientific, Waltham, USA 
Dulbecco's Modified Eagle Medium (DMEM) Thermo Fisher Scientific, Waltham, USA 
Fetal bovine serum (FBS) Sigma-Aldrich, St. Louis, USA 
FuGene® HD Transfection Reagent Promega, Mannheim, Germany 
Hygromycin B Santa Cruz, Dallas, Texas 
L-Glutamine Thermo Fisher Scientific, Waltham, USA 
Matrigel Matrix Corning, Corning, USA 
MEM Non-Essential Amino Acids Solution 
(NEAA) 
Thermo Fisher Scientific, Waltham, USA 
Penicillin/Streptomycin (P/S) Thermo Fisher Scientific, Waltham, USA 
Phosphate Buffered Saline (PBS) Thermo Fisher Scientific, Waltham, USA 
Poly-l-lysine Thermo Fisher Scientific, Waltham, USA 
RPMI 1640 Medium (RPMI) Thermo Fisher Scientific, Waltham, USA 
 
2.1.8. Equipment 
Autostainer 480 S Thermo Fisher Scientific, Waltham, USA 
Balance PT 120 Sartorius, Göttingen, Germany 
BioAnalyser 2100 Agilent Technologies, Santa Clara, USA 
Blot documentation ChemiDoc MP Bio-Rad Laboratories, Hercules, USA 
Centrifuge 5415 D Eppendorf, Hamburg, Germany 
Centrifuge 5417 R Eppendorf, Hamburg, Germany 
Centrifuge Biofuge fresco Thermo Fisher Scientific, Waltham, USA 
Centrifuge Galaxy mini VWR, Darmstadt, Germany 
Centrifuge Megafuge 1.0 Thermo Fisher Scientific, Waltham, USA 
Centrifuge Multifuge 3SR Thermo Fisher Scientific, Waltham, USA 
Cool centrifuge Eppendorf AG, Hamburg, Germany 
Electrophoresis power supply EV243 PEQLAB, Erlangen, Germany 
FACS CantoTM BD Biosciences, Heidelberg, Germany 
Illumina High Seq 2500 Illumina, San Diego, USA 
Illumina Human HT-12 v4 Bead Chip Illumina, San Diego, USA 
iMark Microplate Absorbance Reader Bio-Rad Laboratories, Hercules, USA 
Incubator Cytoperm2 Thermo Fisher Scientific, Waltham, USA 
Incubator Heracell 240i Thermo Fisher Scientific, Waltham, USA 
Leitz Labovert cell culture microscope Leica Microsystems, Wetzlar, Germany 
Magnetic separation rack Active Motif, La Hulpe, Belgium 
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Microscope Axiovert 40 C Carl Zeiss, Oberkochen, Germany 
Microscope DM IRB Leica Microsystems, Wetzlar, Germany 
Microscope Labovert FS Leica Microsystems, Wetzlar, Germany 
Microwave NN 5256 Panasonic, Wiesbaden, Germany 
Nano Drop 1000 Spectrophotometer Thermo Fisher Scientific, Waltham, USA 
Orbital shaker 3005 Gesellschaft für Labortechnik, Burgwedel, Germany 
PCR machine PTC-200 MJ Research, Waltham, USA 
Pipette controller accu-jet BRAND, Wertheim, Germany 
Pipette Set Research Eppendorf AG, Hamburg, Germany 
Power Supply Consort E143 Sigma-Aldrich, München, Germany 
Real-Time PCR ViiA7 Thermo Fisher Scientific, Waltham, USA 
Sample mixer HulaMixer Thermo Fisher Scientific, Waltham, USA 
SDS-Page electrophoresis chamber Mini-
PROTEAN Tetra Cell 
Bio-Rad Laboratories, Hercules, USA 
Shaking incubator Innova 4000 Eppendorf, Hamburg, Germany 
Sterile workbench BSB 6A Gelaire, Sydney, Australia 
Sterile workbench Herasafe Thermo Fisher Scientific, Waltham, USA 
Thermal cycler 2720 Thermo Fisher Scientific, Waltham, USA 
Thermomixer compact Eppendorf AG, Hamburg, Germany 
Tissue-Tek® VIP Sakura Finetek Europe B.V., Alphen aan den Rijn, 
Netherlands 
Trans Blot Turbo blotting chamber Bio-Rad Laboratories, Hercules, USA 
Ultrasonic bath Bioruptor Diagenode, Seraing, Belgium 
Vortex mixer Bio Vortex V1 PEQLAB, Erlangen, Germany 
Vortex mixer Top-Mix 94323 Heidolph Instruments, Schwabach, Germany 
Waterbath TW8 Julabo, Seelbach, Germany 
 
2.1.9. Antibodies 
 
Primary antibodies 
Antibody Application Company # Number 
BRD2 Western Blot Sigma Aldrich HPA042816 
BRD3 Western Blot AbCam ab50818 
BRD4 Western Blot Active Motif 39909 
CD31 Immunohistochemistry PECAM SZ31 
Cleaved PARP Western Blot AbCam ab4830 
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GATA3 Immunofluorescence Santa Cruz sc268 
GDF3 Western Blot AbCam ab38547 
Goat IgG ChIP Santa Cruz sc2028 
HDAC1 Western Blot Santa Cruz sc81598 
Ki67 Immunohistochemistry Dako MIB-1 
LIN28A Western Blot R&D AF3757 
MYC Western Blot Cell Signaling 5605 
NANOG Western Blot Santa Cruz sc134218 
OCT3/4 (C-10) Western Blot, 
Immunofluorescence, co-IP 
Santa Cruz sc5279 
Rabbit IgG ChIP Cell Signaling 2729 
SOX17 ChIP, Western Blot R&D AF1924 
SOX2 ChIP AbCam ab59776 
SOX2 Western Blot R&D MAB2018 
TFAP2C Western Blot, 
Immunofluorescence 
Santa Cruz sc8977 
β-ACTIN Western Blot Sigma Aldrich a5441 
 
Secondary antibodies 
Antibody Application Company # Number 
Alexa-Fluor anti-goat 
secondary antibody 
Immunofluorescence Thermo Fisher 
Scientific 
A11055 
Alexa-Fluor anti-mouse 
secondary antibody 
Immunofluorescence Thermo Fisher 
Scientific 
A11005 
Alexa-Fluor anti-mouse 
secondary antibody 
Immunofluorescence Thermo Fisher 
Scientific 
A11037 
HRP-conjugated anti-
goat secondary antibody 
Western Blot Dako P0160 
HRP-conjugated anti-
mouse secondary 
antibody 
Western Blot Dako P0260 
HRP-conjugated anti-
rabbit secondary 
antibody 
Western Blot Dako P0448 
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2.1.10. qRT-PCR primers 
Target Gene Forward (5’->3’) Reverse (5’->3’) 
ALPL AACATCAGGGACATTGACGTG GTATCTCGGTTTGAAGCTCTTCC 
ATF3 AAGAACGAGAAGCAGCATTTGAT TTCTGAGCCCGGACAATACAC 
BRD2 CTACGTAAAGAAACCCCGGAAG GCTTTTTCTCCAAAGCCAGTT 
BRD3 CCTCAGGGAGATGCTATCCA ATGTCGTGGTAGTCGTGCAG 
BRD4 AGCAGCAACAGCAATGCTGAG GCTTGCACTTGTCCTCTTCC 
BRDT GCTCGGACACAGGAACTCATACG CCACCATTGCTTCTCTCCTCCTC 
CDKN1C GCGGCGATCAAGAAGCTGT GCTTGGCGAAGAAATCGGAGA 
CDX2 TTCCCATCTGGCTTTTTCTG AGAGAAGAGCTGGGGAGGAG 
EOMES CGGCCTCTGTGGCTCAAA AAGGAAACATGCGCCTGC 
GAPDH TGCCAAATATGATGACATCAAGAA GGAGTGGGTGTCGCTGTTG 
GATA3 TCTGACCGAGCAGGTCGTA CCTCGGGTCACCTGGGTAG 
HAND1 AATCCTCTTCTCGACTGGGC TGAACTCAAGAAGGCGGATG 
KIT CGTTCTGCTCCTACTGCTTCG CCCACGCGGACTATTAAGTCT 
LIN28 TGTAAGTGGTTCAACGTGCG TGTAAGTGGTTCAACGTGCG 
NANOG GATTTGTGGGCCTGAAGAAA AAGTGGGTTGTTTGCCTTTG 
NANOS3 ACAAGGCGAAGACACAGGAC AGGTGGACATGGAGGGAGA 
POU5F1 GGGAGATTGATAACTGGTGTGTT GTGTATATCCCAGGGTGATCCTC 
PRDM1 GGGTGCAGCCTTTATGAGTC CCTTGTTCATGCCCTGAGAT 
PRDM14 ACACGCCTTTCCCGTCCTA GGGCAGATCGTAGAGAGGCT 
RHOB GGGACAGAAGTGCTTCACCT CGACGTCATTCTCATGTGCT 
SOX17 GATGCGGGATACGCCAGTGAC GCTCTGCCTCCTCCACGAAG 
SOX2 ATGCACCGCTACGACGTGA CTTTTGCACCCCTCCCATT 
SPRY4 TCTGACCAACGGCTCTTAGAC GTGCCATAGTTGACCAGAGT 
TFAP2C CCCACTGAGGTCTTCTGCTC AGAGTCAC ATGAGCGGCTTT 
THY1 ATCGCTCTCCTGCTAACAGTC CTCGTACTGGATGGGTGAACT 
αHCG GTGCAGGATTGCCCAGAAT CTGAGGTGACGTTCTTTTGGA 
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2.1.11. Primers for ChIP validation 
Name Forward Reverse Reference 
DPPA4 ACCCAGACAAAAGTCAC
CCC 
AAGTCTCCTCCCACTTCC
TG 
[99] 
LEFTY2 TCTCCACTCAGACCCTC
AGA 
GGCAGCCTGAAGAGTTT
TGT 
[99] 
LIN28A GGGTTGGGTCATTGTCT
TTTAG 
AAAGGGTTGGTTCGGAG
AAG 
[100] 
NANOG GCTCGGTTTTCTAGTTCC
CC 
CCCTACTGACCCACCCT
TG 
[3] 
PRDM1 GAGAAGCAGGAATGCAA
GGTC 
GGTCGGAGGCAGTAATT
AGTGG 
[101] 
PRDM14 CCTAGACTGAGGCTCGT
TACT 
ATGCCTGCCTATTGATGA
GC 
[99] 
SOX2 GGATAACATTGTACTGG
GAAGGGACA 
CAAAGTTTCTTTTATTCG
TATGTGTGAGCA 
[102] 
 
2.1.12. Plasmids 
Name Purpose gRNA Sequence 
(5’→3’) 
Reference 
Lenti-SAMv2 Transcriptional activation 
of endogenous genes 
- Addgene number: 75112 
MS2-P65-
HSF1_Hygro 
Transcriptional activation 
of endogenous genes 
(see Lenti-SAMv2) 
- Addgene number: 61426 
pEGFP-N3 GFP expressing control 
vector 
- Clontech number: 6080-1 
pMD2.G envelope expressing 
plasmid for lentiviral 
production 
- Addgene number: 12259 
psPAX2 gag / pol expressing 
plasmid for lentiviral 
production 
- Addgene number: 12260 
PX330-
SOX17gRNA1 
SOX17 Knockout in 
TCam-2 cells (backbone: 
PX330-U6-Chimeric_BB-
CBh-hSpCas9) 
ACGGGTAGCCGTC
GAGCGG 
Cloned from addgene 
number: 42230 
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PX330-
SOX17gRNA2 
SOX17 Knockout in 
TCam-2 cells (backbone: 
PX330-U6-Chimeric_BB-
CBh-hSpCas9) 
GGCACCTACAGCT
ACGCGC 
 
 
Cloned from addgene 
number: 42230 
SOX17 SAM 
gRNA1 
SOX17 Overexpression in 
NCCIT cells (backbone: 
Lenti-SAMv2) 
CTGCCCCCGGGAA
AACTAGC 
Cloned from addgene 
number: 75112 
SOX17 SAM 
gRNA2 
SOX17 Overexpression in 
NCCIT cells (backbone: 
Lenti-SAMv2) 
GTGGGGTTGGACT
GGGACGT 
Cloned from addgene 
number: 75112 
 
2.1.13. Software and databases 
Name Purpose Reference 
CRISPR.mit.edu CRISPR design tool, selection of 
gRNAs and off-target prediction 
http://crispr.mit.edu 
Note: this tool is not available any more 
Ensembl Analysis and visualization of 
genomic data 
http://www.ensembl.org/ 
Genetrail 2 (1.6) Statistical analysis of molecular 
signatures (i.e. Gene Ontology, 
KEGG Pathways) 
https://genetrail2.bioinf.uni-sb.de/ 
 
Graphpad Prism 
version 5.03 for 
Windows 
Customization and design of 
graphs, bar charts and scatter 
plots 
San Diego, California, USA 
HOMER Motif 
Analysis 
Motif discovery and next 
generation sequencing analysis 
for ChIP-seq 
http://homer.ucsd.edu/homer/ 
[103] 
Illustrator CS3 for 
Windows 
Graphics illustration and design 
tool 
Adobe, San Jose, CA, USA 
ImageJ Analysis and graphical illustration 
of immunohistochemical stainings 
http://imagej.nih.gov/ij/ 
Molecular 
Signatures 
Database 
(MiSigDB) 
Compute overlap with other gene 
sets by gene set enrichment 
analysis 
http://software.broadinstitute.org/gsea/msi
gdb/ 
NCBI Collection of biomedical and 
genomic information 
http://www.ncbi.nml.nih.gov/ 
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Papers 3.257 for 
Windows 
Reference software Mekentosj B.V., Dordrecht, Netherlands 
Serial Cloner 2.6 
for Windows 
Provides assistance for DNA 
cloning and vector mapping 
http://serialbasics.free.fr/Serial_Cloner.ht
ml/ 
STRING Analyse and predict protein-
protein interactions 
https://string-db.org 
Venny 2.1 Create Venn diagram 
representing the overlap of 
different datasets 
http://bioinfogp.cnb.csic.es/tools/venny/ 
[104] 
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2.2. Molecular biological methods 
 
2.2.1. Standard cell culture conditions 
Cells were grown at 37°C and 7.5% CO2 and passaged two times / week in order to 
keep sub-confluent conditions. For passaging, cells were washed with PBS and 
incubated with 0.05% Trypsin-EDTA for 3-5 min at 37°C. Trypsin was inactivated by 
addition of standard growth medium. One part of the cell suspension was then 
transferred into a new cell culture flask containing fresh standard growth medium. 
 
2.2.2. Transfection 
24 h prior to transfection, cells were seeded at a defined cell number in 6-well plates. 
Transfection mixtures were prepared using FuGene® HD Transfection Reagent in a 
1:5 ratio (1 µg DNA, 5 µl FuGene) in 100 µl standard growth medium (w/o P/S, w/o 
FBS, w/o L-glutamine) and incubated for 15 min. Cells were supplemented with fresh 
standard growth medium (w/o P/S) and the transfection mix was added for overnight 
incubation. Next day, cells were washed 1x with PBS and supplemented with fresh 
complete standard growth medium.  
 
2.2.3. Protein isolation 
For protein isolation, cells were harvested using 0.05% Trypsin-EDTA and cell 
suspension was pelleted by centrifugation at 12.000 rpm for 5 min. To remove residual 
media components the cell pellet was washed 1x with PBS and then resuspended in 
1x RIPA buffer for protein isolation. The protein lysate was incubated for 10 min on ice 
and then pelleted by centrifugation at 10.000 rpm for 10 min at 4°C. The supernatant 
was stored at -20°C or -80°C. 
 
2.2.4. Western blot analysis 
Prior to Western blot analysis, protein concentrations were determined using the BCA 
protein assay kit. Typically, 20 µg protein (diluted in 1 x Roti-load) were loaded per lane 
on a 12% SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) gel 
together with PageRuler Prestained Protein Ladder and separated by electrophoresis. 
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Proteins were then transferred onto a Roti-PVDF membrane in 1 x Western blot 
transfer buffer using the semi-dry Trans Blot Turbo blotting chamber. Successful 
transfer was confirmed by staining with Ponceau S or Coomassie Brilliant Blue staining 
solution. Membranes were rinsed in distilled H2O or destained using Coomassie 
destaining solution and then blocked in 5% skimmed milk powder / BSA in PBST. 
Membrane was then incubated with primary antibody overnight at 4°C or for 3 hours 
at room temperature. Membrane was then washed 3x in PBST and incubated with 
HRP-conjugated secondary antibody either overnight at 4°C or for 1 hour at room 
temperature. After three additional washing steps in PBST, signal was detected using 
SuperSignal West Pico Chemiluminescent Substrate on a Blot documentation 
ChemiDoc MP. For detection of a second protein, membrane was afterwards 
incubated with 1 x Western blot stripping buffer for 25 min at 65°C to remove bound 
antibodies. The membrane was then washed once in PBST and again processed as 
described above.   
 
2.2.5. Co-immunoprecipitation 
For co-immunoprecipitation (co-IP), typically 50 µl (= 1.5 mg) of Dynabeads® Protein 
G were coated with 10 µg of primary antibody, according to the manufacturer’s 
instructions. After washing the beads-antibody complex with PBS pH 7.4 (+0.02% 
Tween 20) 1 mg of whole protein lysate were added and incubated with the beads 
under constant rotation for 30 min at room temperature. After three washing steps, the 
beads-antibody-antigen complexes were eluted in 15 µl low pH glycine buffer + 5 µl 
Roti-Load for 5 min at 95 °C. The beads were then separated from the antibody-antigen 
complex in a magnetic rack and the clear supernatant was loaded on a 12% SDS-
PAGE gel for visualization. 20 µg protein lysate served as 2% input sample. 
 
2.2.6. RNA isolation 
For RNA isolation, cells were harvested using 0.05% Trypsin-EDTA and cell 
suspension was pelleted by centrifugation at 12.000 rpm for 5 min. To remove residual 
media components the cell pellet was washed 1x with PBS and then RNA was isolated 
using the RNeasy Mini Kit. RNA concentration and purity was assessed using a Nano 
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Drop 1000 Spectrophotometer. A 260/280 nm ratio of 1.8-2.2 was generally accepted 
as ‘pure’ for RNA. 
 
2.2.7. cDNA synthesis and qRT-PCR 
Typically, 500 ng of total RNA were reverse-transcribed into complementary DNA 
(cDNA) using the Maxima Reverse Transcriptase Kit according to the instructions 
specified by the manufacturer. For qRT-PCR, 7.58 ng of cDNA were pipetted in 
technical triplicates with Maxima SYBR Green qPCR Master Mix. For qRT-PCR primer 
details, see 2.1.10. qRT-PCR was performed using the ViiA7 RealTime PCR System. 
Quantitative values were obtained from the Ct and GAPDH was used as housekeeping 
gene. 
 
2.3. JQ1 Project 
 
2.3.1. JQ1 treatment of cell lines 
For JQ1 treatment, cells were seeded at a defined cell number in 6-well plates. After 
24 hours cells were treated with 100, 250 or 500 nM of JQ1 dissolved in DMSO. As 
negative control, cells were treated with equal amounts of DMSO only. 
 
2.3.2. AnnexinV-7-AAD FACS 
For AnnexinV-7AAD FACS, cells were washed with PBS and then harvested using 
0.05% Trypsin-EDTA. Cells were collected in FACS tubes and then stained with PE 
Annexin V and 7-AAD using the PE Annexin V Apoptosis Detection Kit I. Samples were 
measured in a FACS CantoTM. 
 
2.3.3. PI-FACS 
For PI FACS analysis, cells were washed with PBS, harvested using 0.05% Trypsin-
EDTA and collected in a 1.5 ml microcentrifuge tube. Cells were then pelleted by 
centrifugation for 3 min at 5000 rpm. Then, cells were washed with PBS and again 
pelleted for 3 min at 5000 rpm. The remaining pellet was resuspended in 300 µl PBS 
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and 700 µl ice-cold methanol was added dropwise for fixation, while gently vortexing. 
The samples were either stored at -80 °C or further processed for FACS analysis. For 
this, samples were again centrifuged for 3 min at 5000 rpm and the resulting pellet was 
resuspended in 1 ml of DNA staining solution (2.5 µg / ml PI + 0.5 mg / ml RNAse A) 
in PBS. Cells were stained for 15 min in the dark and then measured using a FACS 
CantoTM. 
 
2.3.4. XTT assay 
The effects of JQ1 and romidepsin treatment on cell viability and cell proliferation were 
determined by XTT assay. For this, cells were seeded into 96-well plates at a density 
of 3000 cells / well in 80 µl standard growth medium. The next day different 
concentrations of JQ1 and / or romidepsin were added in 20 µl standard growth 
medium. After 24 / 48 / 72 / 96 hours of treatment 50 µl XTT medium (1 mg / ml in 
standard growth medium) + 1 µl PMS (1.25 mM in PBS) were added to each well. 
Absorbance was measured 4 hours later in an iMark microplate absorbance reader 
(450 nm vs. 650 nm). Samples were measured in four technical replicates. 
 
2.3.5. Illumina humanHT-12 v4 expression array 
For Illumina HumanHT-12 v4 microarray analysis, total RNA was extracted and RNA 
quality was assessed by gel electrophoresis in a BioAnalyser 2100. Samples were 
processed by the Institute for Human Genetics, Bonn, Germany, and measured on an 
Illumina Human HT-12 v4 Bead Chip. Bioinformatic analysis and data normalization 
was done by Andrea Hofman, Institute for Human Genetics, Bonn, Germany. 
 
2.3.6. JQ1 treatment of TGCT-xenografted nude mice 
For xenotransplantation 1 x 107 cells were resuspended in 500 μl of 4°C cold Matrigel 
and injected into the flank of Crl:NU-Foxn1nu mice. During the procedure, samples 
were kept on ice at all times to avoid hardening of Matrigel. Tumours were then grown 
for 2 weeks. Afterwards, mice were treated with JQ1 (+ Romidepsin) to analyse drug 
efficacy in vivo. JQ1 was administered at a dosage of 50 mg / kg on 5 days / week 
intraperitoneally. 10% HP-β-CD solution was used as a vehicle in order to improve 
drug solubility. For combination treatment, mice were injected intraperitoneally with 50 
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mg / kg JQ1 + 0.5 mg / kg romidepsin 3 days / week in 10% HP-β-CD solution. As 
control, mice were injected with solvent only. Injection volume was 10 µl / g of body 
weight. Tumour burden was continuously measured using a calliper. 
 
2.3.7. Tumour dissection for IHC staining 
Tumours were dissected at defined time points and fixed in 4% formaldehyde at 4°C 
overnight. Afterwards tissues were processed in paraffin wax using a Tissue-Tek® VIP. 
For immunohistochemistry, 4 µm sections were cut from embedded tissues and then 
stained in-house using a semi-automatic Autostainer 480 S. Antibody details are given 
in 2.1.9. Ki67 and CD31 stainings were quantified from three individual tumours and 
significance was calculated using a two-tailed t-test. 
 
2.4. Identification of SOX2 and SOX17 targets in TGCT cells 
 
2.4.1. Fixation and chromatin preparation 
For ChIP qPCR chromatin was prepared from 1 x 107 cells / IP. For this, cells were 
fixed in 15 cm cell culture dishes for 30 min at room temperature using Diagenode 
Crosslink Gold. After two washing steps with PBS cells were fixed again for 10 min in 
1% formaldehyde (in PBS). For ChIP-seq analysis cells were fixed for 10 min in 1% 
formaldehyde (in PBS) only. Crosslinking of proteins to DNA is a critical step, since 
poor crosslinking results in low yield, while over-fixation will reduce shearing efficiency 
and negatively affect the reverse cross-linking procedure. 
 
2.4.2. Chromatin immunoprecipitation (ChIP) 
Chromatin immunoprecipitation was typically carried out using 200 µg chromatin lysate 
and 5 µg antibody. The protocol was then performed using the Simple ChIP® 
Enzymatic Chromatin IP Kit. 2% Input (= 2 µg chromatin) and IgG-IP served as 
controls. For verification of successful chromatin immunoprecipitation 10 µl of IP 
samples were amplified using the Genomeplex® Single Cell Whole Genome 
Amplification Kit (WGA4) and subjected to qPCR. Primers were selected according to 
already published information on SOX2-OCT4 binding sites, see 2.1.11. 
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2.4.3. ChIP-sequencing and bioinformatics analysis 
ChIP-seq libraries were generated and processed by Microsynth (Microsynth AG, 
Balgach, Switzerland). Libraries were prepared using the TruSeq ChIP Library 
Preparation Kit. Samples were sequenced on the Illumina High Seq 2500 using 30 M 
single-end reads (1 x 75 bp). Reads were mapped to the human genome (hg38) and 
data was analysed using HOMER (Hypergeometric Optimization of Motif EnRichment) 
Software (http://homer.ucsd.edu/homer/). Peak count frequency was analysed with 
help of the Core Unit for Bioinformatics Analysis, Bonn. 
 
2.4.4. SOX17-knockout in TCam-2 cells 
For the generation of TCam-2 Δ SOX17 cells, TCam-2 cells were transfected with 250 
ng PX330-SOX17gRNA1 + 250 ng PX330-SOX17gRNA2 using FuGENE® HD 
transfection reagent in a 1:5 ratio (= 1 µg DNA : 5 µl FuGENE reagent). SOX17 single 
guide RNAs (gRNAs) were designed and selected using the CRISPR.mit.edu tool. As 
control, cells were transfected with 500 ng pEGFP-N3. 
 
2.4.5. Immunofluorescence 
For immunofluorescence, cells were typically grown in 12-well or 24-well plates. At the 
desired time point, cells were washed with PBS and then fixed in 4% formaldehyde for 
10 min at room temperature. Afterwards, cells were permeabilized using 0.5% Triton 
X diluted in PBS for 5 min at room temperature. After two washing steps in PBS, cells 
were blocked in 2% BSA diluted in PBS for 1 hour at room temperature. Afterwards, 
cells were incubated with primary antibody diluted in blocking solution (500 µl for 12-
well plate, 250 µl for 6-well plate) for 2 hours at room temperature or 4°C overnight. 
After three washing steps in PBS, cells were incubated with Alexa Fluor® secondary 
antibody diluted in blocking solution for 1 hour at room temperature or 4°C overnight. 
Again, cells were washed three times in PBS and then counterstained with DAPI in 
PBS for 5 min at room temperature. Cells were then washed three times in PBS and 
staining was evaluated under the fluorescent microscope. 
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2.4.6. Alkaline phosphatase staining 
Alkaline phosphatase (AP) staining can be used to discriminate pluripotent cells (AP-
positive) from differentiated cell types (AP-negative). For detection of AP activity, cells 
were typically seeded in 6-well plates. At the desired time point of analysis, cells were 
fixed for 1 min in 4% formaldehyde and stained for AP activity using the Alkaline 
Phosphatase Detection Kit. AP-expressing cells will appear red-violet, while AP-
negative cells appear colourless.  
 
2.4.7. SOX17 overexpression in EC cells 
Overexpression of SOX17 in NCCIT cells was achieved using the CRISPR/Cas9 
Synergistic Activation Mediator (SAM) system that was established by the Zhang Lab 
[105]. It includes a catalytically inactive Cas9-VP46 fusion protein, the single guide 
RNA incorporating two MS2 RNA aptamers and a MS2-P65-HSF1 activation helper 
protein. For efficient overexpression two viral particles were generated: I) The MS2-
P65-HSF1 helper virus containing the HSF1 and P65 activation domains and II) the 
SOX17 SAM virus coding for the gRNA specific for the SOX17 upstream regulatory 
region and the Cas9-VP64 fusion protein.  
  
2.4.8. Virus production 
Lentiviral particles were generated using calcium-phosphate precipitation. For this, 
HEK-293T were seeded onto poly-l-lysine coated 10 cm dishes and medium was 
changed to Advanced DMEM containing 2% FBS. Transfection mixtures were 
prepared using the ProFection® Mammalian Transfection System according to the 
following scheme: 
 10 cm dish 
2 M CaCl2 61.5 µl 
Lentiviral Vector DNA 18.5 µg 
Helper DNA (psPAX2) 9.25 µg 
Envelope DNA (pMD2.g) 9.25 µg 
Fill up with H20 to 600 µl 
2x HBS Buffer 600 µl 
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Transfection mixtures were then added dropwise to ensure an even distribution on the 
plate. 5-6 hours later the medium was changed to Advanced DMEM containing 5% 
FBS. Next morning, the medium was again changed to fresh Advanced DMEM 
containing 5% FBS (6 ml / 10 cm dish). Virus supernatant was harvested after 24 and 
48 hours and sterile-filtered using a pore size of 0.45 µm. 
 
2.4.9. Generation of MS2-P65-HSF1 helper cell lines 
MS2-P65-HSF viral particles were generated according to 2.4.8. For lentiviral plasmid 
details (MS2-P65-HSF1) see 2.1.12. Cell lines were then transduced with 500 µl MS2-
P65-HSF1 virus supernatant and afterwards selected for stable vector integration 
under growth in 50 mg / ml hygromycin B medium for 2 weeks. 
 
2.4.10. Transduction of helper cell lines with SOX17 SAM virus 
SOX17 SAM virus was prepared using equimolar amounts of SOX17 SAM gRNA1 and 
SOX17 SAM gRNA2, see 2.1.12. Virus supernatant was generated according to 2.4.8. 
Cell lines were then transduced with 100, 200 or 500 µl SOX17 SAM virus. SOX17 
overexpression was verified by qRT-PCR and Western blot analysis. 
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3. Results I 
As previously described, TGCTs are highly sensitive to chemotherapeutic agents and 
radiotherapy [106]. However, despite cure rates of ≥ 95% TGCTs may develop 
resistance mechanisms to standard therapy regimens. These subtypes are difficult to 
treat and even multiple cycles of high-dose chemotherapy can remain ineffective. In 
this aspect epigenetic drugs open a new avenue to cancer therapy and may present a 
promising alternative to standard therapies [79]. Demethylating agents (5-aza, SGI-
110), histone demethylase inhibitors (CBB1003, CBB1007, CBB3001) and HDAC 
inhibitors (romidepsin) have already shown promising effects in pre-clinical studies [3, 
79, 107, 108]. Additionally, the bromodomain inhibitor JQ1 was tested for its efficacy 
in TGCT cell lines, demonstrating cytotoxic effects (G0/G1 arrest, apoptosis) in EC 
cells at doses ≥ 100 nM and seminoma cells at doses ≥ 250 nM [1, 2, 79]. The 
apoptosis and cell cycle arrest of EC and seminoma cells following JQ1 treatment 
reflects the therapeutic potential of bromodomain inhibition for TGCTs. The first aim of 
this thesis was to analyse the molecular effects of the bromodomain inhibitor JQ1 in 
TGCT cell lines in more detail.  
 
3.1. TGCT cell lines and somatic control cells express the JQ1 targets 
BRD2, BRD3 and BRD4 
JQ1 is an inhibitor of the BET family of bromodomain proteins (BRD2, BRD3, BRD4 
and BRDT). Since JQ1 treatment markedly induced growth arrest and apoptosis in the 
TGCT cell lines TCam-2, NCCIT, NT2/D1 and 2102EP [1, 2], I asked, which BET 
members were expressed and could be inhibited by JQ1 in these cell lines. First, 
mRNA expression in seminoma (TCam-2), EC (NCCIT, NT2/D1, 2102EP) and 
cisplatin-resistant EC (NCCIT-R, NT2/D1-R, 2102EP-R) cells was analysed (Fig. 7 A). 
Sertoli (FS1) and fibroblast (MPAF) served as controls (Fig. 7 A). Across all cell lines 
analysed, we found highest mRNA expression for BRD2 and lower expression for 
BRD3 and BRD4, while BRDT expression was absent. Protein levels of BRD2, BRD3 
and BRD4 were similarly detected in TCam-2, NCCIT, NT2/D1, 2102EP and FS1 cells 
(Fig. 7 B). To see whether expression of BRD2, BRD3 and BRD4 can also be 
confirmed in vivo, I performed a meta-analysis of previously published microarray data 
of TGCT tissues [109]. BRD2, BRD3 and BRD4 were equally expressed in normal 
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testis tissue (NTT), GCNIS tissue, seminoma (SEM) tissue and EC tissue samples 
(Fig. 7 C). Also BRDT was expressed in all analysed tissues (Fig. 7 C). According to 
literature, BRDT should only be expressed in spermatocytes and early spermatids 
[110]. The BRDT expression detected in TGCT and normal testis tissues might come 
from BRDT-expressing germ cells present in the isolated tissues. 
 
Figure 7: Expression of BRD2, BRD3, BRD4 and BRDT in TGCT cell lines and somatic control 
cells. Modified from [2] 
(A) mRNA expression of BRD2, BRD3, BRD4 and BRDT in human TGCT cell lines (TCam-2, NCCIT(-
R), NT2/D1(-R), 2102EP(-R)), Sertoli cells (FS1) and human fibroblasts (MPAF), determined by 
qRT-PCR. Expression levels were normalized to GAPDH as housekeeping gene. 
(B) Western blot of BRD2, BRD3 and BRD4 protein levels in nuclear (NF) and cytoplasmic fractions 
(CF) of TGCT cell lines (TCam-2, NCCIT, NT2/D1, 2102EP) and Sertoli cells (FS1). HDAC1 served 
as loading control.  
(C) mRNA expression of BRD2, BRD3, BRD4 and BRDT in normal testis tissue (NTT) (n = 4), germ 
cell neoplasia in situ (GCNIS) (n = 3), seminoma (SEM) (n = 4) and embryonal carcinoma (EC) (n 
= 3) tissue, as determined by cDNA microarray analysis. Error bars indicate standard deviation 
from the mean. 
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Altogether, these data show that the BET members BRD2, BRD3 and BRD4 are 
mutually expressed across seminoma and EC cell lines and tissues, including the 
cisplatin-resistant subclones. Thus, BRD2, BRD3 and BRD4 may be inhibited by JQ1 
treatment in these cells and therefore responsible for the JQ1-mediated cytotoxicity in 
TGCT cell lines reported previously [1]. However, expression of BRD2, BRD3 and 
BRD4 was also detected in normal testis tissue and somatic control cells (FS1, MPAF). 
Therefore it is still unclear, which side effects JQ1 treatment will have on the testicular 
microenvironment in vivo. Previous experiments could already demonstrate cytotoxic 
effects of JQ1 treatment in the Sertoli cell line FS1 [1], indicating that JQ1 elicits side 
effects in surrounding tissues. 
 
3.2. JQ1 induces apoptosis and cell cycle arrest in TGCT cells and in 
cisplatin-resistant EC cells 
Previous work reported that JQ1 induces apoptosis and G0/G1 arrest in EC lines 
(2102EP, NCCIT, NT2/D1) at concentrations ≥ 100 nM and seminoma cells (TCam-2) 
at concentrations ≥ 250 nM [1]. This was shown by AnnexinV/7AAD FACS and PI 
FACS analysis, respectively [1]. In addition, reduction of cell viability in TGCT cells was 
confirmed by Western blot analysis detecting cleaved PARP (Poly (ADP-ribose) 
polymerase) levels. 500 nM JQ1 treatment resulted in a strong increase in cleaved 
PARP levels in seminoma (TCam-2) and EC cells (NCCIT, NT2/D1, 2102EP) already 
after 24 hours (Fig. 8 A). The normal function of PARP is to repair DNA damage [111]. 
Excessive DNA damage, however, results in cleavage of PARP rendering the enzyme 
inactive [111]. In fact, cleaved PARP is considered a hallmark of apoptotic cells [111]. 
Therefore, rising levels of cleaved PARP levels demonstrate the cytotoxicity of JQ1 in 
TGCT cell lines. 
Since 95% of all TGCT patients are already successfully treated by standard therapy 
regimens (chemo- or radiotherapy), we were particularly interested in the efficacy of 
JQ1 in cells displaying cisplatin-resistance. Therefore, I additionally analysed the 
effects of JQ1 on cell viability and cell cycle of cisplatin-resistant EC cell lines (NCCIT-
R, NT2/D1-R, 2102EP-R). Similar to cisplatin-sensitive cells [1], cisplatin-resistant EC 
lines undergo apoptosis (Fig. 8 B) and G0/G1 arrest (Fig. 8 C) following JQ1 treatment. 
In EC lines NCCT-R and NT2/D1-R apoptosis and G0/G1 arrest was detected already 
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after 16 hours of JQ1 treatment. A prolonged exposure time of 20 hours led to similar 
effects in 2102EP-R. Since the same trend was observed in parental NCCIT, NT2/D1 
and 2102EP cells [1], it can be concluded that JQ1 shows therapeutic effects in both 
cisplatin-sensitive and cisplatin-resistant cells. 
 
 
Figure 8: JQ1 induces apoptosis and G0/G1 arrest in cisplatin-sensitive and cisplatin-resistant 
TGCT cells 
(A) Western blot of cleaved PARP levels in 500 nM JQ1-treated TGCT cell lines compared to solvent 
controls (-). ACTIN was used as loading control. 
(B) Cell viability (in % to control) of JQ1-treated cisplatin-resistant EC lines as determined by AnnexinV-
7AAD FACS analysis. Time after JQ1 treatment is given in hours (h) below. 
(C) Cell Cycle (in % to control) of JQ1-treated cisplatin-resistant EC lines as determined by PI FACS 
analysis. Time after JQ1 treatment is given in hours (h) below. 
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3.3. The molecular effects of JQ1 treatment in TGCT cells 
Microarray data showed that JQ1 treatment of EC (NCCIT) and seminoma (TCam-2) 
cells leads to upregulation of stress markers (CDKN1C, DDIT4, TSC22D1, TXNIP, 
ATF3, RHOB, BTG1, JUN), strong induction of the differentiation marker HAND1, and 
downregulation of pluripotency-associated genes (LIN28, DPPA4, UTF1, ZSCAN10) 
as well as germ-cell related markers (SPRY4, THY1) [1]. We hypothesized that 
deregulation of these genes is responsible for the JQ1-mediated cytotoxicity in TGCT 
cell lines. To confirm the microarray data and to determine whether these deregulations 
are common for all TGCT cells, I measured mRNA expression of CDKN1C, ATF3, 
RHOB, HAND1, POU5F1, LIN28, SPRY4 and THY1 in seminoma (TCam-2) and EC 
cells (NCCIT, NT2/D1, 2102EP). A common effect of JQ1 treatment across all TGCT 
cell lines was the downregulation of germ cell – associated genes SPRY4 and THY1 
(Fig. 9). Further, I verified induction of the stress markers CDKN1C, ATF3 and RHOB 
in the pluripotent EC lines NCCIT and NT2/D1 cells after 100 nM JQ1 treatment (Fig. 
9). Additionally, strong induction of the differentiation marker HAND1 and 
downregulation of pluripotency genes POU5F1 and LIN28 suggested loss of 
pluripotency and induction of differentiation in pluripotent EC cells (Fig. 9). In contrast, 
the nullipotent EC line 2102EP showed mild induction of CDKN1C, ATF3 and RHOB, 
but only at higher JQ1 concentrations (750 nM). Downregulation of pluripotency 
markers POU5F1 and LIN28 and upregulation of HAND1 was similarly seen only at 
higher JQ1 concentrations (750 nM) in this cell line (Fig. 9). It is tempting to speculate 
that 2102EP cells are less sensitive to JQ1-induced deregulation, due to their 
nullipotent character. In contrast to the pluripotent EC lines NCCIT and NT2/D1, 
2102EP cells lack the ability to differentiate into mixed non-seminoma cells. In 
comparison, the seminoma-like cell line TCam-2 shows induction of stress markers 
CDKN1C, ATF3 and RHOB, mild upregulation of the differentiation marker HAND1 and 
downregulation of pluripotency, indicated by loss of LIN28 expression (Fig. 9). mRNA 
levels of POU5F1, however, remained unchanged in TCam-2 cells (Fig. 9).  
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Figure 9: Upregulation of stress markers and downregulation of pluripotency genes in TGCT 
cells following JQ1 treatment. Modified from [2] 
Verification of cDNA microarray data by qRT-PCR. Expression values were calculated as fold change 
compared to solvent control and normalized against GAPDH as housekeeping gene.  
 
To confirm the downregulation of pluripotency after JQ1 treatment in TGCT cells on 
protein level, I screened for changes in POU5F1 (OCT4) and LIN28 expression, as 
well as levels of the stem cell marker and BMP inhibitor GDF3. I detected 
downregulation of GDF3 and POU5F1 in EC lines (NCCIT, NT2/D1) and mild 
downregulation of LIN28 in the seminoma line TCam-2, which is consistent with the 
microarray and qRT-PCR data [1] (Fig. 9-10). Although the effects of JQ1 on 
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pluripotency marker expression are not identical between seminoma (TCam-2) and EC 
(NCCIT, NT2/D1) cell lines, I was able to confirm an overall downregulation of 
pluripotency in both TGCT subtypes on RNA and protein level.  
 
 
Figure 10: Downregulation of pluripotency in TGCT cell lines. Modified from [2] 
GDF3, POU5F1 and LIN28 protein levels in 100 nM JQ1-treated TGCT cell lines compared to solvent 
controls (-). ACTIN was used as loading control and for data normalization.  
 
Notably, the overall state of pluripotency differs between seminoma and EC cells. 
While seminoma cells share the latent pluripotent character of early PGCs, EC cells 
show features of totipotency similar to early ESCs. Hence, EC cells are capable of 
differentiating into cells of embryonic and extra-embryonic lineages. In contrast, 
seminoma cells express some of the well-known pluripotency and stem cell markers 
(e.g. POU5F1, LIN28), but are highly restricted in their differentiation potential. For a 
long time it was believed that seminoma cells can not differentiate at all, however in a 
previous publication by our group it was shown that seminoma cells can differentiate 
into mixed non-seminomatous lineages in presence of TGF-β, EGF and FGF4 [73]. 
Due to the differences in the differentiation potential of seminomas and ECs, however, 
I proceeded with analysing the effects of JQ1 specifically on TGCT pluripotency in 
more detail. Since the pluripotent EC lines NCCIT and NT2/D1 showed much higher 
sensitivity to JQ1 than the TCam-2 cell line or the nullipotent 2102EP cell line, I 
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speculated that JQ1-mediated cytotoxicity may in part be mediated via downregulation 
of pluripotency of these cells.  
Gene set enrichment analysis (GSEA) of the previously obtained microarray data [1] 
revealed enrichment of stem cell signatures among downregulated genes in TCam-2 
(LIM_MAMMARY_STEM_CELL_UP, BENPORATH _ES_1) (Table 4) and an even 
more prominent enrichment of stem cell signatures among downregulated genes in 
NCCIT (BENPORATH_ES_1, BENPORATH_NANOG_TARGETS, KORKOLA_ 
CORRELATED_WITH_POU5F1, BENPORATH_SOX2_TARGETS, BHATTACHA 
RYA_EMBRYONIC_STEM_CELL, CONRAD _STEM_CELL, BENPORATH_ES_2) 
(Table 5). Since the EC cell line NCCIT is capable of differentiating into cells of 
embryonic and extra embryonic lineages I additionally analysed the list of genes 
upregulated following JQ1 treatment by gene ontology analysis. In line with the 
downregulation of pluripotency in this cell line, gene ontology analysis demonstrated 
enrichment of biological processes associated with embryonic differentiation among 
genes induced by 100 nM JQ1 (Table 6). Categorization of these genes into embryonic 
lineages reveals that the majority of these processes are associated with mesoderm 
differentiation (Fig. 11). In summary, this shows that JQ1 treatment of TGCT cells 
results in downregulation of pluripotency or stem cell associated genes. According to 
the GSEA, this downregulation is more significant in the pluripotent EC line NCCIT (p 
≥ 2.41E-59) compared to the latent pluripotent seminoma cell line TCam-2 (p ≥ 7.5E-
13) and downregulation of pluripotency in NCCIT goes in hand with upregulation of 
differentiation markers (mainly mesoderm). 
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Table 4: GSEA of genes downregulated in TCam-2 cells 72 hours after JQ1 
treatment  
Gene Set Name 
 
P-value 
SMID_BREAST_CANCER_LUMINAL_B_DN 1.77E-16 
HOSHIDA_LIVER_CANCER_SUBCLASS_S1 1.82E-13 
LEI_MYB_TARGETS 4.14E-13 
CHICAS_RB1_TARGETS_CONFLUENT 5.56E-13 
RODWELL_AGING_KIDNEY_UP 7.05E-13 
LIM_MAMMARY_STEM_CELL_UP 7.5E-13 
SERVITJA_ISLET_HNF1A_TARGETS_UP 1.47E-12 
BENPORATH_ES_1 4.39E-12 
SMID_BREAST_CANCER_BASAL_UP 4.59E-12 
VERHAAK_AML_WITH_NPM1_MUTATED_DN 6.36E-12 
 
Table 5: GSEA of genes downregulated in NCCIT cells 72 hours after JQ1 
treatment  
Gene Set Name 
 
P-value 
BENPORATH_ES_1 2.41E-59 
BENPORATH_NANOG_TARGETS 1.34E-23 
KORKOLA_CORRELATED_WITH_POU5F1 1.71E-19 
BENPORATH_SOX2_TARGETS 5.9E-19 
KRIEG_HYPOXIA_NOT_VIA_KDM3A 2.28E-18 
ELVIDGE_HYPOXIA_UP 1.27E-15 
BHATTACHARYA_EMBRYONIC_STEM_CELL 1.71E-15 
CONRAD_STEM_CELL 7.56E-15 
BENPORATH_ES_2 1.00E-14 
ELVIDGE_HYPOXIA_BY_DMOG_UP 1.1E-14 
 
Table 6: Gene ontology analysis of genes upregulated in NCCIT cells 72 hours 
after JQ1 treatment  
Process q-value 
heart morphogenesis 1.83e-13 
regionalization 6.62e-12 
regulation of cellular response to growth factor stimulus 5.90e-11 
cardiac chamber development 9.06e-11 
cardiac ventricle development 1.25e-10 
appendage development&limb development 1.39e-10 
cardiac chamber morphogenesis 1.39e-10 
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mesenchymal cell development 1.39e-10 
regulation of transmembrane receptor protein serine threonine kinase 
signaling pathway 
1.39e-10 
stem cell development 1.39e-10 
mesenchymal cell differentiation 2.29e-10 
mesenchyme development 3.21e-10 
appendage morphogenesis&limb morphogenesis 4.22e-10 
cardiac septum development 1.24e-9 
stem cell differentiation 1.72e-9 
regulation of ossification 2.07e-9 
negative regulation of DNA binding 2.85e-9 
connective tissue development 2.86e-9 
osteoblast differentiation 6.12e-9 
positive regulation of ossification 7.76e-9 
epithelial tube morphogenesis 1.06e-8 
odontogenesis of dentin containing tooth 1.06e-8 
regulation of DNA binding 1.06e-8 
cell cell junction organization 1.27e-8 
cell junction assembly 1.62e-8 
cardiac muscle tissue development 1.76e-8 
embryonic appendage morphogenesis&embryonic limb morphogenesis 1.76e-8 
BMP signaling pathway 2.33e-8 
cartilage development 3.39e-8 
in utero embryonic development 3.61e-8 
response to BMP(4)&cellular response to BMP stimulus 3.86e-8 
regulation of osteoblast differentiation 5.96e-8 
cardiac septum morphogenesis 6.48e-8 
regulation of BMP signaling pathway 1.36e-7 
gastrulation 2.66e-7 
outflow tract morphogenesis 3.68e-7 
mesenchyme morphogenesis 5.71e-7 
response to mechanical stimulus 6.81e-7 
stem cell proliferation 1.09e-6 
anterior posterior pattern specification 1.09e-6 
ventricular septum development 1.16e-6 
epithelial to mesenchymal transition 1.24e-6 
endoderm development 1.81e-6 
formation of primary germ layer 1.86e-6 
ventricular cardiac muscle tissue development 1.89e-6 
skeletal system morphogenesis 1.99e-6 
actin filament bundle assembly 2.50e-6 
embryonic organ morphogenesis 2.73e-6 
actin filament bundle organization 2.95e-6 
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regulation of canonical Wnt signaling pathway 3.03e-6 
negative regulation of growth 3.42e-6 
palate development 3.42e-6 
regulation of Wnt signaling pathway 3.42e-6 
embryonic hindlimb morphogenesis 3.64e-6 
kidney epithelium development 4.20e-6 
ureteric bud development 5.37e-6 
regulation of protein localization to nucleus 5.57e-6 
mesonephric tubule development&mesonephric epithelium development 5.63e-6 
positive regulation of osteoblast differentiation 5.75e-6 
segmentation 5.90e-6 
chondrocyte differentiation 6.59e-6 
mesonephros development 6.59e-6 
positive regulation of BMP signaling pathway 6.59e-6 
sensory organ morphogenesis 6.83e-6 
cardiac ventricle morphogenesis 7.98e-6 
regulation of cartilage development 7.98e-6 
positive regulation of transmembrane receptor protein serine threonine 
kinase signaling pathway 
8.43e-6 
regulation of cellular response to transforming growth factor beta stimulus 8.82e-6 
regulation of transforming growth factor beta receptor signaling pathway 8.82e-6 
embryonic forelimb morphogenesis 9.51e-6 
actomyosin structure organization 9.67e-6 
neural crest cell development 1.10e-5 
morphogenesis of embryonic epithelium 1.18e-5 
hindlimb morphogenesis 1.22e-5 
canonical Wnt signaling pathway 1.26e-5 
negative regulation of transcription regulatory region DNA binding 1.29e-5 
negative regulation of cell development 1.42e-5 
adherens junction organization 1.49e-5 
cardiocyte differentiation 1.80e-5 
regulation of stem cell differentiation 2.02e-5 
neural crest cell differentiation 2.08e-5 
forelimb morphogenesis 2.53e-5 
mesoderm development 2.82e-5 
regulation of chondrocyte differentiation 2.82e-5 
skin development 4.38e-5 
extracellular matrix disassembly 4.45e-5 
morphogenesis of a branching epithelium 5.07e-5 
transforming growth factor beta receptor signaling pathway 5.24e-5 
regulation of cell shape 7.12e-5 
morphogenesis of a branching structure 8.59e-5 
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Figure 11: Gene ontology analysis of genes upregulated in NCCIT cells 72 hours after JQ1 
Treatment. Modified from [2] 
Categorization of biological processes enriched among genes upregulated in NCCIT cells 72 hours after 
100 nM JQ1 treatment determined by gene ontology analysis. 
 
Interestingly, in different cancer models (e.g. esophageal squamous cell carcinoma, 
multiple myeloma) JQ1 treatment additionally resulted in strong downregulation of the 
proto-oncogene MYC [93, 97, 112]. In these studies MYC was described as one of the 
primary targets of JQ1 treatment and JQ1-mediated cytotoxicity was dependent on 
MYC downregulation [93]. Since transcription of MYC was described to be regulated 
by BRD4, JQ1-mediated BRD4 inhibition in these cells resulted in downregulation of 
MYC mRNA, further leading to the loss of MYC protein expression. In TGCT cells, 
however, no downregulation of MYC mRNA was observed in response to JQ1 
treatment [1]. Surprisingly, MYC mRNA levels were even upregulated following JQ1 
treatment in seminoma (TCam-2) and EC cells (NCCIT, NT2/D1, 2102EP) [1]. In order 
to see whether MYC upregulation was similarly observed on protein level in TGCT 
cells, I analysed whole protein lysates of seminoma (TCam-2) and EC cells (NCCIT, 
NT2/D1, 2102EP) following JQ1 treatment. I found that MYC protein levels were 
unaltered in EC lines (NCCIT, NT2/D1, 2102EP) and TCam-2 cells at 100 nM JQ1 
(Fig. 12 A). At 500 nM JQ1 TCam-2 cells display mild downregulation of MYC protein, 
while MYC protein levels in EC cells remain unaffected (Fig. 12 B-C). Thus, 
upregulation of MYC mRNA does not correlate with upregulation of MYC protein levels 
in TGCT cells, possibly pointing at post-translational modifications regulating MYC 
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levels. In summary, those TGCT cells being the most sensitive to JQ1-induced 
cytotoxicity (NCCIT, NT2/D1) demonstrated no change in MYC expression. Thus, JQ1-
associated cytotoxicity in TGCT cells seems to be independent of MYC expression. 
Also, downregulation of MYC protein in 500 nM treated TCam-2 cells might be a 
secondary effect of JQ1 treatment, since cytotoxicity of JQ1 in TCam-2 cells is already 
observed at doses ≥ 250 nM. 
 
 
Figure 12: MYC protein levels in JQ1 treated TGCT cell lines. Modified from [2] 
(A-C) Western blot of MYC protein levels in JQ1-treated TGCT cell lines compared to solvent controls 
(-). JQ1 concentrations are indicated below in nM. ACTIN was used as loading control. Time of JQ1 
treatment is given in hours (h). 
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3.4. The molecular effects of JQ1 on the testis microenvironment 
The effects of JQ1 were additionally tested on somatic control cells (adult fibroblasts 
and a Sertoli cell line), demonstrating cytotoxicity (G2/M arrest, apoptosis) also in 
Sertoli cells, while adult fibroblasts remained nearly unaffected (G0/G1 arrest, but no 
apoptosis) [1, 2]. The JQ1-mediated cytotoxicity of Sertoli cells, however, may indicate 
the possibility of side effects in the testicular microenvironment when used in patients. 
I verified JQ1-mediated cytotoxicity in FS1 Sertoli cells additionally by measuring levels 
of cleaved PARP (Fig. 13). In contrast to adult fibroblasts (MPAF), human Sertoli cells 
(FS1) display strong induction of cleaved PARP levels, indicative for JQ1-mediated 
cytotoxicity (Fig. 13). 
 
 
 
Figure 13: JQ1 induces apoptosis in FS1 Sertoli cells but not fibroblasts. Modified from [2] 
Western blot of cleaved PARP levels in 100, 250 and 500 nM JQ1-treated FS1 Sertoli cells and adult 
fibroblasts (MPAF) compared to solvent controls (-). ACTIN was used as loading control. Time of JQ1 
treatment is given in hours (h). 
 
 
To analyse the molecular effects of JQ1 on the testicular microenvironment in more 
detail, I performed microarray analysis of JQ1 treated Sertoli cells (FS1) after 24 and 
72 hours (Fig. 14 A-B). After 24 hours, 31 genes (1 upregulated, 30 downregulated) 
were differentially expressed between JQ1 treated Sertoli cells and solvent controls 
(Fig. 14 A). After 72 hours 33 genes (2 upregulated, 31 downregulated) were 
differentially expressed (Fig. 14 B). In comparison to TCam-2 (24 hours: 242 genes, 
72 hours: 212 genes) and NCCIT (24 hours: 225 genes, 72 hours: 512 genes), the 
number of deregulated genes after JQ1 treatment in FS1 Sertoli cells is much smaller 
(Fig. 14 and 15). Thus, TGCT cells are more susceptible to JQ1-induced gene 
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deregulations than the somatic control cell line FS1. However, similar to TGCT cells, 
FS1 cells respond with cell cycle arrest and apoptosis to JQ1 treatment. It remains 
unclear, which of the deregulated genes is responsible for the cytotoxicity of JQ1 
treatment in FS1 Sertoli cells. 
 
 
Figure 14: Microarray analysis of 100 nM JQ1 treated Sertoli cells. Modified from [2] 
Genes deregulated in FS1 Sertoli cells following 100 nM JQ1 treatment after 24 hours (A) and 72 hours 
(B) determined by cDNA microarray analysis. Expression is given as fold change compared to solvent 
control.  
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Figure 15: Genes commonly deregulated in TGCT and Sertoli cells 
Venn diagram showing genes commonly deregulated in FS1 Sertoli cells, TCam-2 cells and NCCIT cells 
following 100 nM JQ1 treatment after 72 hours, as determined by cDNA microarray analysis. 
 
Notably, none of the genes deregulated in TGCT cells after JQ1 treatment that have 
been annotated a role in cytotoxicity (GADD45B, TSC22D1, TXNIP, RHOB, ATF3, 
JUN, ID2) [2] were deregulated in FS1 Sertoli cells after JQ1 treatment. Further, none 
of the commonly deregulated genes in FS1 Sertoli cells and NCCIT (HIST1H2BK, 
KLF6, NBPF20, NBPF10) or FS1 and TCam-2 (LYPD1, KRT19) are directly regulating 
apoptosis or cell cycle arrest (Fig. 15). Only KLF6 was described to induce apoptosis 
via upregulation of ATF3 in prostate cancer cells [113]. However, following JQ1 
treatment KLF6 was downregulated in FS1 cells, while being upregulated in NCCIT 
cells [1, 2]. Thus, a common mechanism of JQ1-mediated cytotoxicity in TGCT and 
Sertoli cells could not be identified. Although it remains unclear, which of the 
deregulated genes are responsible for the JQ1-mediated toxicity in FS1 cells, it is 
evident that BET inhibition can lead to apoptosis and cell cycle arrest in somatic control 
cells (here: Sertoli cells). I recommend a more detailed analysis of possible side effects 
and adverse events of JQ1 administration, before commissioning the drug for clinical 
use. 
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3.5. Combination therapy with JQ1 and romidepsin in TGCT cell lines 
I noted during the analyses that the genes deregulated by JQ1 treatment in TGCT cells 
were similar to those deregulated by treatment with the HDAC inhibitor romidepsin 
(induction of GADD45A, GADD45B, RHOB, ID2) [1-3]. Since a combination of 100, 
250 or 500 nM JQ1 with 5 nM romidepsin also markedly increased apoptosis levels in 
TCam-2 cells compared to single agent treatment, drug synergy effects for the 
HDACi+BETi combination were postulated [1, 2].  
In order to test, whether a combination of JQ1 and romidepsin will synergistically 
decrease TGCT cell viability compared to single agent treatment I performed XTT 
assay on JQ1 and romidepsin treated TCam-2 and NCCIT cells (Fig. 16). In contrast 
to previous experiments where JQ1 was administered every second day due to its 
relatively short half-life (~1 hour in plasma), in this line of experiments both substances 
were administered only once before the start of the measurement (timepoint: 0 hours 
(h)). Under these conditions administration of neither 100 nM nor 250 nM JQ1 showed 
cytotoxic effects in TCam-2 cells (Fig. 16 A). In contrast, 2 nM romidepsin treatment 
led to a decrease in cell viability of ~ 40% in TCam-2 cells. A combination of 2 nM 
romidepsin with either 100 or 250 nM JQ1 further reduced cell viability to ~ 30%. This 
shows that even though a one-time administration of JQ1 alone has no effect on TCam-
2 cell viability, the substance can significantly increase cytotoxicity of romidepsin 
treatment (Fig. 16 A). Cytotoxicity levels of high-dose romidepsin treatment (5 nM), 
however, are not increased by addition of JQ1.  
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Figure 16: Cell viability of TGCT cells treated with JQ1 and romidepsin. Modified from [2] 
Cell viability of TCam-2 (A) and NCCIT (B) cells treated with JQ1, romidepsin (Rdps) or JQ1 and 
romidepsin (JQ1 + Rdps) in combination determined by XTT assay. Cell viability is given in % to solvent 
control.  
 
Similarly, I observed that a one-time administration of 2 nM romidepsin showed no 
cytotoxic effects in NCCIT cells (Fig. 16 B). In contrast, 100 nM or 250 nM JQ1 led to 
a reduction of cell viability to 40-50% and 5 nM romidepsin treatment led to a reduction 
of cell viability to 50% (Fig. 16 B). While a combination treatment of 100 or 250 nM 
JQ1 + 2 nM romidepsin had no additional effect on cytotoxicity levels, the combination 
of 5 nM romidepsin and 100 or 250 nM JQ1 further decreased cell viability to ~ 20% 
(Fig. 16 B). In summary, these data demonstrate that under certain conditions JQ1 
and romidepsin may show additive or synergistic effects on cytotoxicity levels of TGCT 
cells. However, the interplay of both drugs and their exact efficacy vs toxicity (side 
effects) relationship needs further evaluation using in vivo model systems.  
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3.6. JQ1 treatment of TGCT xenografts  
In order to investigate the efficacy of JQ1 treatment (also in combination with 
romidepsin) in vivo, I analysed tumour growth of NCCIT and NT2/D1 xenografts in CD-
1 nude mice under drug administration. For this, cell lines were injected into the flank 
of nude mice and after two weeks of initial tumour growth mice were intraperitoneally 
(i.p.) injected with drug or solvent control. Tumour growth was continuously monitored. 
Mice treated with JQ1 (50 mg / kg) presented reduced tumour burden compared to 
solvent controls (Fig. 17). This reduction was significant already after 7 days of 
treatment in NCCIT (Fig. 17 A-C) and only 4 days of treatment in NT2/D1 xenografts 
(Fig. 17 D-F).  
 
 
Figure 17: Tumour growth of TGCT xenografts treated with JQ1. Modified from [2] 
Tumour size of NCCIT (A-C) and NT2/D1 (D-F) xenografts treated with JQ1 compared to xenografts 
treated with solvent control (i.p. injection, 5 days / week for two weeks). 
 
A reduction in tumour growth was also indicated by a significant reduction of Ki67+ 
tumour cells in NCCIT (p = 0.026) and NT2/D1 (p = 0.0002) tumours, as determined 
by immunohistochemical staining (Fig. 18 A). Ki67 is a marker of proliferative active 
cells, thus a relative reduction in the Ki67+ cell population shows the growth-inhibitory 
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effects of JQ1 in TGCT tumours. I noted further the reduction of blood vessel 
invagination in JQ1 treated tumours (Fig. 17). In order to quantify this difference, 
NCCIT tumours were additionally stained for the endothelial marker CD31. In line with 
our observations I measured a significant reduction of CD31+ cells in JQ1 treated 
tumour samples (p = 0.018) (Fig. 18 B). Thus, JQ1 does not only significantly inhibit 
TGCT tumour growth, but also blood vessel formation within these tumours. 
 
  
 
Figure 18: Ki67 and CD31 staining of TGCT xenografts treated with JQ1. Modified from [2] 
Ki67 staining of NCCIT and NT2/D1 xenografts treated with JQ1 or solvent control (A) and CD31 staining 
of NCCIT xenografts treated with JQ1 or solvent control (B) (i.p. injection, 5 days / week for two weeks). 
Scale = 100 µm. Errors bars indicate standard deviation from the mean. Significance was calculated by 
student’s t-test. 
 
3.7. Combination therapy with JQ1 and romidepsin in TGCT xenografts 
I then proceeded to analyse the efficacy of a combination therapy with JQ1 and 
romidepsin in NCCIT and NT2/D1 xenografts. For this, cell lines were again injected 
into the flank of nude mice and after two weeks of tumour growth mice were injected 
i.p. with drug or solvent control. Similar to JQ1-treated mice, mice treated with JQ1 (50 
mg / kg) + romidepsin (0.5 mg / kg) presented reduced tumour burden compared to 
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solvent controls (Fig. 19 A-D). Interestingly, JQ1 + romidepsin was only administered 
3 days / week, while JQ1 alone was administered 5 days / week. Thus, fewer 
applications of combination therapy were sufficient to achieve a similar therapeutic 
outcome compared to JQ1 alone. The reduction of tumour growth under combination 
therapy was significant already after 2 days of treatment in NCCIT (Fig. 19 A-B) and 
NT2/D1 xenografts (Fig. 19 C-D). In line, the amount of Ki67+ cells was significantly 
(p = 0.003) reduced in NCCIT xenografts (Fig. 19 E) and, although not significant, 
markedly reduced in NT2/D1 xenografts (Fig. 19 F). These results indicate that TGCT 
patients may benefit from a combination therapy with JQ1 and romidepsin, since the 
combined administration of both substances allows for a less frequent application 
scheme and lower doses.  
 
Figure 19: Tumour growth of TGCT xenografts treated with JQ1 + romidepsin. Modified from [2] 
Tumour size of NCCIT (A, B) and NT2/D1 (C, D) xenografts treated with JQ1 + romidepsin (JQ1 + Rdps) 
compared to xenografts treated with solvent control (i.p. injection, 3 days / week for 10 days). Ki67 
staining of NCCIT (E) and NT2/D1 (F) xenografts treated with JQ1 + romidepsin (JQ1 + Rdps) compared 
to xenografts treated with solvent control.  Errors bars indicate standard deviation from the mean. 
Significance was calculated by student’s t-test.
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4. Discussion I 
Since the development of the first BET inhibitors JQ1 (2011) and I-BET (2010) [114, 
115], a multitude of studies have shown the therapeutic effects of these epigenetic 
compounds in cancer therapy [79, 93, 116-120]. Due to their small-molecule 
characteristics, both substances show high bioavailability even in difficult-to-penetrate 
tissues such as brain and testis [79, 114, 121]. Initially, JQ1 was discussed as male 
contraceptive, due to its inhibitory effect on the testis-specific BET member BRDT [122, 
123]. JQ1-mediated inhibition of BRDT led to a reversible contraceptive effect in mice, 
by completely inhibiting spermatogenesis during course of treatment [122, 123]. 
However, further studies focussed on the role of JQ1 as cancer therapeutic, probably 
owing to the fact that JQ1 does not only inhibit the testis-specific BET member BRDT, 
but also BRD2, BRD3 and BRD4, which are ubiquitously expressed among different 
tissues of the human body. 
Previously, no study had described the effects of JQ1 on testicular cancer, or more 
precisely, on type II TGCTs. Therefore, I analysed the effects of JQ1 in both TGCT cell 
lines and TGCT xenografts and compared it to the effects of JQ1 on somatic control 
cells (fibroblasts and Sertoli cells). JQ1 treatment led to G0/G1 growth arrest and 
apoptosis in both cisplatin-sensitive, as well as cisplatin-resistant TGCT cell lines (Fig. 
20) [1]. Cytotoxicity of JQ1 treatment in TGCT cells increased in a time- and dose-
dependent manner. In both seminoma and EC cells induction of the DNA damage and 
stress response genes GADD45B, TSC22D1, TXNIP, RHOB, ATF3, JUN and ID2 was 
observed (Fig. 20) [1]. Although not formally proven, induction of these genes may 
relate to the JQ1-mediated cell cycle arrest and apoptosis seen in TGCT cells. 
Interestingly, previous studies have shown the transcriptional activation of the 
oncogene MYC via BRD4-mediated pTEFb activation in different cancer types, and 
further MYC downregulation following BRD4 inhibition by JQ1 [112, 124-126]. In some 
cancer types JQ1-mediated downregulation of MYC was even responsible for the 
cytotoxicity of BET inhibition [93, 112]. However, other studies reported JQ1-mediated 
cytotoxicity in cancer cells independent of MYC levels [94, 127]. In this study 
downregulation of the oncogene MYC was not observed in TGCT cells on mRNA level. 
Only on protein level MYC was downregulated in seminoma, but not EC cells. Since 
seminoma cells, however, were in general less sensitive to JQ1 treatment compared 
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to EC cells, downregulation of MYC can be excluded as primary cause of JQ1-
mediated cytotoxicity in TGCT cells.  
One of the main observations of this study was the strong upregulation of the 
differentiation marker HAND1 in both seminoma and EC cells following JQ1 treatment 
and the downregulation of pluripotency-associated genes (such as UTF1, THY1, 
LIN28, ZSCAN10, DPPA4) (Fig. 20) [1, 2]. Interestingly, this effect was even more 
dramatic in EC cells only, which additionally showed robust downregulation of the key 
pluripotency markers NANOG, POU5F1, GDF3 and JARID2 [1, 2]. Whereas 
seminoma cells are restricted in their differentiation potential (a feature termed ‘latent 
pluripotent’), EC cells are capable of differentiating into embryonic and extra-
embryonic cell lineages. Therefore, EC cells not only showed upregulation of the 
differentiation marker HAND1 following JQ1 treatment, but also many other genes 
involved in differentiation processes (mainly mesodermal differentiation). This 
suggests a possible role of BET bromodomain reader proteins in pluripotency 
regulation, at least for TGCT (in particular EC) cells [79]. In support of this hypothesis, 
in mouse ESCs expression of the pluripotency factor NANOG (which is also highly 
expressed TGCTs) is maintained and regulated by the JQ1 target protein BRD4 [90, 
128]. Also, in both human and mouse ESCs, BRD4 occupies regulatory super-
enhancer regions of POU5F1 and PRDM14 stem cell genes, which are similarly 
important for TGCT cell identity and pluripotency [129].  
It is tempting to speculate that BRD4 has a similar role in maintaining pluripotency and 
stem cell identity in EC cells, which share many of the characteristics of ESCs. Also, 
sensitivity of TGCT cells to JQ1 treatment correlates with the downregulation of 
pluripotency and induction of differentiation, since pluripotent EC cell lines (such as 
NCCIT) show higher sensitivity to JQ1 treatment than the nullipotent EC line 2102EP 
and the latent pluripotent seminoma cell line TCam-2. Together, this suggests a 
possible link between TGCT sensitivity towards JQ1 treatment and their ability to 
differentiate.  
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Figure 20: Effects of JQ1 and romidepsin treatment in TGCT cells. Modified from [2]. 
Schematic showing the molecular effects of romidepsin and JQ1 treatment in seminoma (SEM) and EC 
cells.  
 
Next to the observed effects of JQ1 treatment on cell stress and pluripotency levels of 
TGCT cells, in vivo xenograft studies showed a reduced blood vessel formation in JQ1 
treated tumours (Fig. 20). Suppression of angiogenesis in response to JQ1 treatment 
was similarly reported for models of childhood sarcoma, breast cancer as well as non-
cancerous HUVEC (Human umbilical vein endothelial cells) [118, 130, 131]. In these 
cell types, reduction of blood vessel formation resulted from suppression of VEGF-
driven angiogenesis [118, 130, 131]. Downregulation of VEGFB was also noted 
following JQ1 treatment in both seminoma and EC cells [1], thus offering a plausible 
explanation for the loss of tumour vascularization in TGCT xenografts. 
Altogether, the presented data highlight JQ1 as possible therapeutic option for TGCT 
(ECs in particular). A few studies have additionally reported a synergistic effect of BET 
inhibition and HDAC inhibition in different cancer models (such as lymphoma, 
pancreatic ductal adenocarcinoma, breast cancer) [79, 95, 98, 132]. While testing the 
downstream molecular effects of JQ1 on TGCT cell lines I also noted a strong overlap 
of differentially expressed genes in TGCT cells following JQ1 and romidepsin 
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treatment [1]. Further experiments demonstrated an additive effect of JQ1- and 
romidepsin- mediated cytotoxicity in TGCT cells in vitro. The combination (JQ1 + 
romidepsin) treatment of TGCT xenografts further confirmed these findings, since 
combination therapy allowed for lower doses and a less-frequent application of both 
substances compared to single-drug application [2]. It is still not known, however, why 
HDAC inhibitors and BET inhibitors show synergy effects, since both drugs have a very 
distinct mode of action: While HDAC inhibition results in histone hyperacetylation and 
euchromatin formation, BET inhibition prevents the ‘reading’ of the histone code and 
may thereby modulate gene transcription [2]. Borbely et al. and Mazur et al. have 
identified the stress sensors USP17 and CDKN1C as possible common mediators of 
BETi and HDACi-induced cytotoxicity, respectively [2, 79, 98, 132]. Thus, the cellular 
stress response induced by both substances may explain the synergy of combination 
therapy. In theory, different modes of action may apply for different cancer types. 
Therefore, future studies would be necessary to evaluate the molecular background of 
a combination therapy employing BET and HDAC inhibitors in TGCT cells in more 
detail.  
Altogether, I propose JQ1 in combination with romidepsin, as a potential therapeutic 
option for TGCTs. While JQ1 was one of the first lead compounds presented in the 
field of BET inhibitors, several next-generation BET inhibitors (such as ABBV-075, 
BAY1238097, BI 894999) have now been developed, which have already reached 
clinical trials [79, 133-135]. Especially BI 894999 is a highly potent BET inhibitor, 
demonstrating an IC50 of 5 and 41 nM for BRD4-BD1 and BRD4-BD2 bromodomains, 
respectively [133]. In comparison, JQ1 had a considerably higher IC50 of 77 and 22 
nM for BRD4-BD1 and BRD4-BD2 bromodomains, respectively [121]. It is structural 
improvements like these that may positively influence drug specificity and sensitivity 
levels, and thereby also minimize drug-associated adverse events. Clinical trials need 
to explore the pharmacokinetic profile of these compounds in more detail. While I 
believe that the use of these drugs for stage I-II TGCTs is highly unlikely, since 
standard therapy regimens already result in complete remission in most cases, 
epigenetic drugs may present an alternative strategy to treat late-stage or cisplatin-
resistant TGCTs [79]. 
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5. Results II 
 
5.1. Introduction 
The plasticity of seminoma and embryonal carcinoma cells has been described in 
various studies [60, 73, 75, 136]. While it was a longstanding belief that seminomas 
are not able to differentiate and adopt other cell fates, our group was able to show in 
2011 that in presence of FGF4, heparin and TGFβ seminomas differentiate into mixed 
non-seminoma cell fate in vitro [73]. Additionally, it was demonstrated that seminoma 
cells transdifferentiate into an EC-like cell fate after xenotransplantation into the flank 
of nude mice [75]. Inhibition of BMP signalling is an initial driver of this process and 
activates NODAL signalling, which initiates the downregulation of SOX17, as well as 
the upregulation of SOX2 and other stem cell markers [75]. Collectively, these 
publications show that seminomas and EC fates are plastic, dependent on the 
surrounding microenvironment and the associated signalling cues. Regarding the 
described plasticity, it is surprising that seminomas and ECs are so well-discriminated 
by their exclusive expression of SOX2 (EC) and SOX17 (seminoma). It is generally 
accepted that the role of SOX2 in EC cells is similar to the role of SOX2 in ESCs, which 
is being a key determinant of pluripotency and stem cell fate. In seminomas, however, 
knowledge about the role of SOX17 is lacking. Thus, I was interested in whether 
SOX17 may have similar function in seminomas as SOX2 in ECs and whether both 
factors regulate a common set of downstream target genes.  
 
5.2. SOX17 (seminoma) and SOX2 (embryonal carcinoma) partner with 
OCT4, but not NANOG 
In general, SOX factors have weak DNA binding specificity [137]. Higher specificity, 
however, is achieved by partnering with other factors, such as POU transcription 
factors [137]. In ESCs SOX17 partners with OCT4 to bind to the compressed motif 
(CATTGTATGCAAAT-like sequence), thereby driving endodermal genes [70]. By co-
immunoprecipitation I confirmed interaction of SOX17 and OCT4 in seminoma cells 
(TCam-2) (Fig. 21), which was previously demonstrated by us [60]. SOX2 partners 
with the POU transcription factor OCT4 to bind to the canonical motif 
(CATTGTCATGCAAAT-like sequence) in ESCs, thereby driving pluripotency genes 
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[70]. This pluripotency circuitry is further supported by SOX2-OCT4 interaction with the 
stem cell factor NANOG [138]. A similar interaction of SOX2, OCT4 and NANOG was 
postulated to maintain EC pluripotency. By co-immunoprecipitation I verified interaction 
of SOX2 with OCT4 in the EC line 2102EP, while I could not determine direct 
interaction with NANOG protein (Fig. 21). 
 
 
Figure 21: SOX17 and SOX2 interact with OCT4, but not NANOG  
Co-immunoprecipitation of OCT4 and NANOG with SOX17 in TCam-2 cells and with SOX2 in 2102EP 
cells. Immunoprecipitation with no antibody (no AB) served as negative control. 2% Input (= 20 µg 
protein lysate) served as positive control.  
 
Alike SOX2, SOX17 did not interact with the pluripotency factor NANOG (Fig. 21). 
Collectively, this shows that SOX2 and SOX17 partner with OCT4 and can, as a protein 
complex, regulate downstream target genes in EC and seminoma cells. However, 
neither SOX2 nor SOX17 do bind to / partner with NANOG, like it was described for 
the SOX2-OCT4-NANOG regulatory network in ESCs [138]. Thus far, however, we 
cannot exclude that NANOG regulates similar genes as SOX2-OCT4 or SOX17-OCT4 
by binding to nearby DNA binding motifs without a direct SOX2-NANOG and SOX17-
NANOG interaction.   
 
5.3. SOX17 and SOX2 bind to the regulatory regions of pluripotency 
genes in TGCT cells 
In order to determine the role of SOX17 in seminoma cells and compare it to the role 
of SOX2 in EC cells, I proceeded by analysing genome-wide SOX17 / SOX2 DNA 
occupancy in TCam-2 and 2102EP cells, respectively. First, I confirmed suitability of 
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the SOX17 antibody for chromatin immunoprecipiation (ChIP). For this, the SOX17 
ChIP sample was loaded on a 12% SDS gel and SOX17 protein was detected by 
Western blot analysis. I verified presence of SOX17 protein in the SOX17 ChIP sample, 
as well as in the 2% input control and in TCam-2 whole protein lysate (Fig. 22 A) [101]. 
Expectedly, SOX17 was not detected in whole protein lysate of EC lines 2102EP, 
NT2/D1 and NCCIT (Fig. 22 A). A weak signal for SOX17 protein, however, was 
detected in the goat-IgG negative control (Fig. 22 A), indicating a low unspecific 
background signal for the IgG ChIP sample.  
Next, suitability of the SOX2 antibody for ChIP was confirmed (Fig. 22 B) [101]. SOX2 
protein could be detected in the SOX2 ChIP sample, as well as in the 2% input control 
and whole protein lysates of EC lines 2102EP, NT2/D1 and NCCIT (Fig. 22 B). As 
expected, SOX2 protein was absent in the TCam-2 whole protein lysate and the rabbit-
IgG negative control. Notably, the antibody used for SOX2 detection in the Western 
blot was different from the SOX2 antibody used for ChIP-seq. This minimizes the 
possibility that the ChIP-seq antibody binds to an unspecific product, which is not 
SOX2. This experiment was performed together with Martin Fellermeyer during his 
Bachelor Thesis in 2016 [101]. 
It was previously hypothesized by our group that in seminoma cells SOX17 takes over 
a similar role as SOX2 in EC cells, which is the maintenance of pluripotency. We 
hypothesized that SOX17 binds to canonical (SOX2/OCT4) motifs within the regulatory 
regions of pluripotency genes. This is in contrast to ESCs where SOX17 activates 
endodermal genes via the compressed (SOX17/OCT4) motif. Therefore, I tested 
whether SOX17 is enriched at previously described canonical (SOX2/OCT4) binding 
motifs [3, 99, 100, 102, 139]. I detected enrichment of SOX17 at the canonical 
(SOX2/OCT4) binding sites within SOX2, NANOG, DPPA4, LIN28A and PRDM14 
regulatory regions (Fig. 23), strongly suggesting that in seminoma cells SOX17 
regulates pluripotency genes via canonical (SOX2/OCT4) binding sites. 
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Figure 22: Validation of ChIP-grade antibodies. Modified from [101] 
(A) Digested and crosslinked chromatin of TCam-2 cells was immunoprecipitated using a negative 
control goat IgG antibody or the ChIP-grade SOX17 antibody. 2% Input represents 2% of the 
TCam-2 chromatin fraction. Protein lysates of 2102EP, NT2/D1 and NCCIT served as negative 
control. TCam-2 protein lysate served as positive control. 
(B) Digested and crosslinked chromatin of 2102EP cells was immunoprecipitated using a negative 
control rabbit IgG antibody (IgG) or the ChIP-grade SOX2 antibody. 2% Input represents 2% of the 
2102EP chromatin fraction. Protein lysates of 2102EP, NT2/D1 and NCCIT served as positive 
control. TCam-2 protein lysate served as negative control.  
 
 
SOX17 enrichment was stronger for those genes that are highly expressed in TCam-
2 cells (NANOG, LIN28A, DPPA4, PRDM14) (Fig. 23 and 24), while there was no 
enrichment of SOX17 for LEFTY2 detected (Fig. 23). LEFTY2 is exclusively expressed 
in EC cells (Fig. 24). Additionally, I determined whether SOX17 was enriched at a 
compressed (SOX17/OCT4) binding site approximately 900 bp upstream of the TSS 
of  PRDM1 [101] (Fig. 23, red label), which is highly expressed in seminoma and 
TCam-2 cells (Fig. 24). Notably, this compressed-like PRDM1 binding site 
(CATTGTATGCCATC) was manually assessed by screening for the compressed motif 
within the PRDM1 promoter [101]. Indeed, SOX17 was strongly enriched at the 
compressed motif within the PRDM1 promoter (Fig. 23) This is in line with a previous 
publication of Irie et al., showing that SOX17 acts upstream of PRDM1 in maintaining 
PGC fate [6]. In contrast, previously published SOX17 ChIP-seq data in differentiated 
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mesoderm, endoderm or mesendoderm-like lineages showed no enrichment of SOX17 
within the PRDM1 promoter region [140]. Only a distal regulatory region -15300 bp 
upstream of PRDM1 (-of TSS) was detected, which may not have functional relevance 
[140]. This suggests that SOX17 binding to the PRDM1 promoter is a unique feature 
of seminoma cells or PGCs. 
 
 
 
 
Figure 23: SOX17 binds pluripotency genes in TCam-2 cells  
qPCR of known canonical binding motifs in the regulatory regions of SOX2, NANOG, DPPA4, LIN28A, 
LEFTY2 and PRDM14, and a putative compressed binding motif in the regulatory region of PRDM1 in 
the SOX17 ChIP. Measurements were performed of three independent experiments. Goat IgG-ChIP 
served as negative control. 
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Figure 24: Expression of pluripotency genes in TCam-2 and 2102EP cells  
mRNA expression of pluripotency genes  in TCam-2 (n=5) and 2102EP (n=5) cells, determined by 
previously published microarray data [2, 3]. Different datapoints represent different mRNA probes for 
the respective genes. Genes were categorized according to their expression levels in EC and SEM 
(seminoma). The dashed line represents the expression threshold.  
 
 
As control, I then determined enrichment of SOX2 for canonical (SOX2/OCT4) binding 
motifs (Fig. 25). In line with the role of SOX2 as regulator of pluripotency, I detected 
strong enrichment of SOX2 in the regulatory regions of SOX2, NANOG, DPPA4, 
LIN28A, LEFTY2 and PRDM14 (Fig. 25). Notably, all of these genes are also highly 
expressed in 2102EP cells (Fig. 24), suggesting that SOX2 transactivates these 
genes. Next, I showed that there was no enrichment of SOX2 at the compressed 
(SOX17/OCT4) binding site within the PRDM1 regulatory region. 
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Figure 25: SOX2 binds pluripotency genes in 2102EP cells  
qPCR of known canonical binding motifs in the regulatory regions of SOX2, NANOG, DPPA4, LIN28A, 
LEFTY2 and PRDM14, and a putative compressed binding motif in the regulatory region of PRDM1 in 
the SOX2 ChIP. Measurements were performed of three independent experiments. Rabbit IgG-ChIP 
served as negative control. 
 
 
Together, the data demonstrate that in EC cells SOX2 uses some of the canonical 
SOX2-OCT4 binding sites described in ESCs. Therefore, in EC cells SOX2 has a 
similar role like SOX2 in ESCs, which is the maintenance of pluripotency by interacting 
with OCT4 to regulate downstream target genes. Further, SOX2 seems to regulate its 
own expression by binding to the canonical motif within the SOX2 regulatory region, 
thus creating an auto-regulatory feedback loop (Fig. 25). Similarly, SOX17 in 
seminoma cells, at least in part, binds to canonical (SOX2/OCT4) binding motifs. 
Although weak binding of the SOX17-OCT4 complex to canonical (SOX2/OCT4) motifs 
was already described in biochemical assays [141], there was no evidence whether 
this binding may have functional consequences in some cells or simply be a bystander 
effect. Some of the analysed genes showing SOX17 binding are also highly expressed 
in these cells (NANOG, LIN28A, DPPA4), making a regulatory function of SOX17 for 
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these genes in seminoma cells possible. However, it seems that other genes like 
PRDM1 are also regulated via SOX17 binding to its compressed motifs in seminoma 
cells.  
 
 
5.4. The majority of regions bound by SOX17 in seminoma cells contains 
the compressed motif and is found near transcriptional start sites  
In seminoma cells I could demonstrate that SOX17 binds to canonical (SOX2/OCT4) 
and compressed (SOX17/OCT4) binding motifs of pluripotency and germ-cell related 
genes. In 2102EP cells SOX2 binds to canonical SOX2/OCT4 motifs only. In order to 
analyse genome-wide binding occupancy of SOX17 and SOX2 in TGCT cells I next 
performed high-throughput ChIP-sequencing (ChIP-seq). For bioinformatic analysis 
only those peaks were considered significant that were present in the control group 
(Input or IgG) and in the SOX2/SOX17 IP and that were at least four times higher in 
the SOX2/SOX17 IP compared to the control group.  
Analysis of the SOX17 ChIP-seq data revealed a total of 931 and 904 peaks in the 
SOX17 vs IgG and SOX17 vs Input dataset, respectively (8.1). The subsequent 
analyses were performed using the SOX17 vs IgG dataset. Analysis of peak count 
frequency showed that most SOX17 peaks are allocated directly upstream or 
downstream of the transcription start site (TSS) of genes (Fig. 26 A). Further, HOMER 
Motif analysis identified a total of 375 of 931 peaks (=40.28%) harbouring a SOX17 
binding motif and 246 of 931 peaks (=26.24%) harbouring the compressed 
(SOX17/OCT4) binding motif (Fig. 26 B-C). Additionally, 355 of 931 peaks (=38.13%) 
contain the known SOX2 binding motif and 192 of 931 peaks (=20.62%) the known 
OCT4 binding motif (Fig. 26 C). Interestingly, 101 of 931 peaks (=10.85%) contain the 
described canonical (SOX2/OCT4) binding motif (Fig. 26 C). In line with the qPCR data 
this indicates that SOX17 binds, and possibly regulates genes via compressed 
(SOX17/OCT4) (26.24%), but also via canonical (SOX2/OCT4) (20.62%) binding sites. 
Interestingly, also TFAP2C (also known as AP2γ) and PRDM1 (also known as 
BLIMP1) motifs were found among top enriched binding motifs in SOX17-bound 
regions (368 of 931 peaks and 188 of 931 peaks) (Fig. 26 C).  
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Figure 26: SOX17 occupies canonical and compressed binding sites in seminoma cells 
(A) Peak Count Frequency of SOX17 ChIP peaks upstream and downstream of transcription start sites 
(TSS). 
(B) Number and percentage of SOX17 ChIP peaks (SOX17 vs IgG) that harbour the SOX17 binding 
motif and the compressed SOX17/OCT4 binding motif. 
(C) Homer motif analysis of known binding motifs enriched in SOX17 ChIP (SOX17 vs IgG).  
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Both transcription factors are highly expressed in PGCs and described as key 
specifiers of germ-cell fate along with SOX17 [8]. Overall, this reflects the germ-cell 
origin of TCam-2 cells. In PGCs PRDM1 and TFAP2C have been described to 
suppress somatic differentiation [8]. The fact that PRDM1 and TFAP2C binding sites 
are detected close to SOX17 peaks may indicate that some of those genes otherwise 
activated by SOX17 during endodermal differentiation are suppressed by binding of 
TFAP2C and PRDM1 in germ cell tumours. 
In comparison, ChIP-seq data for SOX2 revealed a total of 3314 and 1259 peaks in 
the SOX2 vs IgG and SOX2 vs Input dataset, respectively (8.1). The subsequent 
analyses were performed using the SOX2 vs IgG control dataset. Analysis of peak 
count frequency showed that most SOX2 peaks cluster upstream of the transcription 
start site (TSS) of genes (Fig. 27 A). HOMER Motif analysis identified a total of 962 of 
3314 peaks (=29,03%) harbouring a SOX2 binding motif and 419 of 3314 peaks 
(=12,64%) harbouring the canonical SOX2/OCT4 binding motif (Fig. 27 B-C). 
Additionally, 666 of 3314 peaks (=20.10%) contain the known OCT4 binding motif and 
560 of 3314 (=16.90%) contain the known KLF4 binding motif (Fig. 27 C). This 
indicates that the genes, which are bound by SOX2 can also be bound and regulated 
by the pluripotency factors KLF4 and OCT4. 
Altogether, these findings demonstrate that in seminoma cells SOX17 binds to 
canonical (SOX2/OCT4) motifs, similar to SOX2 in ECs. This way, both SOX17 (in 
seminoma) and SOX2 (in EC) can mediate the regulation of an overlapping set of 
downstream target genes, such as pluripotency genes NANOG, DPPA4, LIN28A and 
PRDM14. Surprisingly, however, many SOX17 peaks detected in TCam-2 cells also 
contain the compressed (SOX17/OCT4) motif. SOX17 binding to this motif is known to 
activate genes responsible for endodermal cell-fate decisions in ESCs. Further 
analysis will show whether the compressed (SOX17/OCT4) motifs bound by SOX17 in 
seminoma cells map to the regulatory regions of endodermal genes and whether this 
binding leads to an activation or a suppression of genes.  
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Figure 27: SOX2 occupies canonical binding sites in EC cells 
(A) Peak Count Frequency of SOX2 ChIP peaks upstream and downstream of transcription start sites 
(TSS). 
(B) Number and percentage of SOX2 ChIP peaks (SOX2 vs IgG) that harbour the SOX2 binding motif 
and the canonical SOX2/OCT4 binding motif. 
(C) Homer motif analysis of known binding motifs enriched in SOX2 ChIP (SOX2 vs IgG).  
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5.5. In seminoma cells SOX17 binds to the regulatory regions of neuro-
ectodermal genes, as well as pluripotency and germ-cell related genes 
In order to see whether the SOX17 peaks obtained in TCam-2 correlate with 
pluripotency gene signatures or endodermal genes I performed gene set enrichment 
analysis (GSEA) using the Molecular Signature Database (MSigDB). Here, individual 
SOX17 peaks were first annotated to the genes with the nearest TSS. GSEA was then 
performed for the two ChIP-seq datasets SOX17 vs IgG and SOX17 vs Input. I 
detected a strong overlap of SOX17 peaks with neuronal signatures and genes 
associated with embryonic development or differentiation (Table 7-8, green labels).  In 
line with the previous ChIP-qPCR data, however, the SOX17 peaks additionally show 
significant enrichment for stem cell-associated signatures, although less pronounced 
(Table 7-8, blue labels). In comparison, the same analysis on SOX2 datasets (SOX2 
vs IgG, SOX2 vs Input) showed robust enrichment for different stem cell-associated 
and pluripotency-associated signatures (Table 9-10, blue labels), while enrichment for 
neuronal signatures was minor (Table 9-10, green labels). 
 
Table 7: MSigDB GSEA of SOX17 targets in TCam-2 (normalized to IgG 
background) 
TERM  logP 
AACTTT_UNKNOWN -27.36 
GO_TISSUE_DEVELOPMENT -26.47 
GO_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT -22.92 
GO_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT -22.17 
CTTTGT_V$LEF1_Q2 -20.95 
GO_REGULATION_OF_CELL_DEVELOPMENT -18.93 
GO_EPITHELIUM_DEVELOPMENT -18.46 
V$HNF3B_01 -17.95 
GGGAGGRR_V$MAZ_Q6 -17.71 
GO_REGULATION_OF_NEURON_DIFFERENTIATION -17.59 
BENPORATH_SOX2_TARGETS -17.53 
AAAYWAACM_V$HFH4_01 -17.52 
BENPORATH_OCT4_TARGETS -17.25 
GO_REGULATION_OF_NEURON_PROJECTION_DEVELOPMENT -17.06 
GO_TUBE_DEVELOPMENT -17.05 
TGGTGCT,MIR-29A,MIR-29B,MIR-29C -17.01 
GO_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS -16.77 
GO_REGULATION_OF_CELL_PROJECTION_ORGANIZATION -16.30 
GO_NEUROGENESIS -16.20 
GO_REGULATION_OF_CELL_DIFFERENTIATION -16.13 
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Table 8: MSigDB GSEA of SOX17 targets in TCam-2 (normalized to 2% input) 
TERM  logP 
AACTTT_UNKNOWN -39.35 
GOZGIT_ESR1_TARGETS_DN -24.50 
TTGTTT_V$FOXO4_01 -24.27 
NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON -18.28 
chr8q21 -16.82 
YNGTTNNNATT_UNKNOWN -16.12 
V$S8_01 -15.70 
V$IPF1_Q4 -15.55 
CTTTGT_V$LEF1_Q2 -15.54 
V$OCT1_04 -15.07 
V$FOXO4_01 -14.92 
CTTTGA_V$LEF1_Q2 -14.86 
GO_NEUROGENESIS -14.54 
PLASARI_TGFB1_TARGETS_10HR_DN -14.34 
YTATTTTNR_V$MEF2_02 -14.11 
AAAYWAACM_V$HFH4_01 -13.93 
ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP -13.89 
WGTTNNNNNAAA_UNKNOWN -13.86 
V$OCT1_07 -13.62 
TGACATY_UNKNOWN -13.20 
 
Table 9: MSigDB GSEA of SOX2 targets in 2102EP (normalized to IgG 
background) 
TERM ID logP 
Chr19p13 -75.26 
Chr12q24 -36.97 
PILON_KLF1_TARGETS_DN -29.89 
BENPORATH_ES_1 -28.60 
BENPORATH_NANOG_TARGETS -28.50 
LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN -22.14 
GCCATNTTG_V$YY1_Q6 -21.10 
BENPORATH_SOX2_TARGETS -21.46 
NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON -21.20 
CTTTGT_V$LEF1_Q2 -21.14 
KORKOLA_CORRELATED_WITH_POU5F1 -20.87 
RAO_BOUND_BY_SALL4 -20.68 
BHATTACHARYA_EMBRYONIC_STEM_CELL -20.61 
BENPORATH_NOS_TARGETS -19.59 
Chr20q11 -18.15 
Chr12p13 -18.01 
LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_UP -17.83 
BENPORATH_OCT4_TARGETS -17.34 
MARTENS_BOUND_BY_PML_RARA_FUSION -17.30 
BLUM_RESPONSE_TO_SALIRASIB_DN -16.73 
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Table 10: MSigDB GSEA of SOX2 targets in 2102EP (normalized to 2% input) 
TERM ID logP 
CTTTGT_V$LEF1_Q2 -19.84 
BENPORATH_ES_1 -18.86 
TTGTTT_V$FOXO4_01 -18.70 
DACOSTA_UV_RESPONSE_VIA_ERCC3_DN -18.61 
AACTTT_UNKNOWN -18.07 
chr1p31 -15.79 
GO_NEGATIVE_REGULATION_OF_NITROGEN_COMPOUND_METABOLIC_P
ROCESS 
-15.28 
chr3q26 -14.32 
V$CDPCR3HD_01 -13.93 
RAO_BOUND_BY_SALL4 -13.76 
TAATTA_V$CHX10_01 -13.30 
GO_NEUROGENESIS -12.98 
V$OCT1_04 -12.21 
DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN -12.07 
CTTTGTA,MIR-524 -12.04 
WGTTNNNNNAAA_UNKNOWN -12.00 
V$HFH3_01 -11.75 
GO_REGULATION_OF_NEURON_DIFFERENTIATION -11.74 
GO_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT -11.54 
V$POU3F2_02 -11.32 
 
 
In order to see whether these genes are not only bound, but also expressed (and 
therefore transactivated by SOX17 and SOX2) in TCam-2 and 2102EP cells I 
performed a meta-analysis of previously published gene expression datasets from 
TCam-2 and 2102EP cells  [1-3] and compared it to the SOX17 vs IgG and SOX2 vs 
IgG datasets, respectively. In TCam-2 cells pluripotency genes are bound by SOX17 
(NANOG, TFAP2C, POU5F1, LIN28B, ZIC3, KLF4, TRIM71, ZIC4) (Fig. 28, 
highlighted in red). Of these only NANOG (peak score: 10.3) and TFAP2C (peak score: 
6.44) are strongly enriched for SOX17 binding. With a peak score < 5 the remainder 
do not seem to be primary targets of SOX17 binding (Table 11). In contrast, 19 genes 
showed a SOX17 peak score > 10 and a gene expression > 8: TUBB, AACS, BCL11B, 
ZHX2, COL23A1, CD9, BEND7, PSEN2, DCTD, NCBP2, GBAS, UBTD2, PSAP, 
ADAMTS1, RNF130, SLC39A10, NANOG, ZNF281, HABP4 (Fig. 28). The majority of 
these genes is linked to neuro-ectodermal development (ZHX2, COL23A1, CD9, 
BEND7, PSEN2, GBAS, UBTD2, PSAP, ADAMTS1 and ZNF281). This suggests a 
role of SOX17 in regulating somatic genes (in addition to pluripotency genes) in TCam-
2 cells, which is in line with the presented MiSigDB GSEA (compare Table 7-8). Next 
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to somatic genes, however, the pluripotency factor NANOG was also among genes 
bound by SOX17 and highly expressed in TCam-2 cells (Fig. 28, Table 11). Notably, 
NANOG seemed to be regulated by SOX17 via different binding sites including the 
canonical motif described before (260 bp upstream of TSS, Fig. 23) and the binding 
site identified in the SOX17 vs IgG dataset (4143 bp upstream of TSS, Fig. 28). 
Interestingly, both regions were also enriched for SOX2 binding in 2102EP cells, as 
well as one more region upstream (9264 bp) and three more regions downstream 
(1871 bp, 7801 bp, 37403 bp) of the NANOG TSS (8.1, SOX2 vs IgG dataset). This 
highlights NANOG as a common target gene of SOX2 and SOX17 in TGCT cells. In a 
previous publication, it was shown that siRNA-mediated knockdown of NANOG in 
TCam-2 cells induces mRNA expression of extraembryonic endoderm- and 
trophectoderm-associated differentiation markers (GATA2, GATA4, GATA6), but no 
changes in cell morphology were observed [142]. It was assumed that upregulation of 
POU5F1 (OCT4) and SOX17 expression seen after NANOG knockdown prevented 
differentiation of TCam-2 cells [142]. Collectively, this shows a role of NANOG in 
supporting the pluripotency network of seminoma cells downstream of SOX17.  
 
 
Figure 28: Scatterplot of TCam-2 gene expression data with SOX17 ChIP-seq peaks  
Scatterplot of TCam-2 gene expression data (y-axis) and SOX17 ChIP-seq (SOX17 vs IgG) data (x-
axis). Pluripotency genes are highlighted in red.  
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Table 11: Top 20 SOX17 (vs IgG)-peaks with gene expression > 8 in TCam-2 
Gene Name Peak Score Gene Expression 
TUBB 15.4 12.9 
AACS 15.1 8.6 
BCL11B 14.6 9.5 
ZHX2 14.1 8.0 
COL23A1 13.9 10.1 
CD9 13.5 11.9 
BEND7 13.2 8.1 
PSEN2 12.6 10.4 
DCTD 12.5 10.1 
NCBP2 11.4 11.5 
GBAS 11.3 9.5 
UBTD2 11.2 8.3 
PSAP 10.7 12.4 
ADAMTS1 10.7 8.5 
RNF130 10.6 10.2 
SLC39A10 10.5 8.7 
NANOG 10.3 11.4 
ZNF281 10.2 10.1 
HABP4 10.1 8.7 
NFIB 9.95 10.0 
 
 
Altogether I found opposing functions of SOX17 in regulating genes involved with 
pluripotency, but also differentiation in seminoma cells. In contrast, in ECs there is a 
clear correlation between the expression of pluripotency-associated genes (GDF3, 
DPPA3, TRIM71, DPPA5, SALL4, PRDM14 and NANOG) and SOX2 binding (Fig. 29, 
Table 12). This finding confirms the role of SOX2 as a positive regulator of pluripotency 
in EC cells and nicely aligns with the previously generated GSEA (compare Table 9-
10) and ChIP-qPCR data (compare Fig. 25). 21 genes showed a SOX2 peak score > 
15 and a gene expression > 8: LASP1, ETV6, LOC643770, NANOG, KPNA2, SLC2A3, 
DPP9, NDUFS7, COMMD7, RCC2, FAM60A, RAC1, EIF5A, VDAC1, UBE2D2, 
HMGN4, SLC2A14, BCAS4, DNAJB6, NACC1 and ABT1 (Fig. 29). Most of these 
genes have a role in self-renewal of stem cells or cancer stem cells and therefore may 
be associated with cancer malignancy [143-149].  
These data show that in EC cells SOX2 binds and activates different regulators of 
pluripotency (i.e. NANOG), similar to the role of SOX2 in ESCs.  Interestingly, SOX17 
may support pluripotency of seminoma cells also in part via transactivation of 
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pluripotency-associated genes, such as NANOG. The functional consequences of 
SOX17 for binding to genes with roles in neuronal differentiation and embryonic 
development, however, remain unclear. So far, a mechanism by which SOX17 acts as 
a repressor of genes has not been described. Therefore, SOX17 most likely binds and 
transactivates these genes.  
 
 
Figure 29: Scatterplot of 2102EP gene expression data with SOX2 ChIP-seq peaks  
Scatterplot of 2102EP gene expression data (y-axis) and SOX2 ChIP-seq (SOX2 vs IgG) data (x-axis). 
Pluripotency genes are highlighted in red.  
 
 
 
Table 12: Top 20 SOX2 (vs IgG)-peaks with gene expression > 8 in 2102EP 
Gene Name Peak Score Gene Expression 
LASP1 58.2 12.4 
ETV6 47.9 8.5 
NANOG 39.7 12.1 
KPNA2 37.8 11.6 
SLC2A3 37.3 13.9 
DPP9 32.5 8.4 
NDUFS7 30.8 10.9 
COMMD7 29.4 10.5 
RCC2 28.4 13.1 
FAM60A 27.5 12.7 
RAC1 27.1 12.7 
EIF5A 26 11.3 
FAM60A 25.3 12.7 
VDAC1 24.5 12.6 
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UBE2D2 22.9 8.9 
HMGN4 22 10.7 
SLC2A14 21.7 8.9 
NANOG 21.6 12.1 
BCAS4 21.6 8.4 
DNAJB6 21.3 10.7 
 
5.6. In seminoma cells SOX17 regulates TFAP2C and PRDM1 expression 
The question remains, why seminoma cells keep a state of latent pluripotency, if the 
majority of genes bound by SOX17 has roles in neuronal differentiation and embryonic 
development. Similar to seminoma cells, human PGCs express TFAP2C, PRDM1 and 
SOX17 at high levels, which form a tripartite transcription factor network governing 
PGC cell fate [1] (Fig. 1). Importantly, TFAP2C and PRDM1 have roles in the 
suppression of somatic differentiation in PGCs [6]. I here showed that in seminoma 
cells SOX17 activates PRDM1 and TFAP2C expression (Fig. 23 and 28). Although 
PRDM1 was not detected as SOX17 target in the SOX17 vs IgG dataset, it was 
detected in the SOX17 vs Input dataset (8.1) and further binding of SOX17 to the 
compressed motif within the PRDM1 regulatory region was demonstrated by qPCR 
(Fig. 23). A closer look at the SOX17 ChIP-seq profiles at PRDM1, TFAP2C and 
SOX17 regulatory regions confirms that SOX17 binds and putatively regulates this 
transcription factor network, including the activation of its own expression (Fig. 30 A-
B). Although SOX17 was not calculated as SOX17 ChIP-seq target in the 
bioinformatics analysis (maybe due to the stringent settings of the analysis), the ChIP-
seq profile indicates that SOX17 may indeed regulate its own expression (Fig. 30 A). 
Although SOX17 additionally binds somatic genes (linked to in neuro-ectodermal 
development) in seminoma cells, these findings indicate a regulatory role of SOX17 for 
maintaining latent pluripotency via activation of PRDM1 and TFAP2C expression, 
thereby in turn suppressing somatic differentiation. A meta-analysis of our SOX17 
ChIP-seq data with PRDM1 and TFAP2C ChIP-seq (i.e. in human fetal testis) data 
could help to confirm this hypothesis.  
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Figure 30: SOX17 regulates the SOX17-PRDM1-TFAP2C network in seminoma  
(A) SOX17 ChIP-seq profiles at PRDM1, TFAP2C and SOX17 genetic loci (log2 scale). IgG ChIP-seq 
profiles are given as negative control. 
(B) STRING analysis demonstrating interaction of SOX17, PRDM1 and TFAP2C. 
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5.7. SOX17 maintains latent pluripotency of seminoma cells 
Since seminomas always show high expression of both SOX17 and OCT4, an 
essential role of these two transcription factors for maintaining seminoma cell fate was 
suggested. So far, I could demonstrate that SOX17 binds to somatic (i.e. 
neuroectodermal) genes, but also to pluripotency genes in seminoma cells via the 
compressed (SOX17/OCT4) and the canonical (SOX2/OCT4) binding sites. I have 
hypothesized that the transactivation of PRDM1 and TFAP2C expression by SOX17 
may be essential to suppress the somatic differentiation program in seminoma cells 
otherwise activated by SOX17. Now, functional analysis needs to demonstrate whether 
a loss of SOX17 results in suppression of TFAP2C and PRDM1 expression, as well as 
an overall loss of pluripotency and induction of differentiation.  
Therefore, I continued by analysing the effects of SOX17 depletion in seminoma cells. 
For this, TCam-2 cells were transfected with two different single guide RNAs (gRNAs) 
homologous to the second exon of the SOX17 gene locus. CRISPR/Cas9-mediated 
gene editing using both gRNAs should result in a deletion of approximately 130 bp 
(Fig. 31). TCam-2 cells contain six copies of chromosome 8 [59], where SOX17 is 
encoded. Therefore CRISPR/Cas9-mediated gene editing results in a mixture of cells 
displaying deletions in 0-6 alleles of SOX17. 
 
 
 
Figure 31: CRISPR/Cas9 mediated gene editing of SOX17 gene locus  
Two gRNAs were designed, directed against the second exon of the human SOX17 gene (yellow 
arrows). CRISPR/Cas9-mediated gene editing using both gRNAs should result in a final deletion of 
approximately 130 bp. 
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Within 72 hours following transfection of TCam-2 cells with the CRISPR/Cas9 
constructs qRT-PCR demonstrated significant reduction of SOX17 expression, 
suggesting successful gene editing at least in some cells (Fig. 32). Additionally, I was 
able to demonstrate significant downregulation of the pluripotency markers NANOG, 
TFAP2C, POU5F1, PRDM14, ALPL and PRDM1 (Fig. 32). All of these genes were 
shown to be bound by SOX17 according to our ChIP analysis. The fact that 
downregulation of SOX17 results in downregulation of these genes shows that SOX17 
transactivates these genes. Furthermore, these analyses show that downregulation or 
loss of SOX17 ultimately results in a loss of the latent pluripotent state in seminoma 
cells, possibly allowing for cellular differentiation. Notably, since differentiated cells 
lose their capacity to self-renew and divide the derivation of single cell clones was 
prohibited and the following analyses were performed on the TCam-2 Δ SOX17 bulk 
population only. 
 
 
Figure 32: Expression of pluripotency and germ cell markers after depletion of SOX17 in TCam-
2 cells  
qRT-PCR of ChIP-validated targets of SOX17-mediated transcription (red) in TCam-2 Δ SOX17 bulk 
population and GFP-transfected TCam-2 as control (72 hours following transfection). Expression is 
normalized against GAPDH as housekeeping gene. 
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While reduction of SOX17 and its downstream target genes NANOG, TFAP2C, 
POU5F1, PRDM14, ALPL and PRDM1 was clearly evident on mRNA level, protein 
levels of TFAP2C, OCT4, LIN28A and NANOG in the TCam-2 Δ SOX17 bulk  
population were not affected (Fig. 33). However, due to the heterogeneity of the TCam-
2 Δ SOX17 bulk population and the presence of SOX17 wildtype cells within this 
population, Western blot analysis of the whole protein lysate may not have been 
sensitive enough to detect the effects of SOX17 depletion in individual single cells. 
Also, mRNA and protein levels can deviate from one another, due to the prolonged 
half-life of proteins compared to mRNA. 
 
 
 
Figure 33: Depletion of SOX17 in TCam-2 cells  
Western blot showing levels of SOX17, TFAP2C, OCT4, LIN28A and NANOG protein 72 hours following 
CRISPR/Cas9 mediated gene editing of SOX17 gene locus in the TCam-2 Δ SOX17 bulk  population 
(Δ SOX17). The wildtype control represents TCam-2 cells that were transiently transfected with a GFP-
coding plasmid. ACTIN was used as loading control. 
 
 
The analysis of TCam-2 cell morphology 10-15 days following gene editing of SOX17, 
however, revealed signs of cell differentiation, such as the formation of polynucleated 
cells and an enlarged cytoplasm within these differentiated cell colonies (Fig. 34). 
Differentiated areas were negative for the pluripotency marker alkaline phosphatase 
(AP), while cells resembling TCam-2 wildtype cells stained positive for AP activity (Fig. 
35). In comparison, TCam-2 control cells that were transfected with a GFP-coding 
plasmid remained 100% positive for AP activity (Fig. 35). This confirms that the 
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reduction or loss of SOX17 in TCam-2 cells leads to the downregulation of pluripotency 
resulting in induction of differentiation.  
 
Figure 34: Morphology of TCam-2 Δ SOX17 bulk 
Morphology of TCam-2 cells 10 and 15 days following CRISPR/Cas9 mediated gene editing of SOX17 
gene locus (right) compared to wildtype TCam-2 control cells (left). Scalebar = 250 µm. 
 
 
Figure 35: Alkaline phosphatase activity of TCam-2 Δ SOX17 bulk 
AP activity of TCam-2 cells following CRISPR/Cas9 mediated gene editing of SOX17 gene locus (right) 
compared to TCam-2 (GFP-transfected) control cells (left). Scalebar = 250 µm. 
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However, since the analysis of the whole protein lysate by Western blot was not 
sensitive enough to detect loss of TFAP2C and OCT4 on protein level in the TCam-2 
Δ SOX17 bulk population, I additionally performed immunofluorescence staining on 
individual cells that stained either weakly or completely negative for SOX17 protein 
(Fig. 36). As expected, those cells that showed only weak staining for SOX17 protein 
also showed reduced levels of OCT4 and TFAP2C protein. This correlates with the 
ChIP-seq and qRT-PCR data and again confirms TFAP2C and OCT4 as direct targets 
of SOX17-mediated transcriptional activation in TCam-2 cells and shows that depletion 
of SOX17 results in loss of pluripotency and germ-cell-identity in TCam-2. Since 
morphological alterations already suggested induction of differentiation of TCam-2 
cells (Fig. 34), I addressed the question whether the cells differentiate into random cell 
fates or if the induced differentiation is restricted to a specific cell fate. 
Due to the resemblance to multinucleated trophoblast giant cells I analysed expression 
of trophectodermal markers (GATA3, HAND1, αHCG, CDX2, EOMES) (Fig. 37), as 
well as additional germ-cell related markers (SPRY4, NANOS3) (Fig. 37) in the TCam-
2 Δ SOX17 bulk population. Notably, in humans HAND1 is expressed in the 
trophectoderm layer, where it regulates formation of the amniotic membrane [150]. 
GATA3 is expressed within the stem cell compartment of the placenta [151]. Human 
chorionic gonadotropin (αHCG) is a hormone involved in trophoblast differentiation and 
fusion [152]. qRT-PCR demonstrated a loss in germ-cell related markers and 
significant induction of GATA3, HAND1, as well as upregulation of αHCG (Fig. 37). 
Upregulation of GATA3 was additionally confirmed by immunofluorescence staining 
(Fig. 37). 
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Figure 36: SOX17, OCT4 and TFAP2C protein expression in TCam-2 Δ SOX17 bulk 
Immunofluorescence showing expression of SOX17, TFAP2C and OCT4 protein following 
CRISPR/Cas9-mediated gene editing of SOX17 gene locus. The wildtype control represents TCam-2 
cells that were transiently transfected with a GFP-coding plasmid. Scalebar = 250 µm. 
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Figure 37: Expression of germ cell markers and trophoblast differentiation markers after 
depletion of SOX17 in TCam-2 cells  
qRT-PCR of germ cell related markers (brown) and markers of extra-embryonic lineages (green) in 
TCam-2 Δ SOX17 bulk and GFP-transfected TCam-2 as control. Expression is normalized against 
GAPDH as housekeeping gene. 
 
Altogether this indicates that reduction or loss of SOX17 in TCam-2 cells forces the 
cells to initiate differentiation to a trophectodermal cell fate. Interestingly, GATA3 
protein was only detected in TCam-2 cells that were low, but not completely devoid of 
SOX17 protein (Fig. 38). Thus, it seems like different levels of SOX17 lead to formation 
of different cell types, meaning only a reduction but not a complete loss of SOX17 will 
lead to a GATA3+ cell population. Collectively, this shows that SOX17 is essential to 
maintain the latent pluripotency of seminoma cells and to prevent cellular 
differentiation. The analysis of additional markers specific for embryonic (mesoderm, 
endoderm, ectoderm) lineages, as well as for different extra-embryonic cell types of 
the placenta may help to fully understand the plasticity and differentiation potential of 
TCam-2 cells after reduction or complete loss of SOX17. 
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Figure 38: SOX17 and GATA3 protein expression in TCam-2 Δ SOX17 bulk population 
Immunofluorescence showing expression of SOX17 and GATA3 protein following CRISPR/Cas9 
mediated gene editing of SOX17 gene locus. The wildtype control represents TCam-2 cells that were 
transiently transfected with a GFP-coding plasmid. Scalebar = 250 µm. 
 
 
 
5.8. In TGCT cells NANOG is a common downstream target of SOX2 and 
SOX17 
So far, analyses have shown that both SOX2 and SOX17 are key determinants of 
TGCT cell fate by activating expression of pluripotency genes and preventing 
differentiation (either directly or via downstream factors, such as PRDM1 and 
TFAP2C). By comparing SOX2- and SOX17 regulated genes (meaning those genes 
that are bound by SOX2 in EC and SOX17 in seminoma cells), I calculated a common 
overlap of 56 genes (Fig. 39 A). Expectedly, NANOG was found as a common 
downstream target gene of SOX2 in EC and SOX17 in seminoma cells (Fig. 39 A). 
Furthermore, GSEA of these 56 genes revealed that 13 of these genes (CDC42EP4, 
ID1, SGK1, PSEN2, KRT18, PDPN, NANOG, FRAT2, AP3B1, SERINC3, NIF3L1, 
HN1, ALKBH7) are additional NANOG targets in ESCs (gene set: 
‘BENPORATH_NANOG_TARGETS’) [153]. These findings again highlight NANOG as 
a supporting factor in maintaining TGCT cell fate (and pluripotency). Although SOX2 
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and SOX17 do not physically interact with NANOG in EC and seminoma cells, 
respectively, NANOG regulates some of the same target genes.  
Together with other known factors and regulators of pluripotency (TRIM71, LIN28B, 
KLF4, TFAP2C, ALPL) [67, 154-157] that are also bound by SOX2 in EC and SOX17 
in seminoma cells, NANOG forms a regulatory network supporting TGCT pluripotency 
(Fig. 39 B). Collectively, these results suggest that in seminoma cells SOX17 is able 
to take over the role of SOX2 in regulating a set of target genes with roles in 
pluripotency maintenance (via the canonical motif). The binding of SOX17 (and not 
SOX2) to compressed motifs within regulatory regions of somatic genes, however, 
illustrates that both transcription factors are not completely redundant to one another 
in regulating TGCT cell fate. 
 
 
Figure 39: SOX2 and SOX17 regulate a common set of pluripotency genes  
(A) Venn diagram depicting common overlap of SOX2- and SOX17-regulated genes in TGCT cells 
(B) STRING diagram shows interaction of pluripotency regulators that are regulated by SOX2 in 
2102EP and SOX17 in TCam-2 cells. 
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5.9. The Role of SOX2 and SOX17 in TGCT plasticity 
As previously described, we already showed that seminoma cells differentiate into an 
EC-like phenotype after xenotransplantation into the flank of nude mice [75]. During 
this transition SOX17 is downregulated and SOX2 is upregulated. However, so far no 
transition of EC cells to seminoma-like cells was ever demonstrated. We asked 
whether a transition of EC to seminoma could be induced by overexpression of SOX17. 
Therefore, I used the dCas9 CRISPR synergistic activator system (SAM) to induce 
expression of SOX17 in the EC cell line NCCIT. Lentiviral transduction with 100, 200 
and 500 µl SOX17 SAM virus led to a dose-dependent induction of SOX17 protein 
(Fig. 40 A). SOX17 overexpression following transduction with 500 µl virus was further 
confirmed by qRT-PCR (Fig. 40 B). However, this did not lead to morphological 
changes in NCCIT cells (Fig. 40 C). Also, protein levels of OCT4 did not change 
following overexpression of SOX17 (Fig. 40 A).  
I continued to analyse the downstream effects of SOX17 overexpression on selected 
markers by qRT-PCR. Although there was significant overexpression of SOX17 
detected after transduction with 500 µl SOX17 SAM virus (Fig. 40 B), there was no 
significant change in the expression levels of the pluripotency and germ cell-associated 
genes POU5F1, KIT, TFAP2C and PRDM14, which were all identified as targets of 
SOX17 in seminoma cells (Fig. 41, 8.1). Here, it is necessary to note that POU5F1, 
TFAP2C and PRDM14 are already highly expressed in EC cells, therefore no further 
induction may be expected. In contrast, however, PRDM1 and KIT are markers of 
seminomas (Fig. 24). This may explain, why a significant induction of PRDM1 and 
mild, but not significant induction of KIT were observed (Fig. 41). 
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Figure 40: SOX17 overexpression in NCCIT Cells  
(A) Western Blot of SOX17 and OCT4 protein levels in NCCIT cells after transduction with 100, 200 
and 500 µl SOX17 SAM virus (SOX17 OE). As negative control, NCCIT cells were transduced with 
mCherry virus. TCam-2 protein lysate served as positive control. ACTIN was used as loading 
control. 
(B) qRT-PCR demonstrating SOX17 overexpression in NCCIT cells after transduction with 500 µl 
SOX17 SAM virus (SOX17 OE). As negative control, NCCIT cells were transduced with mCherry 
virus. Expression levels were normalized to GAPDH as housekeeping gene. 
(C) Morphology of NCCIT cells 72 hours after transduction with 500 µl mCherry virus (left) or SOX17 
overexpression (SOX17 OE) SAM construct (right). Scalebar = 250 µm. 
 
 
But does the overexpression of SOX17 and downstream effectors (i.e. PRDM1) lead 
to a transition into a seminoma-like cell fate? Since no morphological changes were 
seen (Fig. 40 C) and so far only PRDM1 upregulation was detected, it seems like the 
overexpression of SOX17 alone is not sufficient to force an EC to seminoma transition, 
at least in the NCCIT cell line. Also, SOX2 was still expressed at high levels (Fig. 41) 
Importantly, SOX2 expression is absent in PGCs, TCam-2 and seminoma cells. In 
presence of both SOX2 and SOX17 the two factors might compete for OCT4 binding. 
Thus, in order to achieve a conversion of EC to seminoma cells it may be necessary 
to additionally knockout / knockdown or inhibit SOX2. 
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Figure 41: The effects of SOX17 overexpression in EC cells on the expression of SOX17 target 
genes 
qRT-PCR of selected genes in NCCIT cells after transduction with 500 µl SOX17 SAM virus (SOX17 
OE). As negative control, NCCIT cells were transduced with mCherry virus. Expression levels were 
normalized to GAPDH as housekeeping gene.
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6. Discussion II 
Here, I showed that SOX2, which is highly expressed in EC cells, partners with OCT4 
to bind to canonical (SOX2/OCT4) binding sites on the DNA. This way, SOX2 regulates 
important players of pluripotency in ECs, such as SOX2, NANOG, DPPA4, LIN28A, 
SALL4, TRIM71, GDF3 and PRDM14. I therefore conclude that SOX2 in EC cells has 
a similar role as SOX2 in ESCs, which is to maintain pluripotency and to prevent 
differentiation. Although NANOG does not directly interact with SOX2 and OCT4 in 
ECs to regulate downstream target genes, I believe that it has a supporting role in 
pluripotency maintenance downstream of SOX2. 
In seminoma cells we find a high expression of SOX17. In this cell type SOX17 partners 
with OCT4 to bind to both compressed (SOX17/OCT4) and canonical (SOX2/OCT4) 
binding sites on the DNA. Gene set enrichment analysis has shown that the majority 
of SOX17-bound genes in seminoma cells are having roles in neuronal differentiation 
(such as ZHX2, COL23A1, CD9, BEND7, PSEN2, GBAS, UBTD2, PSAP, ADAMTS1 
and ZNF281). This is surprising, since seminoma cells maintain a latent pluripotent 
state and do not spontaneously differentiate into embryonic (and / or neuronal) 
lineages like ECs, evident by the expression of i.e. LIN28, PRDM14, TFAP2C, OCT4 
and NANOG. Only in presence of TGFβ, EGF and FGF4 it was demonstrated that 
TCam-2 cells differentiate into mixed non-seminoma lineages (then showing features 
of choriocarcinomas, teratomas and yolk-sac tumours) [73]. But what prevents the 
differentiation of seminoma cells into neuronal lineages? Most importantly, I could 
show that SOX17, in seminoma cells, also binds and regulates markers of pluripotency, 
such as NANOG, DPPA4, LIN28A, PRDM14, POU5F1 and TRIM71. Therefore SOX17 
directly contributes to the expression of the seminoma pluripotency cluster and in this 
respect replaces SOX2 in EC cells.  Additionally, SOX17 induces expression of the 
PGC specifiers PRDM1 and TFAP2C. Both factors are known to suppress somatic 
differentiation in PGCs [8]. Thus, PRDM1 and TFAP2C may similarly suppress 
(neuronal) differentiation in seminoma cells. In line with this hypothesis, I could 
demonstrate that many of those regions bound by SOX17 in seminoma cells (i.e. 
neuronal genes) harbour additionally binding motifs of PRDM1 and TFAP2C. So, in 
seminoma cells SOX17, PRDM1 and TFAP2C could cooperate to maintain TGCT cell 
fate and prevent somatic differentiation. 
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In line, loss of SOX17 in seminoma cells resulted in loss of TFAP2C and PRDM1 
expression, resulting in differentiation into trophectodermal-like lineages. Therefore, it 
seems plausible that SOX17 has a regulatory function for maintaining pluripotency in 
seminoma cells, in part via activation of PRDM1 and TFAP2C expression, but also by 
directly activating expression of germ-cell and pluripotency-associated target genes, 
such as NANOG, DPPA4 and LIN28A (Fig. 42). It would be interesting to see, whether 
expression of TFAP2C or PRDM1 protein could rescue the effects of loss of SOX17 in 
seminoma cells and prevent differentiation. 
Interestingly, we have shown in a different study that the cancer-testis antigen PRAME 
is also repressing differentiation of seminoma cells (Fig. 42) [136]. PRAME is highly 
expressed in seminoma and TCam-2 cells and absent in ECs [136]. PRAME 
knockdown in seminoma cells led to a downregulation of pluripotency and germ-cell-
related markers and induction of genes associated with endodermal or mesodermal 
differentiation [136]. Also, during seminoma to EC transition downregulation of SOX17 
was first followed by downregulation of PRAME, which suggested that PRAME acts 
downstream of SOX17 [75, 136]. However, here PRAME was not identified as a direct 
target of SOX17-mediated transcription. Nonetheless, our previous analyses indicate 
that PRAME also represses somatic differentiation in seminoma cells, without being a 
direct transcriptional target of SOX17 (Fig. 42). 
While we had already postulated a role for SOX17 in maintaining pluripotency of 
seminoma cells, I could now additionally show that loss of SOX17 induces 
differentiation of these cells into extra-embryonic lineages. In a previous study by Irie 
et al. it was demonstrated that siRNA-mediated knockdown of SOX17 in TCam-2 cells 
leads to a loss of pluripotency- and germ cell- related markers [6]. However, the 
authors did not investigate the long-term effects of SOX17 knockdown in TCam-2 cells. 
Here, the differentiation of seminoma cells into extra-embryonic cell types after SOX17 
loss resembles the differentiation of seminoma cells seen after treatment with TGFβ, 
EGF and FGF4 into mixed non-seminoma [73], although this differentiation was not 
accompanied by a loss in SOX17 expression [73]. 
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Figure 42: Transcription factor network maintaining seminoma pluripotency 
SOX17 and OCT4 interact and bind to the DNA, thereby activating expression of somatic genes and 
genes associated with pluripotency, including NANOG. Also, SOX17 regulates TFAP2C and PRDM1 
expression, which in turn are able to suppress somatic differentiation and maintain pluripotency. PRAME 
may additionally support the pluripotency network of seminoma cells by repressing somatic 
differentiation. 
 
 
Nonetheless, it seems interesting that seminoma cells respond to different signalling 
cues (i.e. treatment with TGFβ, EGF and FGF4) or dysregulations (i.e. loss of SOX17) 
with the differentiation into extraembryonic lineages that resemble mixed non-
seminoma / choriocarcinoma. Especially the multinucleated cell types within these 
differentiated colonies are reminiscent of syncytial trophoblastic cells. Such 
trophoblast-like foci are sometimes seen within patient seminoma samples [158], thus 
the data presented here could serve to explain the development of these foci. In light 
of the presented data, I speculate that distinct signalling cues or cytokines present 
within the tumour microenvironment could favour a downregulation of SOX17 levels in 
seminomas, thereby inducing seminoma differentiation into extra-embryonic cell tyes.  
 
In conclusion, seminomas may only keep their cell identity by expressing SOX17 (and 
its partner OCT4). Due to the resemblance of seminoma cells to GCNIS and PGCs, 
seminomas are considered the default pathway of GCNIS progression. Inhibition of 
BMP signalling, however, can result in a seminoma to EC transition, accompanied by 
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downregulation of SOX17 and upregulation of SOX2 [75]. In turn, the overexpression 
of SOX17 alone did not lead to a shift in EC cell identity towards a seminoma 
phenotype, nor did it alter SOX2 levels. This is despite the fact that OCT4 has a much 
higher affinity for the SOX17 DNA complex, at least on compressed motifs (binding 
energy: −3.86 ± 0.74 kcal/mol), than for the SOX2 DNA complex at canonical motifs 
(binding energy: 8.09 ± 0.73 kcal/mol) [71]. One theory in favour of a preferred SOX2-
OCT4 binding to canonical motifs in ECs would be that the DNA is more accessible at 
regions containing the canonical motif, while DNA accessibility is restricted at regions 
containing compressed motifs (i.e. by DNA methylation). Additional ATAC-seq on EC 
and seminoma chromatin could therefore help to investigate this hypothesis. 
Interestingly, although SOX2 levels were not altered upon overexpression of SOX17 
in ECs, we find a mutual exclusive expression of SOX2 and SOX17 in TGCT subtypes. 
Several hypotheses try to explain this phenomenon: In TCam-2 cells Kushwaha et al. 
proposed that SOX2 repression is mediated by histone methylation (H3K27me3) via 
the polycomb repressive complex [159]. In colorectal cancer expression of SOX2 is 
suppressed by the SOX17 target miR-371-5p [160]. However, I could not identify miR-
371-5p as a SOX17 target in TCam-2 cells. Also, it seems like SOX17 induction alone 
is not sufficient to alter SOX2 levels in EC cells in vitro. In the future, it would be 
interesting to investigate the mechanism by which SOX17 is repressed during TCam-
2 to EC conversion (after xenotransplantation into the flank of nude mice) in more 
detail, in order to understand whether a similar conversion was also possible from EC 
to seminoma. Also, it would be interesting to see how SOX2 knockout / knockdown 
affects the outcome of SOX17 overexpression in EC cells.  
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8. Appendix 
 
8.1. Top 500 ChIP-seq Peaks of SOX2 and SOX17 ChIP in TGCT Cells 
SOX2 vs IgG  SOX2 vs Input  SOX17 vs IgG  SOX17 vs Input 
Peak 
Score 
Annotated 
Gene 
 Peak 
Score 
Annotated 
Gene 
 Peak 
Score 
Annotated 
Gene 
 Peak 
Score 
Annotated 
Gene 
150.2 LINC00324  58.0 MIR4521  20.6 TBX3  15.7 KIAA1456 
86.5 MIR4521  45.4 PRSS16  18.6 TRPS1  14.7 SPOCD1 
75.6 LOC105374988  41.8 PRSS16  17.6 MIR5692A1  13.2 BEND7 
73.9 RNVU1-6  41.5 NLGN1-AS1  17.2 DAPL1  13.1 LOC105369739 
67.2 LINC01962  40.9 LINC01012  17.1 SPOCD1  13.0 SLC6A6 
58.2 LASP1  38.6 RNVU1-6  17.0 EPHB1  12.9 MIR4318 
51.8 MIR5188  37.3 LINC01962  17.0 SCARNA3  12.9 TUBB 
51.4 HIST1H4H  35.3 LINC01623  15.8 KIAA1456  12.6 COL23A1 
49.6 LINC01012  34.7 LOC105374988  15.7 LINC01716  12.4 MC2R 
48.8 PRSS16  34.1 OR4D9  15.4 TUBB  12.2 C1orf100 
47.9 ETV6  33.8 LOC105374988  15.1 AACS  12.0 PTPN5 
46.4 BICD1  32.6 LINC01962  15.1 UTS2B  11.6 EIF2S2 
46.4 LOC643770  30.5 MIR4638  14.7 PPFIBP2  11.4 XXYLT1 
43.8 KCTD2  30.3 LOC105374988  14.6 BCL11B  11.4 PIF1 
43.4 PRSS16  28.9 ETV6  14.3 LINC01991  11.4 CD9 
43.4 OR4D9  27.5 MIR3162  14.2 CRYGB  11.3 CACHD1 
43.0 LINC01623  25.8 MIR3162  14.2 LOC284581  11.3 PRKAR2B 
42.0 MIR4638  25.4 HFE2  14.1 ZHX2  11.0 NUAK1 
41.5 NLGN1-AS1  25.4 WWTR1  13.9 COL23A1  10.9 LINC00251 
41.4 LINC01962  25.3 KCTD2  13.5 CD9  10.7 SSUH2 
40.6 LOC105374988  25.3 CASP16P  13.4 LOC729732  10.5 LOC729732 
39.7 NANOG  23.5 LINC00324  13.2 BEND7  10.3 PER4 
37.8 KPNA2  22.4 HIST1H4H  12.8 ZNF853  10.2 UTS2B 
37.3 SLC2A3  22.4 LINC00533  12.6 PSEN2  10.1 HABP4 
36.6 PRSS16  22.2 OR1F1  12.5 DCTD  9.95 ASIC2 
36.4 HES7  21.8 NDUFS7  12.4 MIR4454  9.95 SNX16 
36.2 OR1F1  21.5 RNY1  12.3 PIF1  9.76 MIR5692A1 
34.7 OR1F1  21.3 DNAJB6  12.2 GPR37L1  9.66 MIR3116-2 
34.6 LINC01012  21.3 ZNF184  12.1 SSUH2  9.56 GBAS 
34.2 LINC01012  21.2 HIST1H4H  12.1 BDNF  9.37 LOC441155 
33.9 TRIM7  20.9 SLC45A1  11.9 LINC00483  8.98 LINC02104 
33.7 ZFP64  20.4 OR6S1  11.9 MIR4318  8.88 PSAP 
33.5 MIR3162  19.8 CFAP126  11.8 SRGAP3-AS3  8.78 GSTA3 
33.3 MDM4  19.7 ABT1  11.8 MC2R  8.69 ZSCAN2 
32.5 DPP9  19.1 OR1F1  11.7 LINC02104  8.59 LOC102724804 
31.7 MIR3162  19.0 BTN3A2  11.6 DDX11-AS1  8.59 GC 
31.5 CHST14  19.0 RCC2  11.5 SERPIND1  8.59 ZAP70 
30.8 HIST1H4H  19.0 RN7SL2  11.5 TPRG1  8.49 RSPO3 
30.8 NDUFS7  18.9 MARCKS  11.5 C4orf51  8.39 ZFAT-AS1 
30.6 CASP16P  17.9 ZFP64  11.4 NCBP2  8.39 NXPH1 
30.3 MIR5188  17.9 LASP1  11.4 CACHD1  8.39 CFAP44-AS1 
30.1 WWTR1  17.7 HIST1H4H  11.3 TMEM132B  8.39 PPFIBP2 
29.9 KIAA1551  17.7 PRDM14  11.3 GBAS  8.30 MIR3139 
29.4 COMMD7  17.7 DPP9  11.2 ZAP70  8.20 BDNF 
29.4 LINC00324  17.5 LOC101929011  11.2 SLC6A6  8.20 LOC101928988 
29.2 LINC00533  17.2 CCDC129  11.2 UBTD2  8.10 RIPK2 
29.2 LINC01556  17.0 HM13-AS1  11.1 MIR1915  8.10 CLRN1 
28.4 RCC2  16.8 DPPA5  11.1 LOC102724532  8.10 FRAT1 
27.6 KIAA1551  16.3 SNX16  11.1 SPRY4-IT1  8.00 LINC02095 
27.5 MIR3162  16.2 LINC00443  11.0 MIR3116-2  8.00 OTUD4 
27.5 FAM60A  16.1 HIST1H4H  10.9 FAM49A  7.91 ZNF724 
27.2 KIAA1551  15.9 LINC01556  10.8 
EPB41L4A-
AS2 
 7.91 PDZD8 
27.2 LINC00339  15.8 MPPED2  10.7 ADAMTS1  7.91 FRAS1 
27.1 RAC1  15.7 LOC100996654  10.7 PSAP  7.81 COL17A1 
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26.0 EIF5A  15.7 MIR4643  10.7 TMPRSS11E  7.81 MIMT1 
25.8 PLVAP  15.2 OR6S1  10.6 PYDC2  7.81 CYP7A1 
25.6 OR6S1  15.2 MIR3162  10.6 RNF130  7.71 IER2 
25.3 FAM60A  15.2 PRSS16  10.5 GSTA3  7.71 CARS 
25.2 OR1F1  15.2 MIR3143  10.5 SLC39A10  7.61 PRKD1 
24.9 HIST1H4H  15.0 EIF5A  10.4 CCZ1B  7.52 LINC01005 
24.8 MLLT1  15.0 MIR5188  10.3 NANOG  7.52 C8orf34-AS1 
24.7 CTC1  14.9 LINC01012  10.3 LYST  7.52 ATL2 
24.5 VDAC1  14.9 TRIM55  10.2 LOC102724579  7.42 ZBTB7C 
24.4 ALOXE3  14.8 MIS18BP1  10.2 ZNF281  7.32 KHDRBS3 
24.4 LOC100049716  14.8 HCG16  10.2 MIR646  7.32 LOC101927881 
24.3 HM13-AS1  14.8 MIR4634  10.1 LOC105369739  7.22 YWHAZ 
24.3 AMN1  14.6 LINC02016  10.1 HABP4  7.22 LINC01381 
24.2 ZNF184  14.4 VN1R10P  10.1 MIR548I1  7.12 ZNF281 
23.8 HCG16  14.3 DOT1L  9.95 LOC101929341  7.12 LOC101928304 
23.5 LINC00533  14.3 MDM4  9.95 SNX16  7.12 ESRRB 
23.5 LINC01623  14.3 ZYG11A  9.95 NFIB  7.03 AGBL4-IT1 
23.1 SCAMP4  14.1 KIAA1551  9.95 CCDC179  7.03 MIR548XHG 
23.0 DOT1L  14.0 RBMS3-AS1  9.95 ARTN  7.03 SUSD3 
23.0 MPZL1  14.0 ZNF184  9.86 COL17A1  7.03 CNTN4-AS1 
22.9 UBE2D2  13.8 LINC01623  9.76 IER2  6.93 SMG8 
22.9 LINC01012  13.8 ARHGEF3  9.76 PTPN5  6.93 LINC00862 
22.7 SLC45A1  13.8 SOX5  9.76 MIR141  6.93 SIAE 
22.7 GNGT2  13.5 USP7  9.66 NARS2  6.83 DAPL1 
22.4 OR2V2  13.5 CCNH  9.66 LOC101928988  6.73 KIT 
22.4 HES7  13.4 ZBED9  9.66 EIF2S2  6.73 PRDM1 
22.2 RNY1  13.2 ZNF184  9.56 TFDP2  6.73 ALDH3B2 
22.1 LINC01556  13.1 LINC00339  9.56 H3F3A  6.73 GUCY1A3 
22.0 HMGN4  13.1 CHST14  9.56 MIR548AG2  6.64 CXCR4 
21.7 SLC2A14  13.0 LINC00533  9.37 LOC441155  6.64 MIR4454 
21.7 BTN3A2  12.9 SSB  9.37 KIDINS220  6.54 CXorf21 
21.6 BCAS4  12.7 PRSS16  9.37 XXYLT1  6.54 IQCF1 
21.6 NANOG  12.6 CLEC3A  9.37 LOC105369739  6.54 CNGB1 
21.3 DNAJB6  12.6 LINC01822  9.27 SPRY4-IT1  6.54 CCDC179 
21.3 ZNF692  12.5 MIR5188  9.27 CPNE8  6.54 ENPP2 
21.1 PRSS16  12.5 ZNF184  9.17 ZNF592  6.44 RBFOX1 
20.6 A2ML1  12.5 ZHX2  9.08 LOC101928797  6.44 MIR181C 
20.6 CFAP126  12.3 LINC01012  9.08 GSN  6.44 LOC100506885 
20.4 LINC01498  12.2 LINC01012  9.08 MIMT1  6.34 DDX11-AS1 
20.3 ZYG11A  12.1 ZNF483  8.98 LOC105375075  6.34 LOC101929544 
20.3 NACC1  12.1 SMARCA2  8.98 KALRN  6.25 HULC 
20.2 ABT1  12.1 LINC01012  8.88 POU5F1  6.25 KIDINS220 
20.2 TMPO-AS1  12.0 SMARCC2  8.88 SOX5  6.25 SLC39A11 
20.0 RNY3  11.8 HTR1F  8.88 LINC01356  6.15 LINC01060 
19.8 LOC100996654  11.8 NOBOX  8.78 PCDH1  6.15 NR2F2 
19.8 LINC00941  11.8 OR1F1  8.78 LINC01951  6.15 NDUFB6 
19.8 SLC2A14  11.8 FBRS  8.78 KRT18  6.05 LOC105376360 
19.7 RN7SL2  11.7 SMARCA2  8.78 PGAP1  6.05 IRX5 
19.5 MIR6883  11.7 SHISA2  8.78 RNF11  6.05 LOC101928008 
19.5 ZNF184  11.6 DDAH1  8.69 CARS  6.05 CDH18 
19.4 RNF112  11.6 LRIG1  8.59 MIR3977  6.05 BASP1 
19.4 SLC2A14  11.4 PLEKHB2  8.49 TSPAN9  5.95 LOC102725080 
19.3 PRDM14  11.4 LINC01629  8.49 PUM2  5.95 PMAIP1 
19.3 LINC01012  11.4 MIR5692B  8.39 LINC02114  5.95 NR2F6 
19.3 GNG7  11.4 HK3  8.39 FTO  5.95 MIR8084 
19.3 HIST1H4H  11.3 CNN1  8.39 ZNF552  5.95 LINC02032 
19.1 OSCP1  11.3 MIR5188  8.39 BICD1  5.95 RNF130 
19.1 PLXDC1  11.2 HSPA6  8.30 
MACROD2-
AS1 
 5.95 ESRP1 
19.1 MIR193BHG  11.2 NIFK-AS1  8.30 FSCN1  5.95 ZNF565 
19.0 MIR4638  11.2 KPNA2  8.30 CCDC129  5.86 CBR4 
19.0 OR1M1  11.2 DUSP6  8.30 CRHBP  5.86 PYDC2 
19.0 MIR4472-2  11.1 MKRN1  8.20 CAND1.11  5.86 LOC101928797 
19.0 DPPA5  11.1 LINC01012  8.20 SMYD3  5.86 STARD13 
18.9 MARCKS  11.1 AFF1  8.20 MIR4634  5.76 NRF1 
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18.8 PLLP  11.1 ERCC1  8.20 ZFAT-AS1  5.76 ARSJ 
18.6 LOC105376805  11.1 NACC1  8.20 IL20RB  5.76 TPTE 
18.5 TRIM7  11.1 MIR3690  8.20 SLC45A1  5.76 DDX18 
18.4 LINC01012  10.8 MORC3  8.10 EDIL3  5.76 KIAA1456 
18.4 B4GALT5  10.8 GRPR  8.10 NCEH1  5.66 DNAJB6 
18.2 UBE2D2  10.8 GNGT2  8.00 SPIDR  5.66 OCM 
18.2 LINC01841  10.8 PLEKHG2  8.00 MIR3191  5.66 RPA1 
18.2 PCCB  10.8 ILF2  8.00 LOC100130298  5.66 MIR6085 
18.1 LOC100507468  10.7 TIA1  8.00 BAMBI  5.66 FAM83A 
18.0 PCDH1  10.7 CASP16P  8.00 TMEM87B  5.66 PRDM14 
18.0 PSMB2  10.5 LINC01448  7.91 ZNF724  5.56 TSN 
18.0 FOXK2  10.5 SLC35D3  7.91 IQCF1  5.56 C5orf66-AS1 
18.0 RASSF8-AS1  10.5 APOBEC3F  7.91 LOC101927735  5.47 SDK1 
17.9 USP48  10.4 RPL36  7.91 GREB1L  5.47 MIR1915 
17.9 KIAA1551  10.4 MUC4  7.81 PMAIP1  5.47 HDAC2 
17.7 LINC01623  10.4 LOC100131289  7.81 MIR135B  5.47 FAM136A 
17.7 OAT  10.3 PIH1D1  7.81 LINGO2  5.47 TMEM261 
17.6 NANOGNB  10.3 GLOD5  7.81 TIFAB  5.37 LOC100289230 
17.6 SRCIN1  10.2 RCOR1  7.81 LOC100128386  5.37 MIR610 
17.6 SALL4  10.2 MIR9-2  7.71 ZBTB2  5.37 LINC02003 
17.5 LOC101929011  10.2 PLAGL1  7.71 CFAP44-AS1  5.37 PIN1P1 
17.5 MIR3143  10.2 ZBTB5  7.71 CYP4A22  5.37 DCTD 
17.3 ZBTB8OS  10.2 TERF1  7.61 MIR548AU  5.37 LOC100192426 
17.3 KDM4C  10.2 GPD2  7.61 MIR548A2  5.37 BCL9 
17.2 LINC01012  10.0 HIST1H4H  7.61 ZFAT-AS1  5.37 ATP6V1G3 
17.2 CCDC129  10.0 GGACT  7.61 ADAMTS6  5.37 PPM1A 
17.1 PMS2CL  9.89 ZC3HAV1L  7.61 TFRC  5.37 NPAS3 
17.0 MIR193A  9.89 ANKRD1  7.61 TAB2  5.37 LOC102546299 
17.0 ATF1  9.89 NANOG  7.52 TBCE  5.37 LOC101927056 
17.0 SNORA38B  9.77 TRIP4  7.52 PDP1  5.27 SMYD3 
17.0 
C7orf55-
LUC7L2 
 9.77 LOC105374988  7.52 DCD  5.27 C1orf105 
16.8 UBE2G1  9.77 SIAH2  7.42 IGSF5  5.27 MIR383 
16.8 PCGF6  9.77 PCLO  7.42 ZBTB7C  5.27 MGC27382 
16.8 LINC00443  9.64 LINC01947  7.42 LOC105374428  5.27 LINC01375 
16.8 ZNF184  9.51 UBE2D2  7.42 PDZD8  5.27 NABP1 
16.8 SMARCC2  9.51 LINC00324  7.42 KIZ  5.17 MDH1 
16.7 EEF2K  9.51 SLC35F3  7.32 KHDRBS3  5.17 OR6S1 
16.7 PMS2P4  9.38 RIF1  7.32 GBA3  5.17 LOC101927847 
16.6 LINC01447  9.38 SPATA45  7.32 ENPP2  5.17 MIR3191 
16.6 VSIG10  9.38 GRIA3  7.32 LINC01267  5.17 FIS1 
16.4 MLXIPL  9.25 REST  7.32 LOC101927881  5.17 ITGA9-AS1 
16.4 MELK  9.25 BTN3A2  7.32 LINC02095  5.17 WDR36 
16.4 LINC02016  9.25 CLPP  7.32 FSCN1  5.17 LOC730100 
16.3 SNX16  9.25 LINC00533  7.32 TCERG1L  5.17 UMODL1-AS1 
16.2 MTA3  9.12 RPA3  7.32 MIR6085  5.08 ABCB5 
16.2 AXIN2  9.12 ZBTB8B  7.32 NUDT12  5.08 MACROD2 
16.2 FOXK2  9.12 MIR3675  7.22 PLXNA2  5.08 CFHR5 
16.2 ZNF815P  9.12 TTC39B  7.22 MIR3139  5.08 GBA3 
16.1 ZNF184  9.00 LOC284788  7.12 CCAT2  5.08 TEAD1 
16.1 RLIM  9.00 ALOXE3  7.12 LOC728715  5.08 DPPA5 
15.9 
BORCS7-
ASMT 
 9.00 LOC102724623  7.12 UMODL1-AS1  5.08 LOC100129216 
15.9 LOC101926933  9.00 MDM4  7.03 GPR156  5.08 GTF2I 
15.8 SMU1  8.87 JAKMIP2-AS1  7.03 AGBL4-IT1  5.08 KIAA0513 
15.8 MPPED2  8.74 MIR4666B  7.03 LOC102724404  5.08 KCTD3 
15.8 USP7  8.74 LINC01589  7.03 SEPT9  5.08 KYNU 
15.8 ZYG11A  8.74 RRAGC  7.03 AQP6  5.08 CUEDC1 
15.8 OR1F1  8.74 LOC101928782  7.03 EPHA3  4.98 PTPRD-AS2 
15.7 MIR4643  8.61 PMS2CL  7.03 MIR548XHG  4.98 REXO1L2P 
15.7 AKAP3  8.61 COX5A  6.93 LSAMP-AS1  4.98 MIR548AD 
15.7 LOC105374988  8.61 ASIC2  6.93 COL4A1  4.98 LINC01923 
15.5 MIR5188  8.61 LOC101929154  6.93 MIR4266  4.98 MBNL1 
15.5 RAB11B  8.61 ZNF717  6.93 C9orf72  4.98 PCGEM1 
15.5 DUSP6  8.61 RIMS2  6.93 LOC102723886  4.98 FREM3 
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15.4 RNF130  8.48 RNF112  6.93 SPOCK2  4.98 SLC6A15 
15.3 VN1R10P  8.48 LINC00922  6.83 COL23A1  4.98 LOC102467223 
15.3 SMARCD2  8.48 WNT11  6.83 WSPAR  4.98 DCAF4L2 
15.2 PARP11  8.48 KLRG2  6.83 SLC35D2  4.98 LINC00603 
15.2 OR6S1  8.48 MIR591  6.83 SCUBE3  4.98 PSTPIP2 
15.0 LOC100131289  8.48 TXLNG  6.83 PRLH  4.98 HNF4G 
15.0 TIA1  8.48 HOXB1  6.83 ZNF521  4.88 GABRA6 
14.9 HOXB1  8.35 ZNF692  6.83 TNFAIP8  4.88 LINC01676 
14.9 LOC440570  8.35 COL17A1  6.83 PLXNA2  4.88 COL23A1 
14.9 LINC01716  8.22 SALL4  6.73 ITPRIP  4.88 PRDM14 
14.9 BTN3A2  8.22 OTX2  6.73 LINC00534  4.88 SNTG1 
14.8 LINC01623  8.22 CSF2RA  6.73 LOC101928304  4.88 ST6GALNAC1 
14.8 MIR4634  8.22 MIR629  6.73 GTF2I  4.88 KCNC2 
14.8 NPM1  8.22 DDX53  6.64 CXCR4  4.88 CUBN 
14.8 MIS18BP1  8.22 CECR1  6.64 DPPA5  4.88 FRMD4A 
14.6 ARHGEF3  8.22 EDIL3  6.64 RNF130  4.88 SRSF10 
14.6 ANG  8.10 AK4  6.54 GC  4.88 STMN1 
14.5 ELAVL1  8.10 KLF9  6.54 MIR1204  4.88 ZNF703 
14.4 ZBED9  8.10 EDDM3B  6.54 KIAA0513  4.88 MLN 
14.4 RPN1  8.10 LOC100270746  6.54 LOC102723672  4.88 DGKB 
14.3 PRSS16  8.10 LINC00533  6.54 MIR205  4.88 KLF6 
14.3 HEATR3  8.10 LINC01012  6.44 OLFM2  4.88 CH25H 
14.3 ARHGEF10L  8.10 MYO1E  6.44 FRMD6  4.88 TBCEL 
14.3 TRIM55  8.10 FTO  6.44 CCZ1B  4.88 LRRIQ3 
14.1 SMARCA2  7.97 LINC00533  6.44 DMRT1  4.88 MOG 
14.1 CECR1  7.97 C19orf25  6.44 TFAP2C  4.78 ALPL 
14.1 MIR21  7.97 MIR4268  6.44 LOC100506885  4.78 RIN1 
14.0 SUMO2  7.97 LINC01320  6.44 KLRB1  4.78 PLOD1 
14.0 FCGR2A  7.97 TRA2B  6.34 C5orf66-AS1  4.78 PPFIA2 
14.0 SLC25A39  7.97 LOC102546229  6.34 AGK  4.78 LINC01655 
14.0 FLJ41278  7.97 MIR548AQ  6.34 GALNT8  4.78 MLLT10P1 
14.0 MKRN1  7.97 LOC100507468  6.34 COL2A1  4.78 TMPRSS11B 
14.0 RBMS3-AS1  7.97 TRA2B  6.34 C1orf105  4.68 LINC01037 
14.0 PHC1  7.97 ITSN1  6.34 LOC101928674  4.68 MIR1915 
14.0 MIR2117  7.84 SHISA5  6.34 LOC101929544  4.68 LINC02032 
13.9 WNT11  7.84 LINC01556  6.34 C17orf64  4.68 TMUB2 
13.9 HOXB1  7.84 RAB5C  6.34 BMPR1A  4.68 ZC2HC1A 
13.9 PPM1B  7.84 HSPA7  6.25 TRABD2A  4.68 MIR7977 
13.8 TXLNG  7.71 MIR3143  6.25 CHCHD6  4.68 LOC105376430 
13.8 SOX5  7.71 XACT  6.25 NMNAT2  4.68 BRWD3 
13.6 SLC2A14  7.71 MIR193BHG  6.25 LINC01696  4.68 LOC102723886 
13.6 LOC643770  7.71 MIR3663  6.25 CNTLN  4.68 COL3A1 
13.6 ZNF184  7.58 SOX6  6.25 SUMO1P1  4.68 UST-AS1 
13.6 PLEKHB2  7.58 LINC01867  6.25 SLC39A11  4.59 USH2A 
13.5 MIR4472-2  7.58 MIR371A  6.15 TNFRSF6B  4.59 NRXN1 
13.5 ATP5G1  7.58 FEM1A  6.15 PKP1  4.59 SGIP1 
13.5 SERBP1  7.58 EPHA3  6.15 ZMIZ1-AS1  4.59 KCNK2 
13.5 ZNF184  7.45 SEMA3A  6.15 PXDN  4.59 LINC00971 
13.5 NINJ2  7.45 RIOX1  6.15 IGF2BP1  4.59 LOC105369893 
13.5 CCNH  7.45 LINC01012  6.15 LOC105376430  4.59 DEFB1 
13.4 POM121L2  7.45 LOC101927159  6.15 CST5  4.59 SLAMF1 
13.4 KLRG2  7.45 LINC01447  6.15 CNGB1  4.59 GSX1 
13.4 ZNF839  7.45 PDCL  6.15 NR2F2  4.59 BRINP3 
13.2 DHRS7B  7.45 DHRS7B  6.05 LINC01496  4.59 LOC101928509 
13.1 MIR5188  7.45 ZNF592  6.05 RIPK2  4.59 BCAR3 
13.1 SHISA5  7.45 DRD1  6.05 CHN2  4.59 CYP4F35P 
13.1 CLDN3  7.45 FAM60A  6.05 ABCG2  4.59 SLC6A15 
13.0 LINC00533  7.45 MIRLET7I  6.05 CXorf21  4.59 OR2AP1 
13.0 GPD2  7.32 CDX2  6.05 LOC101928008  4.59 LINC01267 
12.9 CNN1  7.32 RBM43  6.05 INPP4A  4.59 USP44 
12.9 SH2B3  7.32 GRM3  6.05 ALPL  4.59 SHOX2 
12.9 PSMB3  7.32 PABPC4L  5.95 BCAR3  4.59 PABPC4L 
12.9 RNU6-7  7.20 FAM181B  5.95 MIR8084  4.59 LINC01884 
12.9 LINC01775  7.20 SMARCA1  5.95 CFL1  4.49 KCNC2 
12.9 SSB  7.20 MAOA  5.95 LOC100507468  4.49 CRB1 
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12.7 CERS4  7.20 TLK1  5.95 ESRRB  4.49 LINC01947 
12.7 KDELR2  7.20 RBM17  5.95 LINC01210  4.49 CWF19L2 
12.6 CFAP126  7.20 HSPA9  5.95 SLC36A4  4.49 DOCK3 
12.6 CCND2  7.07 ACTR3B  5.95 ZNF565  4.49 LINC01720 
12.6 SMARCA2  7.07 DPYD-AS2  5.95 SUGCT  4.49 TYRP1 
12.6 MIR589  7.07 PMS2P4  5.86 FAM222B  4.49 PRG4 
12.6 CLEC3A  7.07 PTPRZ1  5.86 LMO7-AS1  4.49 LINC01815 
12.6 CCND2  7.07 LINC01440  5.86 LINC01699  4.49 MKRN9P 
12.5 RCOR1  7.07 LOC101928386  5.86 GRK5  4.49 PRRC2B 
12.5 SUZ12P1  7.07 TPRG1-AS1  5.86 FAM188B  4.49 UNC80 
12.5 SEPHS1  7.07 NICN1  5.86 ITGB1  4.49 DOK5 
12.5 GACAT3  6.94 RNF113A  5.86 SCGB1A1  4.49 LRIG3 
12.5 ELAVL1  6.94 TMEM214  5.86 PABPC4L  4.49 SNTG1 
12.5 CFAP126  6.94 LOC101928519  5.86 CYP1B1  4.49 LINC01370 
12.5 ZHX2  6.94 KCMF1  5.86 FBXW4  4.49 DCN 
12.3 LINC01012  6.94 LOC101929154  5.86 UBALD2  4.39 SLC6A5 
12.3 CNR2  6.94 LINC01340  5.86 SLC39A1  4.39 COMMD1 
12.3 SERBP1  6.94 LINC01714  5.76 SALL1  4.39 DGKB 
12.3 COX6A1  6.94 TOB2P1  5.76 DNTT  4.39 OR6N1 
12.3 IER2  6.81 RNF187  5.76 ESRP1  4.39 FRAT2 
12.3 BISPR  6.81 CNTN4  5.76 LOC101929011  4.39 LINC02127 
12.2 ZC3HAV1L  6.81 RBFOX1  5.76 ARSJ  4.39 LINC01142 
12.2 LINC01819  6.81 TMPRSS11E  5.76 DDX18  4.39 LRBA 
12.2 FBRS  6.81 LOC646241  5.76 CABLES1  4.39 HPVC1 
12.2 HDAC11-AS1  6.81 ZNF777  5.76 CAAP1  4.39 CLEC14A 
12.2 UPP1  6.81 RAB11FIP2  5.76 LOC101928894  4.39 LINC01790 
12.2 DNMBP  6.81 LINC00648  5.76 NMNAT3  4.39 LOC100507468 
12.1 CLPP  6.81 PACRG-AS2  5.76 EPHB3  4.39 ANKS1B 
12.1 EEF2  6.81 POM121L2  5.66 DNAJB6  4.39 SKIL 
12.1 HSPA6  6.68 GLRA4  5.66 FRAT2  4.39 DPP4 
12.1 HK3  6.68 KCND2  5.66 OCM  4.39 ALG10 
12.1 ZNF483  6.68 BMP7-AS1  5.66 RPA1  4.39 MIR4445 
12.1 ADGRL1  6.68 C9orf85  5.66 SLAMF1  4.39 LOC100507468 
12.1 FXR2  6.68 SEPHS1  5.66 CFLAR  4.39 DPY19L2 
12.1 GAST  6.68 EIF3E  5.66 ID1  4.39 SLC4A4 
12.0 PLIN3  6.68 RHOU  5.66 THBD  4.39 MIR4735 
12.0 RPL36  6.68 JARID2  5.66 FAM196B  4.29 ZBED8 
12.0 SNORD118  6.68 GGA3  5.66 PPIF  4.29 SYT1 
12.0 DPRXP4  6.68 POLG  5.66 BMF  4.29 MIR3919 
11.8 HTR1F  6.68 MIR513C  5.66 MLN  4.29 CA10 
11.8 NOBOX  6.68 BRAT1  5.66 LOC105376360  4.29 SLC24A2 
11.8 METTL21A  6.68 LINC00324  5.56 LOC646730  4.29 DCLK2 
11.8 MIR3690  6.55 MIR4699  5.56 AOAH-IT1  4.29 BASP1 
11.7 NUP85  6.55 CCDC57  5.56 DDX11-AS1  4.29 LINC01851 
11.7 TTLL6  6.55 RHBDD2  5.56 DDX3X  4.29 PKIA 
11.7 SHISA2  6.55 LINC01623  5.56 FBXL19-AS1  4.29 GPR149 
11.7 CERS5  6.55 LINC00269  5.56 PLPP3  4.29 SLC36A4 
11.7 PINK1  6.55 VWC2  5.56 ADAMTSL4  4.29 LINC01822 
11.7 ALOXE3  6.55 UBE2G1  5.56 TSPAN18  4.29 TIA1 
11.6 ILF2  6.55 MIR4654  5.56 DET1  4.29 LOC102467226 
11.6 FAM212B-AS1  6.55 DAPK1  5.56 KCTD15  4.29 MKRN9P 
11.6 APOBEC3F  6.55 ZNF184  5.56 ASIC2  4.29 MIR3974 
11.6 LINC01822  6.55 MC4R  5.56 EGFEM1P  4.29 MIR181B1 
11.6 SLC2A14  6.55 PLS3  5.56 PNPT1  4.29 ZNF804A 
11.6 SIAH2  6.55 
ADAMTS19-
AS1 
 5.56 ADAMTS14  4.29 PXDNL 
11.4 LINC01629  6.55 LINC00533  5.47 CCDC50  4.29 ST3GAL1 
11.4 TEX43  6.55 SERPINI1  5.47 NCOR2  4.29 FRMD6-AS1 
11.4 LOC102723557  6.43 CREB5  5.47 TMEM170B  4.29 KITLG 
11.4 YIPF4  6.43 MIR6087  5.47 LINC01696  4.29 LOC105369860 
11.4 CHMP6  6.43 TERC  5.47 KRTCAP3  4.29 SPRED2 
11.4 MORC3  6.43 LINC01381  5.47 MATR3  4.29 LMO7-AS1 
11.4 LINC01448  6.43 HOOK1  5.47 HULC  4.29 MIR4735 
11.4 CP  6.43 LINC01320  5.47 SLC2A1-AS1  4.29 SI 
11.4 PWWP2A  6.43 AFF2  5.47 HNF1B  4.29 TMEFF2 
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11.4 RFX1  6.43 MYNN  5.47 PRPF6  4.29 LINC01070 
11.3 FBN3  6.43 CHSY3  5.47 STARD13  4.29 FZD4 
11.3 POLR2G  6.43 SARS  5.37 ASB1  4.29 KCNQ5 
11.3 TLE2  6.30 ABCA1  5.37 GPX5  4.29 MIR548AE1 
11.3 MUC4  6.30 NTN1  5.37 LINC02003  4.29 YTHDC2 
11.3 GGACT  6.30 SERBP1  5.37 GDF6  4.29 LINC01111 
11.2 ABCA13  6.30 TBC1D32  5.37 GALNT2  4.29 PDE4B 
11.2 RPUSD3  6.30 GFRA1  5.37 XRCC5  4.29 MIR149 
11.2 LHFPL4  6.30 LINC00972  5.37 GRHPR  4.29 MIR4999 
11.2 EIF4B  6.30 UBXN11  5.37 PPM1A  4.29 LRFN5 
11.2 LINC00941  6.30 MIR3162  5.37 RARRES3  4.29 LINC01620 
11.2 CAND2  6.17 RCC1  5.37 CUBN  4.29 LINC02010 
11.2 NIFK-AS1  6.17 LINC01609  5.37 LOC101927056  4.29 XIRP2 
11.2 TTC39B  6.17 TMEM106B  5.37 ARID1B  4.29 FUNDC2P2 
11.1 UIMC1  6.17 MORF4L1  5.37 TMUB2  4.20 MIR8065 
11.1 RIF1  6.17 METTL21A  5.27 PKDCC  4.20   
11.1 LINC01783  6.17 PTPRG  5.27 FAM86DP  4.20 LINC01419 
11.1 AFF1  6.17 TYRP1  5.27 DDX11-AS1  4.20 PTPRR 
11.1 GADD45GIP1  6.17 SHOX2  5.27 LRRC4B  4.20 IZUMO3 
11.1 ERCC1  6.17 FBXW2  5.27 UXS1  4.20 PTCHD1 
10.9 WDR66  6.17 PFKFB4  5.27 IRX6  4.20 C1orf140 
10.9 CROCC  6.17 LEFTY2  5.27 IER2  4.20 NKAIN3 
10.9 MOG  6.17 RNASE12  5.27 PAG1  4.20 TRIM2 
10.9 DDAH1  6.04 LOC101927139  5.27 PDE2A  4.20 NR4A3 
10.9 CLEC4C  6.04 MYLIP  5.27 PSORS1C2  4.20 MGAT4C 
10.9 MGC12916  6.04 KDM4B  5.27 PRRC2B  4.20 DUSP10 
10.9 LRIG1  6.04 LINC01716  5.27 LOC101928540  4.20 LOC440982 
10.9 MIR3675  6.04 POLR2G  5.27 MIR3664  4.20 CASP8 
10.8 ZMYND8  6.04 EOMES  5.27 NEAT1  4.20 CYP1B1 
10.8 GRPR  6.04 DAP  5.27 LOC102724933  4.20 ADAMTS20 
10.8 PLEKHG2  6.04 LINC00906  5.27 CASC18  4.20 MAP4K5 
10.8 UBXN11  6.04 NAALADL2  5.27 WI2-2373I1.2  4.20 LINC01170 
10.8 MSH6  6.04 ID3  5.27 RARG  4.20 LINC01322 
10.8 VDAC1  6.04 LARP1B  5.27 ALX1  4.20 ZNF335 
10.8 ATPIF1  6.04 EYA1  5.17 AKAP1  4.20 LINC01239 
10.8 UNC13B  6.04 COMMD7  5.17 MIR569  4.10 NRP1 
10.8 MIR4472-2  6.04 MYOF  5.17 ALDH7A1  4.10 MIR4735 
10.7 IGFBP4  6.04 DDX43  5.17 ATP6V1C2  4.10 GXYLT1 
10.7 FCHO1  5.91 CRLF2  5.17 DKK1  4.10 LINC01609 
10.7 APTR  5.91 SLTM  5.17 GREB1L  4.10 FGF20 
10.7 LINC01857  5.91 DLGAP1-AS2  5.17 ST3GAL1  4.10 DGKB 
10.7 LINC00922  5.91 PABPC1P2  5.17 JUP  4.10 IGSF5 
10.5 ARID3A  5.91 SNX16  5.17 ZNF302  4.10 BACH1-IT2 
10.5 TMEM214  5.91 LINC01036  5.17 C11orf58  4.10 RCC2 
10.5 MTMR14  5.91 DPP10  5.17 CDH10  4.10 SEMA6D 
10.5 VAMP2  5.91 MIR5188  5.17 LOC100507468  4.10 FAM19A2 
10.5 SLC35D3  5.91 SGIP1  5.17 WBSCR17  4.10 FGFR3 
10.4 MAN1C1  5.91 LOC101929555  5.17 CDH4  4.10 KCNIP4-IT1 
10.4 RPL6  5.91 LOC101929570  5.17 RRM1  4.10 CDCA7L 
10.4 OR2B2  5.91 MIR1263  5.17 RFK  4.10 DIRC1 
10.4 TNRC18  5.91 TRPC7  5.17 OPRM1  4.10 LINC00524 
10.4 LOC100507468  5.91 MIR4426  5.17 LINC01070  4.10 LINC01031 
10.4 LINC01947  5.91 SRSF10  5.17 MIR4427  4.10 LINC01935 
10.4 ZNF184  5.91 TDGF1  5.08 SLC28A3  4.10 NFATC1 
10.4 MELK  5.91 LOC101928909  5.08 CSF1  4.10 NFIB 
10.4 LINC01267  5.91 SMU1  5.08 CHCHD6  4.10 LINC01239 
10.4 WSB1  5.78 RN7SL1  5.08 LINGO2  4.10 LINC01554 
10.4 RAF1  5.78 CD99L2  5.08 CFAP126  4.10 PELO 
10.4 RNF112  5.78 MIR4459  5.08 HSPA8  4.10 LOC102723895 
10.4 ANG  5.78 ETV1  5.08 USP32  4.10 MROH9 
10.4 UHRF1BP1L  5.78 RPS24  5.08 LOC102724890  4.10 LOC100129138 
10.4 RRAGC  5.78 LMX1B  5.08 NRP1  4.10 PLSCR2 
10.4 LHX5  5.78 RMND5B  5.08 HNRNPAB  4.10 MTAP 
10.3 CASP16P  5.78 STK10  5.08 LOC100130298  4.10 SP3 
10.3 TIMP4  5.78 SAMD5  5.08 ECE1  4.10 DNAH7 
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10.3 GLOD5  5.78 EPHA3  5.08 LINC01063  4.10 MIR2053 
10.3 PFKFB4  5.78 RIPK1  5.08 RIMS1  4.00 PTPRD 
10.3 PIH1D1  5.78 YWHAE  5.08 KYNU  4.00 TMEM178A 
10.3 MIR648  5.78 LINGO2  4.98 OTUD4  4.00 P2RY1 
10.3 RPEL1  5.78 MTF2  4.98 TTC25  4.00 FAM46A 
10.3 HNF1A-AS1  5.78 SNUPN  4.98 KDELR2  4.00 OR2L5 
10.3 SPATA45  5.78 WDR59  4.98 NUDCD1  4.00 KCNB2 
10.2 LINC01164  5.78 LINC01623  4.98 ZFAT  4.00 FGF13 
10.2 RCC2  5.78 MIR371A  4.98 PLAGL1  4.00 APBB2 
10.2 SRCIN1  5.65 KLF4  4.98 WWP2  4.00 NUDT12 
10.2 LOC105369723  5.65 SLC44A1  4.98 ETV4  4.00 LINC01343 
10.2 ZBTB5  5.65 PLOD2  4.98 LINC01139  4.00 LOC102723833 
10.2 TERF1  5.65 OR1F1  4.98 C20orf85  4.00 FRG1BP 
10.2 RPN1  5.65 SSTR2  4.98 GNPDA2  4.00 LOC105377143 
10.2 CERS4  5.65 FAM212B-AS1  4.98 TRIM24  4.00 LINC01467 
10.2 WWTR1-AS1  5.65 SLC2A3  4.98 KIF15  4.00 CEBPZ 
10.2 ADGRL1  5.65 PRUNE1  4.88 ZNF608  4.00 MIR5688 
10.2 NANOG  5.65 RPL34-AS1  4.88 GC  4.00 LOC100506474 
10.2 MIR9-2  5.65 AACSP1  4.88 SLC36A4  4.00 SI 
10.2 PLAGL1  5.65 NRXN3  4.88 MIR3917  4.00 LRRC4B 
10.2 STYK1  5.65 LAMA2  4.88 RSPO3  4.00 SOX2-OT 
10.2 BCAT1  5.65 TMEM106B  4.88 PDK1  4.00 DKK1 
10.0 ZNF184  5.65 OSCP1  4.88 RBFOX1  4.00 LOC101927849 
10.0 ZNF335  5.65 NXPH1  4.88 FAM19A5  4.00 LINC01324 
10.0 SLC44A1  5.65 TMEM14EP  4.88 PSKH2  4.00 LINGO2 
10.0 ZNF675  5.65 NATD1  4.88 LMX1B  4.00 ELAVL2 
10.0 CASC21  5.65 LOC100996251  4.88 LINC01090  4.00 LOC105376633 
10.0 ZMYND8  5.65 SOX2-OT  4.88 CUEDC1  4.00 ADGRB3 
10.0 RAB5C  5.65 OR5AR1  4.88 NSD1  4.00 RELN 
10.0 LYZL1  5.65 PIM2  4.88 COL4A1  4.00 FOXN3-AS2 
10.0 BASP1  5.53 LOC100132831  4.88 KLF6  4.00 MIR1-1HG 
10.0 FGD4  5.53 ZMYND8  4.88 ISG20  4.00 LINC01473 
10.0 LOC284788  5.53 TRAPPC8  4.88 NBPF3  4.00 SATB2 
10.0 WNT5B  5.53 TMEM2  4.88 TBCEL  4.00 MIR205 
10.0 DENND2A  5.53 LINC01012  4.88 CTSO  4.00 NLN 
10.0 ATF7IP  5.53 ASMT  4.78 LINC00964  4.00 PRG4 
9.89 FAM60A  5.53 LRP1B  4.78 SP4  4.00 LOC105373782 
9.89 MIR5188  5.53 YIPF5  4.78 RHOB  3.90 LRP12 
9.89 TNFAIP8L1  5.53 FOXN3  4.78 ZBTB10  3.90 UGT2A3 
9.89 TERC  5.53 LINC01242  4.78 LINGO2  3.90 CHRM3 
9.89 SPNS3  5.53 LOC105369860  4.78 TADA3  3.90 LINC01948 
9.89 SRCIN1  5.53 PCLO  4.78 TMEM132D  3.90 LINC01923 
9.89 MACF1  5.53 C17orf112  4.78 NDUFS5  3.90 BRINP3 
9.89 ANKRD1  5.53 SPEN  4.78 TENM3  3.90 PRDM14 
9.89 LOC105369632  5.53 SNORD12  4.78 CNDP1  3.90 LINC01995 
9.89 RPH3A  5.53 OTUD4  4.78 KIAA1456  3.90 PSAT1 
9.89 ZNF184  5.53 CCDC62  4.78 CENPN  3.90 STARD7 
9.77 KIF2C  5.53 ANKS1B  4.78 LINC00551  3.90 LINC01467 
9.77 TGFBR2  5.40 SFRP2  4.78 PTPRS  3.90 LOC102723831 
9.77 PXN  5.40 CWC27  4.78 EEF1A1  3.90 SFRP2 
9.77 OR6S1  5.40 LINC01756  4.78 MIR4792  3.90 MIR6827 
9.77 PCLO  5.40 CASP16P  4.78 TYRO3  3.90 MIR4735 
9.77 GRIA3  5.40 DHX15  4.78 LOC101927043  3.90 CDAN1 
9.77 UBE2G1  5.40 NEGR1  4.78 SLAMF7  3.90 TUSC1 
9.77 LOC105374988  5.40 PHF12  4.78 MIR2053  3.90 LOC102724053 
9.77 RAD52  5.40 ASGR2  4.78 PRSS36  3.90 TOX 
9.77 TRIP4  5.40 LOC101928834  4.78 SPATA6  3.90 LOC100129434 
9.77 RP9P  5.40 LINC01320  4.78 FUZ  3.90 OR4A5 
9.77 MORF4L1  5.40 CDKL3  4.78 LINC01291  3.90 LOC105375972 
9.77 ZFP36L2  5.40 TMEM261  4.78 USP32  3.90 LOC100506474 
9.77 RHBDD2  5.40 SKAP2  4.78 BMPR1A  3.90 KCNC2 
9.77 SPEN  5.40 SPATA16  4.78 DEFB131  3.90 GOLIM4 
9.77 EIF2AK1  5.40 IAPP  4.78 KIAA1614  3.90 PRRX1 
9.64 SLC2A14  5.40 FAT4  4.78 LOC646241  3.90 LINC01239 
9.64 C19orf25  5.40 LOC100506474  4.68 FAM84B  3.90 HDAC9 
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9.64 SYT6  5.40 MIR3686  4.68 MIR4454  3.90 RAB17 
9.64 DNM1L  5.40 GPRIN3  4.68 PYGL  3.90 BSPRY 
9.64 RIOX1  5.40 PER4  4.68 MIR1915  3.90 GLRA3 
9.64 SLC2A14  5.40 PRRC2C  4.68 UBQLN4  3.90 LGR5 
9.64 MIR1303  5.40 ATF6  4.68 LINC00303  3.90 STMN2 
9.64 BRDT  5.40 LOC101929926  4.68 ITGB5  3.90 UBE2N 
9.64 PIK3CB  5.40 PTBP2  4.68 SRD5A2  3.90 TRHR 
9.64 GDF3  5.40 LRRC7  4.68 C8orf58  3.90 DOK5 
9.64 GCNT2  5.40 LOC101927434  4.68 APP  3.90 LINC01014 
9.51 ZBED9  5.40 LINC01242  4.68 FGF13  3.90 LINGO2 
9.51 RPA3  5.40 CASC21  4.68 MIR548AQ  3.90 RANBP17 
9.51 YWHAE  5.40 ATR  4.68 PHTF2  3.90 LOC102546299 
9.51 ASIC2  5.40 MIR4521  4.68 HEG1  3.90 EGFEM1P 
9.51 SLC35F3  5.40 LINC00276  4.68 TSPAN18  3.90 FAM196B 
9.51 HCG27  5.40 LINC01947  4.68 BRWD3  3.90 CADM2-AS2 
9.51 NTN1  5.40 HNF1A-AS1  4.68 MIR4463  3.90 PLCB1 
9.51 TRIM71  5.40 PRSS16  4.59 SERBP1  3.90 MAML3 
9.51 BRAT1  5.27 PRKACB  4.59 TFDP2  3.90 THADA 
9.51 LOC102546229  5.27 VPS41  4.59 AGO3  3.90 TNFSF18 
9.51 MYNN  5.27 TYRP1  4.59 LOC101927847  3.90 SLC16A7 
9.51 LINC01267  5.27 ZNF184  4.59 POMC  3.90 LINC02141 
9.38 LINC01381  5.27 SLC29A2  4.59 LOC101928254  3.90 LINC01239 
9.38 MIR23A  5.27 ZNRF1  4.59 SNAPC1  3.90 EEF1A1 
9.38 PEMT  5.27 SEMA3E  4.59 AMOTL2  3.90 MMP16 
9.38 VAMP1  5.27 PRR16  4.59 FGF18  3.90 PDPN 
9.25 SNURF  5.27 LOC101927356  4.59 LINC01005  3.90 P2RY1 
9.25 NANOG  5.27 MUC19  4.59 ZBTB5  3.90 LOC440982 
9.25 PGPEP1  5.27 LINC02032  4.59 MIR548AG2  3.90 CNGB3 
9.25 LINC00620  5.27 HIST1H4H  4.59 FGFR1  3.90 MIR548AD 
9.25 LINC00533  5.27 SGK1  4.59 FAM86EP  3.90 GBE1 
9.25 CLEC7A  5.27 MIR4699  4.59 NKAIN1  3.90 KCNN2 
9.25 LOC100507468  5.27 DCN  4.49 YWHAZ  3.90 RNF133 
9.25 CLINT1  5.27 DOCK3  4.49 LINC01962  3.90 EPDR1 
9.25 BMPR2  5.27 CACHD1  4.49 LRRN3  3.90 TMEM139 
9.25 PRSS16  5.27 TOX  4.49 LINC00552  3.90 ISG20 
9.25 GTF2I  5.27 TTC27  4.49 CWF19L2  3.90 LOC100507377 
9.25 LINC00533  5.27 LINC01947  4.49 TRERF1  3.90 FYB 
9.25 FLNB  5.27 MSH6  4.49 LINC01170  3.90 NTS 
9.25 REST  5.27 PRICKLE1  4.49 PSAP  3.90 SLC24A2 
9.25 SENP2  5.27 CFD  4.49 PBX3  3.90 CDC14C 
9.25 CDH1  5.27 PPM1B  4.49 ZNF826P  3.90 LINC00971 
9.25 LOC100270746  5.27 FGF12  4.49 LINC01488  3.90 MIR2053 
9.25 KDM4B  5.27 SPRED2  4.49 SSUH2  3.90 TFCP2L1 
9.25 VWF  5.27 LINC00299  4.49 SSUH2  3.90 LINC01222 
9.12 AP2A2  5.27 MIR7157  4.49 MIR205HG  3.90 LOC401134 
9.12 OLFM2  5.27 XK  4.49 THSD4-AS2  3.90 MIR7641-2 
9.12 TP53  5.27 LINC01322  4.49 MAP4K4  3.90 FAM188B 
9.12 SLC2A14  5.27 CCDC171  4.49 HUS1  3.81 KCNC2 
9.12 CASC17  5.27 MIR548AD  4.49 HUS1  3.81 RPS29 
9.12 HSPB1  5.27 HES7  4.49 KPNA2  3.81 PKIA 
9.12 DFNA5  5.27 DCUN1D1  4.49 TMCC1  3.81 CNTNAP4 
9.12 PRR13  5.27 JAK2  4.39 FOLR1  3.81 PITPNM2 
9.12 CCDC9  5.27 LINC00693  4.39 SPARC  3.81 ZIC4 
9.12 PUM1  5.27 SNORA38B  4.39 LINC01101  3.81 HDGF 
9.12 LOC101927637  5.27 LINC00533  4.39 ESCO1  3.81 MIR4300 
9.12 FOXJ2  5.27 KANK1  4.39 LOC105369739  3.81 LOC102723883 
9.12 TRAPPC8  5.27 ZNF714  4.39 TMEM72  3.81 KCNV1 
9.12 LRP6  5.27 CTR9  4.39 PLCD4  3.81 GRM5 
9.12 DAZL  5.27 SULT6B1  4.39 SSBP3  3.81 MIR4735 
Genes are annotated according to distance of ChIP-seq peak to the nearest transcription start 
site (TSS)
Publications 
 
 
 
118 
 
9. Publications 
 
2019 Epigenetic drugs and their molecular targets in testicular germ cell 
tumours  
Jostes S, Nettersheim D, Schorle H 
Nature Reviews Urology 
 
2018 Deciphering the molecular effects of romidepsin on germ cell 
tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or 
induction of romidepsin effectors. 
Nettersheim D, Berger D, Jostes S, Skowron M, Schorle H 
J Cell Mol Med. 2018 Nov 20 
 
2018 Signals and Transcription Factors for Specification of Human Germ 
Cells 
Jostes S, Schorle H 
Stem Cell Investigations 2018; 5:13 
 
2017 Xenografting of Cancer Cell Lines for In Vivo Screening of the 
Therapeutic Potential of HDAC Inhibitors 
Nettersheim D, Jostes S, Schorle H 
Methods Mol Biol. 2017 
 
2016 Re-visiting the Protamine-2 locus: deletion, but not 
haploinsufficiency, renders male mice infertile. 
Schneider S, Balbach M, Jikeli J, Fietz D, Nettersheim D, Jostes S, 
Schmidt R, Kressin M, Bergmann M, Wachten D, Steger K, Schorle H 
Sci Rep. 2016 Nov 11;6:36764 
 
2016 The bromodomain inhibitor JQ1 triggers growth arrest and 
apoptosis in testicular germ cell tumours in vitro and in vivo 
Jostes S, Nettersheim D, Fellermeyer M, Schneider S, Hafezi F, 
Honecker F, Schumacher V, Geyer M, Kristiansen G, Schorle H 
J Cell Mol Med. 2016 Dec 27 
 
2016 A signalling cascade including ARID1A, GADD45B and DUSP1 
induces apoptosis and affects the cell cycle of germ cell cancers 
after romidepsin treatment 
Nettersheim D, Jostes S, Fabry M, Honecker F, Schumacher V, Kirfel J, 
Kristiansen G, Schorle H 
Oncotarget. 2016 Aug 27. 
 
2016 Elucidating human male Germ Cell Development by studying  
Germ Cell Cancer 
Nettersheim D, Jostes S, Schneider S, Schorle H 
Reproduction. 2016 Oct 152(4):R101-13 
 
Publications 
 
 
 
119 
 
2016 The cancer/testis-antigen PRAME supports the pluripotency 
network and represses somatic germ cell differentiation programs 
in seminomas 
Nettersheim D, Arndt I, Sharma R, Riesenberg S, Jostes S, Schneider S, 
Hölzel M, Kristiansen G, Schorle H 
Br J Cancer. 2016 Aug 9;115(4):454-64 
 
2016 SOX2 is essential for in vivo reprogramming of seminoma-like 
TCam-2 cells to an embryonal carcinoma-like fate 
Nettersheim D, Heimsoeth A, Jostes S, Schneider S, Fellermeyer M, 
Hofmann A, Schorle H 
Oncotarget. 2016 Jul 26;7(30):47095-47110 
 
2015 BMP Inhibition in Seminomas Initiates Acquisition of Pluripotency 
via NODAL Signaling Resulting in Reprogramming to an Embryonal 
Carcinoma 
Nettersheim D, Jostes S, Sharma R, Schneider S, Hofmann A, Ferreira 
HJ, Hoffmann P, Kristiansen G, Esteller MB, Schorle H 
PLoS Genet. 2015 Jul 30;11(7):e1005415 
 
Acknowledgements 
 
 
 
120 
 
10. Acknowledgements 
Allen voran möchte ich mich bei meinem Doktorvater Prof. Dr. Hubert Schorle 
bedanken. Bereits 2013 gab er mir die Möglichkeit seine Arbeitsgruppe und die hier 
angestrebten wissenschaftlichen Projekte und Ziele im Rahmen eines Labor-
Praktikums kennen zu lernen. Gerne habe ich hier auch das Projekt meiner 
anschließenden Masterarbeit begonnen, welches ich im Rahmen der Doktorarbeit 
weiterführen und ausbauen konnte. Prof. Dr. Schorle hat mich vertrauensvoll auf 
meinem wissenschaftlichen Weg begleitet und mir zu jeder Zeit das Gefühl vermittelt 
mit Fragen oder Problemen an ihn herantreten zu können. Für seine Hilfe und seine 
geleistete Vorbereitung auf meinen wissenschaftlichen Werdegang bin ich sehr 
dankbar. 
Außerdem gilt mein Dank Priv. Doz. Dr. Reinhard Bauer für die freundliche Bereitschaft 
das 2.-Gutachten meiner Arbeit zu übernehmen. Zudem bedanke ich mich bei Prof. 
Matthias Geyer für eine erfolgreiche Kollaboration, sowie die Zusage Teil meiner 
Prüfungskommission zu sein und bei Prof. Dr. Ian Brock für die Bereitschaft als 
fachfremdes Prüfungsmitglied der Kommission anzugehören. 
Der Sander Stiftung danke ich für die finanzielle Unterstützung des SOX2/SOX17 
Projekts, ohne welches die letzten beiden Jahre meiner Promotion nicht möglich 
gewesen wären. Der Monika Kutzner Stiftung danke ich für die finanzielle 
Unterstützung des JQ1 Projekts. Außerdem bedanke ich mich bei GlaxoSmithKline, 
dem DAAD und dem Bonner Forum Biomedizin für die Erstattung von Reisekosten 
und Konferenzgebühren. Mithilfe dieser Gelder war es mir möglich meine 
wissenschaftlichen Ergebnisse im nationalen und internationalen Rahmen zu 
diskutieren und mich mit anderen Wissenschaftlern auf diesem Gebiet auszutauschen. 
Ferner gilt mein Dank allen aktuellen und ehemaligen Mitarbeitern der Pathologie. 
Besonders Prof. Dr. Daniel Nettersheim hat mich während seiner Zeit als Post Doc 
unter Prof. Schorle immer tatkräftig unterstützt und mir bei der Projektplanung, sowie 
dem Schreiben von Publikationen hilfreich zur Seite gestanden. Ich möchte mich auch 
besonders bei Gaby Beine, Franziska Kaiser, Simon Schneider, Jan Langkabel, 
Blanca Randel, Anna Pehlke und Caroline Schuster bedanken. Auch dank ihnen war 
die Zeit in der Pathologie ein tolles Erlebnis für mich und ich bin dankbar für so viel 
Freundlichkeit und Zusammenhalt innerhalb der Arbeitsgruppe. Nicht zuletzt möchte 
ich mich bei meiner Familie, meinem Partner und bei meinen Freunden bedanken, 
welche auch außerhalb der Arbeitsgruppe immer ein offenes Ohr für mich hatten und 
mich während dieser herausfordernden Zeit unterstützt haben.  
